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Erythropoietic protoporphyria (EPP) is a genetic disorder with a 'pseudodominant' mode 
of inheritance. Typically, patients present in childhood with photocutaneous sensitivity. 
This is a result of a defect in ferrochelatase (FECH), the terminal enzyme in haem 
biosynthesis, causing accumulation of protoporphyrin IX. In most cases, a single, 
primary FECH mutation is identified in EPP families, but unlike classic dominant 
inheritance, many mutation carriers are clinically asymptomatic. These individuals have 
approximately 50% FECH activity, while symptomatic individuals have a FECH activity 
of <50%. This has recently been attributed to a common polymorphism (IVS3-48C) that, 
when inherited in trans to a deleterious allele, leads to reduced FECH expression below 
a critical threshold limit and symptomatic EPP. This study characterised a cohort of 
South African EPP subjects from 17 families by identification and assessment of FECH 
sequence variations, including the disease-associated IVS3-48C polymorphism. PCR 
amplification and subsequent SSCP analysis of the coding region and surrounding 
intronic sequences of FECH was performed. Fragments corresponding to gel mobility 
shifts were sequenced to identify the variation. Restriction endonuclease analysis was 
employed to determine the frequencies of these variations, including the IVS3-48C 
polymorphism, in a study cohort of symptomatic and asymptomatic family members, 
and a matched control cohort. Ten sequence variations were identified, including the 
IVS3-48T/C polymorphism and 4 previously described common polymorphisms. The 
molecular basis of EPP was established for 15 of the 17 families. Unexpectedly, a 5bp 
deletion in exon 7 (757 _761deIAGAAG) was present in 12 of these families. The other 
mutations were family-specific and included 2 previously described splice-site mutations 
(IVS3+2T>G and IVS7+1 G>A) and a novel 7bp deletion in exon 4 
(356_362deITTCAAGA). A second novel variation (IVS10-61G/A), was shown to be a 
common polymorphism. The hypomorphic (IVS3-48C) allele appears to modulate the 
phenotypic expression of EPP in the South African EPP cohort as previously observed 
in other populations. In light of the above-mentioned results, the study investigated 
whether individuals positive for the 757 _761deIAGAAG deletion share a common 
ancestral allele with respect to FECH. Genotyping of the study cohort and 50 control 
samples for microsatellite markers surrounding FECH was completed for manual 
haplotype construction. A common restricted haplotype was confirmed in all families in 
which the 757 _761deIAGAAG deletion segregates as a familial trait, and for which 
complete family triads were available. This suggests a single mutational event for the 












Introduction - Porphyrins 



















The porphyrias are a group of metabolic disorders that result from enzymatic defects in 
the haem biosynthetic pathway. Most are inherited. Generally, 7 different types of 
porphyria can be distinguished and are conveniently classified according to the specific 
haem biosynthetic enzyme deficiency observed. The most commonly encountered 
forms of porphyria in South Africa include variegate porphyria (VP), acute intermittent 
porphyria (AlP) and the acquired form, porphyria cutanea tarda (peT) (Eales and 
Dowdle 1968; Meissner and Hift 2005). The porphyrias are normally considered rare. 
However, in certain areas, genetic founder effects have given rise to a higher incidence 
of a particular type of porphyria [e.g. AlP in Northern Sweden (Lee and Anvret 1991) 
and VP in South Africa (Meissner et al. 1996; Warnich et aL 1996; Groenewald et al. 
1998)]. 
Another form of inherited porphyria, erythropoietic protoporphyria (EPP), occurs in 
South Africa, although in our experience, of lower prevalence than is seen in some 
other parts of the world. To date there have been no molecular studies of EPP in South 
African patients. A few case reports at a clinico-biochemical level have been 
documented (Sweeney et af. 1963; Findlay et al. 1966; Leeming and Kramer 1968; van 
der Walt and Heyl 1971; Eales et al. 1978a; Eales et al. 1978b), and EPP is considered 
in the differential diagnosis of the porphyrias in South African laboratories (Day 1978). 
The focus of this dissertation is the molecular characterisation of a cohort of South 
African EPP patients; thus EPP will be reviewed in chapter 2. However, as the 
porphyrias result from enzyme deficiencies in the haem biosynthetic pathway, with the 
consequent accumulation of porphyrin intermediates, it is pertinent to give a brief 













Porphyrins are rigid, planar structures consisting of a macrocycle of four pyrrole rings 
interconnected by four methine (-C=) bridges (Figure 1.1) (Meissner et at. 2001). The 
four pyrrole rings have been designated A, B, C and 0 while a, 13, y and () denote the 
four methine bridges (Fischer and Orth 1934; Moore et al. 1987a). There are eight 
positions for the attachment of side chains when the tetrapyrrole macrocycle is in the 
oxidised state, and depending on their precise configuration these give rise to different 
isomeric forms. The specific side chains present determine the physico-chemical 
properties of the porphyrin. 
Figure 1.1. General porphyrin structure (from Moore et at 1987a) 
1.1.2. Properties 
The complex ring structure of porphyrins has the capacity to bind metals, e.g. iron to 
form haem, magnesium to form chlorophyl/s and cobalt bound to corrins (modified 
porphyrin rings) used in vitamin B12 synthesis (Scott 1972; Battersby and McDonald 



















These metalloporphyrins occur throughout the plant and animal kingdoms where they 
play essential roles in many processes, such as oxygen transport, electron transport, 
reduction of molecular oxygen and photosynthesis (Bissell 1985; Moore 1990). 
Porphyrins, the "pigments of life" (Battersby et aL 1980), are highly coloured, 
conjugated compounds, which exhibit red fluorescence on absorption of near ultraviolet 
(UV) light (Battersby 1978; Meissner et al. 2001), The absorption spectra show 
absorption in the visible region of the electro-magnetic spectra with a major band at 
j-400nm i.e, the Soret band (Soret 1883), 
The property of fluorescence has been utilised to study porphyrins and the associated 
porphyrias (e,g_ diagnosis through the measurement of excreted porphyrins) since the 
beginnings of porphyrin research. The origins of porphyrinology can be tracked to the 
acid treatment of haemoglobin to produce "iron-free haematin" which was purple-red in 
colour by Scherer, Berzelius and MOlder in the 18405 (Moore et aL 1987b), 
Porphyrinogens (hexahydroporphyrins) are unstable, colourless porphyrin intermediates 
in which the methine bridges are reduced to methylene bridges (Meissner et aL 2001). 
They do not fluoresce and are readily oxidised to their corresponding porphyrin on 
exposure to oxygen, 
1.1.3. Porphyrin and haem biosynthetic pathway 
Haem synthesis in mammals requires a well-defined, tightly controlled pathway and is 
accomplished by the sequential catalytic reactions of eight distinct enzymes (Figure 
1,2). Synthesis is initiated in the mitochondrion, continues in the cytosol and is 
completed in the reducing environment of the mitochondrion once again. 
The first step is the condensation of succinyl-CoA and glycine in the mitochondrion, 
catalysed by the pyridoxal phosphate-containing enzyme o-aminalevulinic acid (ALA) 
synthase, to form ALA which is transported into the cytoplasm (Michal 1999), ALA 
dehydratase catalyses the condensation of twa ALA moieties to produce 
porphobilinogen (PBG), the monopyrrole subunit of the porphyrin ring, Next, four 
molecules of PBG condense in a head-ta-tail manner producing a linear tetrapyrrole 
intermediate, hydroxymethylbilane (Moore et al. 1987 a), The enzyme responsible for 

















Working concurrently with PSG deaminase, uroporphyrinogen III cosynthase performs 
the necessary intramolecular rearrangement and ring closure, to form uroporphyrinogen 
III via a spiro intermediate. Uroporphyrinogen decarboxylase yields coproporphyrinogen 
III by step-wise decarboxylation of the four acetate side chains of uroporphyrinogen III 
(Dailey 1997). Hydroxymethylbilane is converted non-enzymatically into 
uroporphyrinogen I if uroporphyrinogen III cosynthase is not present (Michal 1999). This 
isomer cannot be metabolised further and is lost to haem synthesis. The process 
returns to the mitochondrion where coproporphyrinogen III oxidase converts it to 
protoporphyrinogen IX by oxidative decarboxylation of the two propionate side chains to 
yield vinyl substituents on the two pyrrole rings. Protoporphyrin IX is formed by 
protoporphyrinogen IX oxidase (PPOX) via a 6-electron oxidation (Dailey 1997). 
Ferrochelatase (FECH), located in the inner mitochondrial membrane, catalyses the 
final step of haem biosynthesis by the insertion of iron into protoporphyrin IX to yield 
protoheme (Jones and Jones 1969; Meissner et al. 2001). FECH will be reviewed in 
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Figu re 1.2. Haem biosynthetic pathway in mammals showing 
compartmentalisation reactions in the mitochondria and cytosol 
(from A. E. Medlock, PhD dissertation, University of Georgia, 2002) 











In mammals, haem synthesis is an efficient, tightly-regulated process that ensures 
homeostatic concentrations of haem in the body. Erythropoietic and hepatic cells are 
the primary sites of haem synthesis. It appears that synthesis in these two tissues is 
regulated differently, although in both cases primary regulation is at the level of ALA 
synthase (Moore et al. 1987 c). Regulation and differential expression of other enzymes 
are likely to occur. The two isoforms of the ALA synthase enzyme used for non-
erythroid haem synthesis (ALAS 1) and erythroid haem synthesis (ALAS2) (Watanabe et 
al. 1983, 1984; Bishop et al. 1990) are encoded by two distinct mRNA molecules with 
different regulatory and untranslated regions (Cox et al. 1991). Haem itself activates 
regulatory mechanisms or inhibits ALA synthase directly, as is characteristic of feed-
back regulation (Andrew and Riley 1990). These mechanisms include repressing its 
synthesis and blocking the transport of synthesised ALAS1 into the mitochondria 
(Hamilton et al. 1991; Lathrop and Timko 1993), specifically in the liver and non-
erythroid tissues of higher animals (Meissner et al. 2001). Earlier reports proposed that 
ALAS 1 regulates haem at a translational level (Scholnick 1972) and at a transcriptional 
level (Srivastava 1988). However, studies by Roberts and Elder (2001) on the ALAS 1 
promoter, and by Guberman et al (2003) on transcription factor binding sites support 
transcriptional regulation of ALAS1. 
ALAS2 regulation is different. Expression and regulation of erythroid haem synthesis 
are linked to differentiation events initiated by erythropoietic iron availability and globin 
chain production (May et al. 1995; Weiss et al. 1997). Regulation of both hepatic and 
erythroid haem synthesis is a complex issue and there is much additional information in 
the literature. However, as it is not directly relevant to this dissertation, this regulation is 













1.2. The porphyrias 
A deficiency of any enzyme in the haem biosynthetic pathway described above (section 
1.1.3, pg. 3), may lead to a specific porphyria due to abnormal accumulation of the 
porphyrin intermediates and/or their precursors ALA and PBG (Nordmann and Puy 
2002). Clinically, the porphyrias may present with acute neurological attacks and/or 
photocutaneous sensitivity (Elder et al. 1990). Hence the two most useful ways of 
classifying the porphyrias are by the site of their primary enzyme deficiency and the 
presence/absence of acute attacks (see Table 1.1). 
Table 1.1. Summary of the clinical and molecular characteristics of the porphyrias 
Disorder Affected Enzyme Clinical Effects Inheritance 
0- Aminolaevulinate o-Aminolaevulinate Acute attack Autosomal recessive 
dehydratase dehydratase 
deficiency porphyria 
Acute intermittent Porphobilinogen Acute attack Autosomal dominant 
porphyria deaminase 
Congenital Uroporphyrinogen Photosensitivity Autosomal recessive 
erythropoietic cosynthase 
porphyria 
Porphyria cutanea Uroporphyrinogen Photosensitivity Acquired (t75%) or 
tarda decarboxylase autosomal dominant (~25%) 
Hereditary Coproporphyrinogen Acute attack and/or Autosomal dominant 
coproporphyria oxidase Photosensitivity 
Variegate porphyria Protoporphyrinogen Acute attack and/or Autosomal dominant 
oxidase Photosensitivity 
Erythropoietic Ferrochelatase Photosensitivity Autosomal recessive or 
protoporphyria complex (see section 2.3.1) 
The most common inheritance pattern observed amongst the porphyrias is autosomal 
dominant inheritance. Recessive and complex forms of inheritance are encountered. 
Porphyria cutanea tarda is frequently acquired, though autosomal dominant inheritance 
is also possible (Badminton and Elder 2005; Meissner and Hift 2005). Rare cases of 
other forms of porphyria, acquired as a result of somatic mutations, have been 











It is important to note, however, that incomplete penetrance is a feature of the dominant 
forms of porphyria, and not all individuals express a clinical porphyric phenotype. Of 
these asymptomatic individuals, a proportion will exhibit biochemical porphyrin 
abnormalities, while others show no disease phenotype, despite carrying a deleterious 
gene for the specific haem enzyme (Elder et aL 1990; Kauppinen 2005). The porphyrias 
can therefore be considered "Iow-penetrance genetic conditions" (Badminton and Elder 
2005). Both genetic and environmental factors underlying susceptibility and expression 
of the disease have been, and continue to be, active areas of research. 
1.2.1 Diagnosis and treatment of the porphyrias 
Accurate, timeous diagnosis of porphyria is important Rational diagnostic approaches 
involve both clinical and laboratory investigations and are aimed at: a) establishing 
whether a patient has porphyria; b) assessing whether the presenting symptoms are 
due to the porphyria and c) correctly typing the porphyria in order to provide appropriate 
treatment and advice for the patient and family (Meissner and Hift 2005; Anderson et al. 
2005). The most common laboratory investigations centre around the use of porphyrin 
and porphyrin precursor measurements, and the demonstration of a porphyria-related 
mutation in the relevant gene. Metabolite measurements include urinary ALA/PSG, 
faecal, urinary and plasma porphyrin concentrations and plasma fluorescence emission 
spectroscopy ("plasma fluoroscan") (Meissner and Hift 2005). Management of the acute 
attack involves confirming the diagnosis, removal of any known precipitating factors 
(e.g. porphyrinogenic drugs), analgesia, fluid therapy and the only uniformly effective 
specific therapy; administration of haem arginate or haemin (Hift and Meissner 2005). 
Management of the skin disease in porphyria attempts to minimise the accumulation of 
porphyrins, reduce exposure to UV light and avoid minor trauma. The skin disease of 
peT is particularly rewarding to treat in that most cases can be considered "curable", 
since removal of specific trigger factors, such as alcohol exposure and hepatic iron 
overload, is commonly followed by remission (Kirsch et aL 1998). 
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FECH and EPP 
Erythropoietic protoporphyria (EPP) is an inherited disorder resulting from a deficiency 
of ferrochelatase (FECH), the final enzyme of the haem biosynthetic pathway 
(Bonkowsky et al. 1975; de Goeij et al. 1975). 
2.1 Ferrochelatase 
Ferrochelatase (E.C. 4.99.1.1, protoheme ferro-lyase) is constitutively expressed in all 
cell types because of the demand for haem by haemoproteins including those involved 
in reduction-oxidation reactions such as the respiratory cytochrome complexes. FECH 
activity, however, is highest in the liver for cytochrome P450 synthesis, and in 
erythroblasts for haemoglobin synthesis during the final stages of erythropoiesis 
(Brenner and Fraser 1991; Tugores et at. 1994; Fujita 1997). 
2.1.1. Catalytic mechanism 
The FECH enzyme probably employs an ordered, sequential bi-bi reaction mechanism 
in which Fe2+ binds to the enzyme before the porphyrin and the two protons are 
abstracted from the porphyrin following release of haem (Figure 2.1) (Dailey and 















Chemical reaction: Fe2+ + PPIX -------. Haem + 2H 
PPIX Haem 
1 E.Fe.PPIX r t ~ E.Fe .. II> .. II> E.2H .. 
E.Haem.2H 
Figure 2.1. Schematic representation of the reaction 
mechanism employed by FECH (from Dailey and Fleming 1983) 





In the catalytic process, metal binding to FECH is followed by distortion of the porphyrin 
macrocycle into a non-planar structure (Franco et al. 2000) which facilitates porphyrin-
metal chelation and the release of haem (Lavallee 1988; Blackwood et al. 1997; 
Ferreira 1999; Burden et al. 1999). Simultaneous tilting or doming of the four pyrrole 
rings of the porphyrin, resulting in the distortion of yeast FECH, was demonstrated by 
resonance Raman spectroscopy (Blackwood et al. 1998; Sellers et aL 2001). Crystal 
structures of FECH of both Bacillus subtilis (AI-Karadaghi et al. 1997; Lecerof et al. 
2000) and human (Wu et al. 2001) support this proposed mechanism (Figure 2_1) and 













Figure 2.2. A) Space-filling diagram and 8) ribbon diagram of FECH 
showing putative iron-binding and melallation residues; D383 and H231 (A) 











There is general consensus that macrocycle distortion is thermodynamically stable and 
will allow release of the product following catalysis (Dailey and Dailey 2003). Although 
this FECH mechanism is likely to be relatively conserved amongst species, the model 
for iron entry into the active site pocket may only apply to mitochondrial-associated 
eukaryotic FECHs and may differ amongst other species, particularly amongst soluble 
FECHs of some bacterial species (Sellers et al. 2001). 
2.1.2. Protein characterisation 
Ferrochelatase has been purified from various sources, including the yeast 
Saccharomyces cerevisiae (Camadro and Labbe 1988), rat (Taketani and Tokunaga 
1981), mouse (Karr and Dailey 1988) and human liver (Mathews-Roth et al. 1987). 
Human FECH, a 423 amino acid protein, has a molecular mass of approximately 42kDa 
(Mathews-Roth et al. 1987). Radiation inactivation showed that the functional size of 
FECH in bovine liver is approximately 80kDa suggesting two subunits of approximately 
40kDa (Straka et al. 1991), in contrast to Bacillus subtilis FECH which is a monomeric 
protein (AI-Karadaghi et aL 1997). Crystallisation of human FECH confirmed that the 
human enzyme is a homodimer (Burden et al. 1999; Wu et al. 2001). 
Nuclear-encoded eukaryotic FECH is synthesised in the cytoplasm and then 
translocated to the matrix side of the mitochondrial membrane (Camadro and Labbe 
1988). Translocation of FECH across the mitochondrial membrane requires a 
transmembrane potential (Karr and Dailey 1988). It is converted to the active form on 
proteolytic cleavage of a leader peptide of 30-80 amino acids (62 in human FECH) 
which is essential for intracellular targeting and localisation of FECH and, in turn, for 
optimal functioning of the enzyme (Nakahashi et al. 1990; Prasad and Dailey 1995; 

















Mammalian FECHs are distinct from yeast, plant and prokaryotic FECHs in that they 
contain a "uniquely coordinated", novel prosthetic group, a [2Fe-2S] cluster (CYS-X205-
* Cys-XrCys-XrCys ) (Dailey et al. 1994; Ferreira et al. 1994; Wu et al. 2001), This 
cluster, although necessary for enzyme function, does not appear to be involved in 
catalysis and is distinct from the Fe2+ binding site (Dailey et al. 1994), It is however 
labile and degrades rapidly in the presence of nitric oxide, causing inhibition of FECH 
activity, A possible role for this regulation may be a defence mechanism against 
bacterial infection to decrease iron availability for the pathogen (Sellers et aL 1996). 
More recently, structural studies have suggested that the cluster may anchor the C-
terminal domain of the monomer at the dimer interface thereby indirectly facilitating 
dimerisation (Wu et aL 2001). 
Three highly conserved cysteine residues in human FECH are ligands for the [2Fe-2S] 
cluster (Crouse et aL 1996), These occur in a 30 to 50-residue C-terminal extension 
that is unique to eukaryotic FECH (Dailey et al. 1994), while the fourth cysteine lies 
approximately 200 residues towards the amino terminus (Sellers et al. 1998). 
Crystallisation and characterisation of human FECH and the [2Fe-2S] cluster revealed 
that the iron positions for the cluster are consistent with those observed for [2Fe-2S] 
clusters in other proteins (Burden et al. 1999). 
* X represents any amino acid 












The first 3-dimensional structure for FECH was determined for the Bacillus subtillis form 
of the protein. Two similar domains (consisting of four-stranded f3-sheet flanked by a-
helices) forming a cleft was suggested to be a potential binding site for protoporphyrin 
IX (AI-Karadaghi et al. 1997). 
The first crystallisation of a recombinant human FECH was obtained by Burden et al in 
1999 and was followed by the resolution of the structure to 2.0 A (Wu et al. 2001). Each 
mature FECH monomer consists of amino acids 65-423 and a [2Fe-2S] cluster. The 
FECH dimer (Figure 2.3A) has a mass of approximately 86kOa and has 580 associated 
water molecules (Wu et al. 2001). Approximately 300 amino acids form a catalytic core 
and are conserved in all FECHs (Ferreira 1999). The entrance to the active site of 
FECH is lined with hydrophobic residues arranged linearly as hydrophobic ridges. A 12-
residue hydrophobic lip in this region is thought to mediate membrane association. This 
positioning allows the poorly soluble porphyrin substrate and haem molecule to be 
transported via the mitochondrial membrane. A possible metal-binding site, facing the 
mitochondrial matrix, is suggested to be the initial binding site for ferrous iron at 
conserved residues His 231 and Asp 383, before being shuttled along a path of 
conserved residues (Trp 227 and Tyr 191) to the active site (Wu et aL 2001; Sellers et 
al. 2001). 
The active site pocket (Figure 2.38) is highly conserved and is hydrophilic. The most 
conserved residue is His 263 which is located in the active site of all known FECH 
proteins. Other conserved residues (Asp 340, Glu 343, Glu 347, His 341) line one side 
of the active site, forming an acidic path from the protein surface to the catalytic core. In 
addition, Arg 164 a d Tyr 165 are conserved and probably lie on the opposite side of 
the protoporphyrin IX macro cycle to these residues (Wu et al. 2001). Site-directed 
mutagenesis experiments confirmed the essential role of these residues for FECH 
function since mutation of residues His 263, Asp 340 and Glu 343 resulted in no 
measurable FECH activity (Kohno et al. 1994; Sellers et al. 2001). 
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Figure 2.3. Ribbon drawings of human FECH showing: 
A) the structure of the dimer, including the positions of 
residue 390 of the C-terminal extension and C 196 and; 
8) the active site pocket with key residues H263, E343 











2.1.4. FECH gene 
The gene for FECH was first cloned from Saccharomyces cerevisiae in 1990 (Labbe-
Bois 1990) and in the mouse in 1991 (Brenner and Frasier 1991). Sequence homology 
among FECH genes is <10% (Wu et al. 2001). The human cDNA transcript was initially 
cloned and sequenced by Nakahashi et al in 1990. The transcript is approximately 
2.5kb in length of which 1.3kb is coding (Taketani et al. 1992). Two mRNAs, transcribed 
from a single gene, with differences in their 3'-polyadenylation signals have been 
reported. It was suggested that the transcripts encode a housekeeping form expressed 
in all cells, and an erythroid-specific form (Nakahashi et al. 1990; Tugores et al. 1994; 
Taketani and Fujita 1995). Human FECH is the product of a single gene that maps to 
chromosome 18q21.3, spans approximately 45kb and consists of 11 exons (Brenner et 
al. 1992; Taketani et al. 1992). Unlike other enzymes of the haem biosynthetic pathway, 
FECH is transcribed from a single promoter in erythrocytes and other tissues (Taketani 
et al. 1992). This promoter lies in an area rich in CpG islands (>80% C+G nucleotides) 
and does not contain the usual TA TA and CAA T boxes. Consensus cis-elements that 
are recognised by erythroid-specific factors including NF-E2 and GATA-1 and the 
ubiquitous Sp1 transcription factor are present instead, and may regulate differential 
expression of FECH. The activity of the promoter is 3-4 fold higher in erythroid cells, 
and is likely to be repressed by negative regulatory elements in the region 1 kb 
upstream from the transcription start site (Tugores et al. 1994). The high C+G content 
of the proximal promoter region, extending into exon 1 and intron 1, is characteristic of 
many housekeeping genes. This region is highly accessible to regulatory proteins as it 
cannot be tightly packed into chromatin and can therefore be constitutively expressed 
(Tugores et al. 1994; Lewin 2000). 
When conducting a molecular study of FECH, it is important to be aware of the 
existence of a FECH pseudogene to ensure that similar sequences are not erroneously 
amplified and mistaken for the expressed gene. The characteristics of this pseudogene 













2.1.5. FECH pseudogene 
A pseudogene of approximately 30kb with overall nucleotide sequence identity of >80% 
to the functional FE.CH gene was Identified by Whitcombe et al In 1994. No 
corresponding intronic sequences in the open reading frame were identified. The 
sequence does not encode a functional protein, as numerous insertions and deletions 
disrupt the reading frame of the transcript. Multiple termination codons are dispersed 
throughout the transcript and can be identified in all three reading frames. Fluorescence 
in situ hybridisation of metaphase chromosomes localised the pseudogene to 3p22-p23 
(Whitcombe et al. 1994). Alignment of the FECH cDNA with the genomic sequence for 
this region of chromosome 3 revealed that exons 2-11 are closely homologous to the 
pseudogene with 82-93% nucleotide sequence identity but only 63% homology in the 
5'-region, including exon 1. The pseudogene is thought to be the product of reverse 
transcription of human FECH mRNA which was subsequently transposed to 
chromosome 3. Accumulation of mutations in this transcript finally resulted in a non-
functional, processed-type human FECH pseudogene n chromosome 3. No 
pseudogene transcripts were detected in human liver tissue or reticulocytes although it 















2.2. EPP - Clinical aspects 
Erythropoietic protoporphyria, unlike the other commonly encountered porphyrias, is 
characterised by the onset, in early infancy, of life-long photocutaneous sensitivity 
(Deleo et al. 1996). The partial deficiency of FECH leads to accumulation of 
protoporphyrin IX, primarily in erythrocytes, plasma, skin and liver and is responsible for 
the clinical and pathological effects of the disease (de Goeij et al. 1975~ Bloomer et aL 
1991). Although previously thought to be more common in males, both sexes appear to 
be equally affected (Cripps and MacEachern 1971, Rufener 1987; Todd 1994). In South 
Africa, the prevalence of EPP has not previously been determined. However, 17 
affected families have been documented by the lennox Eales UCT Porphyria 
laboratories, which is the major referral centre for porphyric patients in South Africa. 
The world-wide incidence of EPP is considered low. There is an estimated incidence of 
1 :75000 (Went and Klasen 1984) in the Netherlands 1: 130000 (Murphy et al. 1985) and 
1 :200000 (Elder et al. 1990), in the United Kingdom (UK), 1 :79000 in Northern Ireland 
(Todd 1993, 1994) and at least 1 :200000 in Sweden (Wiman et a/. 2003). The largest 
cohorts of patients reported to date appear in the more recent literature, viz. in Finland 
(Kauppinen and Timonen 2005: 36 patients), the UK (Whatley et al. 2004: 105 patients; 
Holmes et al. 2006: 223 patients), France (Gouya et al. 2006: 241 patients), and the 
USA (Chen et al. 2002: 34 patients and Risheg et al. 2003: 52 patients). 
2.2.1. History of EPP 
EPP was first reported in 1953 by Kosenow and Treibs and named and defined by 
Magnus et al in 1961. The patient observed by Magnus et al (1961) presented initially 
with solar urticaria, and had experienced symptoms since the age of eight. Skin 
photosensitivity was greatest in the Soret band 400-410nm with erythema, itching and 
development of weals. Urinary porphyrins were normal. Both the red cells and faeces 
contained increased amounts of protoporphyrin IX and coproporphyrin. 
The first South African case of EPP, an 11 year old male of European ancestry, was 
















2.2.2. Clinical presentation of EPP 
The clinical symptoms observed in EPP include photosensitivity to visible light and, in 
rare cases (±1-7%), fatal liver disease with cholelithiasis (Frank and Doss 1989; Baart 
de la Faille et al. 1991; Nordmann 1992; Cox 1997; Meerman 2000; A Anstey, Cardiff -
personal communication 2005). Patients describe erythema, oedema, pruritus and a 
burning sensation following short exposure to visible light (Deleo et al. 1976). A 
common observation among EPP patients is a decreasing tolerance to sunlight on 
subsequent exposures, called the "priming phenomenon" (poh-Fitzpatrick 1989). In 
contrast to other photosensitive porphyrias, cumulative damage is minor and is 
restricted to elliptical scarring on the hands and face or thickening of the skin on the 
knuckles and bridge of the nose. The lack of obvious permanent features may lead to 
diagnosis being delayed for several years (Todd 1994; Varma 2000). 
less common symptoms associated with the disease include painful changes in the 
fingernails and toenails, extreme temperature sensitivity, chills, and petechiae (Rufener 
1987). Several case reports attest to the association of anaemias with EPP (Leone 
2000; Davenport 2004), and larger studies support this. Went and Klasen found that, in 
a cohort of 200 EPP subjects, the mean haemoglobin concentration was 1.5g/dl lower 
than the mean concentration in their unaffected relatives. In a recent study in the UK, 
one third of a cohort of 223 EPP individuals were found to be anaemic (A Anstey and 
M. Badminton, Cardiff - personal communication 2006). Mild hypochromic microcytic 
anaemia is reported to occur in approximately 25% of EPP patients (Mathews-Roth 
1974; Elder 1990; Cox et al. 1998; Lecha 2003). Romeo (1977), in a review of the 
porphyrias, refers to a frequent, mild hemolytic anaemia in EPP but this is unsupported 
by data. Baart de la Faille et al (1991) reported that 50% of a personal cohort of Dutch 
patients had microcytic anaemia with iron depletion. He reported evidence that the 
circulating erythrocytes appeared to represent a young population, possibly the result of 
mild photohaemolysis 
Key et al (1992) reported two cases in whom severe haemolytic anaemia appeared to 
complicate advanced liver disease, and which was further exacerbated by the operative 
procedure associated with liver transplantation. Indeed, in the Cardiff study of 223 EPP 
individuals referred to above, anaemia was independently associated with liver disease 
in EPP. Both poor absorption of iron from the gut and inadequate haemoglobin 














The anaemia observed in EPP appears to be due to deficient iron utilisation rather than 
a deficiency of iron itself (Cox et al. 1998) and Rademakers et al (1993) observed 
mitochondrial iron deposition in patient erythroblasts to support this. Brun et al (1988) 
showed that protoporphyrin IX concentrations are lower in mature erythrocytes than in 
reticulocytes. He suggests that protoporphyrin IX may dissociate from haem binding 
sites on the globin molecule in erythrocytes as they mature resulting in lower 
haemoglobin concentrations and therefore anaemia. 
An assessment of the psychosocial aspects of EPP in 12 patients revealed that the 
patients had gradually learned how much sun they could tolerate (Rufener 1987). 
Typically, they would move indoors or into the shade whenever they sensed they would 
burn. However, school pupils found this more difficult as they felt they could not excuse 
themselves repeatedly from certain activities. Detachment from their surroundings was 
reported, as well as changes in personality, including nervousness, tension, 
aggressiveness, hypersensitivity and suicidal ideation. 
2.2.3. Biochemical diagnosis of EPP 
Biochemical diagnosis of EPP is based primarily on the presence of elevated levels of 
protoporphyrin IX in erythrocytes, blood plasma and faeces (Elder et al 1990; 
Bonkovsky and Barnard 1998; Thunnel et al 2000; Murphy 2003). An explaination for 
this accumulation of protoporphyrin IX is detailed further in sections 2.2.4 and 2.2.5. 
A rapid-screening test for raised erythrocyte protoporphyrin IX concentrations, which 
included ether/acetic acid separation followed by hydrochloric acid extraction of 
porphyrins from red blood cells (RBC), with subsequent visualisation under UV light, 
was described in 1965 by Rirnington and Cripps. Since then there have been many 
variations on this, some qualitative and some quantitative, but all have utilised 
protoporphyrin IX spectral properties. Today high performance liquid chromatography 
(HPLC) methods with fluorescence detection (Gray et al. 1977; Guo et al. 1991) and 
fluorescence methods based on Piomelli (1977) are routinely employed for assay of 












The plasma "fluoroscan", first described by Poh-Fitzpatrick (1980), is an efficient front-
line test to determine increased porphyrin concentrations in blood plasma by 
fluorescence spectroscopy and is important for the differential diagnosis of porphyrias 
(VP, EPP and PCT/AIP) (Pathak and West 1982; Meissner and Hift 2005). Plasma is 
diluted in phosphate-buffered saline and then scanned at an emission wavelength of 
570-650nm, using a fluorescence spectrophotometer set at a fixed excitation 
wavelength of 405nm. An emission maximum peak at 632nm is indicative of increased 
protoporphyrin IX and therefore EPP (Elder et al. 1990). In VP, which is also associated 
with the retention of protoporphyrin IX, the emission peak occurs at 625nm, apparently 
because in this condition the porphyrin is bound to a peptide (Lamola et al. 1981). A 
tightly bound protein porphyrin complex has been isolated from the plasma of a patient 
with VP and fluorescence studies by Lamola (1982) show that when free protoporphyrin 
IX is bound to haemoglobin (probably not at the active site), fluorescence is emitted at 
626nm (Long as and Poh-Fitzpatrick 1982). However, membrane-bound protoporphyrin 
IX has an emission maximum at 634nm (Lamola 1982). 
In South Africa it has been shown that plasma "fluoroscanning" is more sensitive and 
specific than faecal porphyrin determination for the diagnosis of VP (Meissner and Hift 
2005). However, not all symptomatic individuals with EPP display a plasma peak at 
632nm and in some samples the peak is shifted to ±625nm which is more typical of VP. 
Quantitative analysis of erythrocyte porphyrins, and/or DNA analysis, Will however 
make the distinction between VP and EPP (Atkins and Nedorost 2003; Meissner and 
Hift 2005). 
It is important to note that erythrocyte protoporphyrin IX may be raised in other 
conditions, including lead poisoning and iron deficiency anaemia (Bonkovsky and 
Barnard 1998). However, in these cases the predominant porphyrin species observed is 
zinc-chelated protoporphyrin IX (ZPP) rather than the free protoporphyrin IX 
characteristic of EPP (Lamola and Yamane 1974). In cases of lead intoxication ZPP 
accumulates in erythrocytes because lead inhibits FECH by interfering with the binding 
of iron to protoporphyrin IX (Bailey and Needham 1986; Dailey 1990). Zinc is a good 
substrate for FECH and in iron-deficiency anaemia it can be used as a substitute for 
Fe2+ when this is in short supply (Dailey et al. 2000). Zn2+ competes with Fe2+ for the 
chelatase at low iron levels, resulting in the incorporation of Zn2+ into protoporphyrin IX 
(Camadro and Labbe 1982; Camadro et aI.1984). 
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Accumulation of ZPP in the above conditions is not associated with photosensitivity 
(Rimington and Cripps 1965; Piomelli et al. 1975; Haeger-Aronson 1982). ZPP does not 
diffuse out of the erythrocytes into the plasma (Lamola et al. 1975) and thus no 
photosensitivity occurs as there is no porphyrin accumulation in the skin; in contrast to 
EPP where free protoporphyrin IX readily diffuses into the plasma and the skin. The 
absence of raised faecal levels of protoporphyrin IX in individuals with lead toxicity and 
iron-deficiency anaemia supports this explanation (Piomelli et al. 1975). 
2.2.4. Pathogenesis of photocutaneous sensitivity in EPP 
Photosensitivity associated with EPP occurs as a direct consequence of the 
accumulation of porphyrin intermediates, specifically protoporphyrin IX, in RBCs and 
the skin (Harber et al. 1982). During erythropoiesis a high rate of haem synthesis 
occurs. The partial block at the level of FECH results in an accumulation of 
protoporphyrin IX in maturing RBCs in the bone marrow. Protoporphyrin IX may diffuse 
from these cells as they circulate in the blood stream, and become bound to, amongst 
other proteins, haemopexin and albumin in the plasma (Schothorst et al. 1970; Lamola 
1982). In addition, light-induced transfer of protopor hyrin IX from RBCs to endothelial 
cells may occur because of their close proximity to dermal capillaries (Brun 1990; Brun 
and Sandberg 1991). Violet light can penetrate the skin and reach the upper dermal 
layers. When excess porphyrins in the endothelial cells are exposed to this light, 
particularly in the Soret band (400-410nm), they absorb radiant energy; raising the 
ground state orbital electrons of protoporphyrin IX to an "excited", unstable singlet state 
and subsequently to their triplet state (Todd 1994) (see Figure 2.4). The stable triplet 
state of the "excited" protoporphyrin IX allows it to react with ground-state molecular 
oxygen, and reactive oxygen species are produced, which may induce cell damage 
and/or lysis primarily via membrane lipid peroxidation (Goldstein and Harber 1972; 
Girotti 1990; Williams et al. 1994; Takeshita et al. 2004). Photodamage may not be 
confined to loss of cellular membrane integrity. Protoporphyrin IX was observed to 
accumulate specifically in Iysosomes of fibroblasts, and lysosomal membranes are also 
targets for photo-oxidation. Further damage includes cross-linking of proteins and 


















In addition to the direct consequences, "excited" protoporphyrin IX has also been found 
to activate the complement system leading to mast cell activation, generation of 
inflammatory mediators and chemotaxis of polymorphonuclear leukocytes (Lim et al. 
1984; Poh-Fitzpatrick 1985; Meerman 2000). Continuous endothelial damage and 
subsequent repair accounts for the thickened and waxy appearance of the skin, due to 
the generation of new basal lamina (Honigsmann et al. 1976; Lim 2005). Thus these 
mechanisms are likely to explain the typical buming sensation, swelling, itchiness and 
redness described by EPP patients on exposure to sunlight (Todd 1994). 
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Figure 2.4. Proposed mechanism of the pathogenesis of 











2.2.5. Pathogenesis of liver disease in EPP 
As mentioned earlier, a proportion of individuals with EPP, approximately 1-7%, 
develop liver disease (Doss and Frank 1989; Baart de la Faille et al. 1991; Nordmann 
1992; Cox 1997; Meerman 2000; A Anstey, Cardiff - personal communication 2005). 
This appears to result from the accumulation of protoporphyrin IX in the liver (Bloomer 
and Enriquez 1982). Protoporphyrin IX is not water-soluble and therefore cannot be 
excreted by the kidneys. The liver excretes the majority of the protoporphyrin IX via the 
bile and therefore high levels of protoporphyrin IX can be detected in the faeces. 
However, due to the high biliary concentration of protoporphyrin IX, crystallisation may 
occur, resulting in cholelithiasis with resultant biliary obstruction (Meerman 2000). In 
severe cases, intracellular protoporphyrin IX accumulation of the bile ducts with 
resulting clinical sequelae has been observed in Kupffer cells, hepatocytes and biliary 
canaliculi (Komatsu 2000a). 
The porphyrin excretory spectrum appears to change in EPP individuals with end-stage 
liver disease. Normally, the porphyrin profile in urine is normal and high levels of 
protoporphyrin IX are recorded only in the faeces. In patients with advanced liver 
disease, urinary uroporphyrin and coproporphyrin concentrations are also significantly 
elevated while faecal uroporphyrin, coproporphyrin and mesoporphyrin concentrations 

















2.3. EPP - Molecular aspects 
Incomplete penetrance is a feature of many of the porphyrias, including AlP and VP 
(Wang et al. 1995)~ There has, however, been long-standing debate over the mode of 
inheritance of EPP. In 1984 Went and Klasen proposed a three-allele system to explain 
the inconsistent inheritance of EPP. In their study of 200 patients, representing 91 
Dutch families, they concluded that the genetic model of disease pointed to a recessive 
mode of inheritance, yet the pattern and presence of an occasional fluorescent red cell 
within family members was autosomal dominant in nature. Thus the mode of 
inheritance of EPP has been described as autosomal dominant with incomplete clinical 
penetrance (10-20%) (OMIM +17700). Indeed, the apparent discordance in disease 
manifestation between the patient and carrier parent has been particularly puzzling in 
many EPP studies, at least until recently~ 
2.3.1. Inheritance of EPP 
An autosomal dominant disease, by definition, requires a single deleterious allele for 
disease expression~ Where an enzyme is defective as a result of a dominant disorder, 
one would expect to measure an approximate 50% reduction in catalytic activity, as the 
wild type allele would continue to produce normal protein. However, individuals who are 
heterozygous for FECH mutations exhibitt50% normal activity and are typically 
asymptomatic (Gouya et al. 1996; Cox et al. 1998), while symptomatic EPP patients 
consistently show 15-25% FECH activity even in the absence of clear evidence of 
compound heterozygosity (Brenner et al. 1992; Schneider-Yin 2000). 
That said, a few cases have been reported in which EPP is inherited in a true 
autosomal recessive manner, as a result of compound heterozygosity (Lamoril et al. 
1991; Sarkany et al. 1994a; Poh-Fitzpatrick et al. 2002; Whatley et al. 2004). The 
prevalence of true recessive inheritance of EPP in the UK and France has been 
reported as 3% and 4%, respectively (Whatley et al. 2004; Gouya et al. 2006) 
An early mechanism proposed for the difference in FECH activity between symptomatic 
and asymptomatic individuals with, apparently, a single mutated allele is a dominant-
negative effect from the deleterious FECH allele. As FECH is a homodimer, it is 
possible that the holoenzyme may only be active if it contains two wild type subunits. 
The presence of a mutant subunit in the dimer would inactivate the wild type subunit 
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resulting in total loss of activity (Brenner et al. 1992; Wu et al. 2001). This has been 
debated (Sarkany et al. 1994b; Wang et al. 1994; Gouya et al. 1996). Indeed, Ohgari et 
al (2005) showed that a dimer consisting of one mutant and one wild type FECH 
molecule is active, the degree of activity depending on the mutation. However, enzyme 
activity was less than 50% of a wild type homodimer, suggesting that only the wild type 
subunit functioned in catalysis. Najahi-Missaoui and Dailey (2005) confirmed that wild 
type/mutant type heterodimers have between 0 and 50% enzyme activity. They 
proposed that a subset of FECH mutations, particularly those that disrupt the [2Fe-2S] 
cluster, or are present at the dimer interface, may give the EPP clinical phenotype via 
this dominant-negative mechanism, even in the absence of the disease-associated 
IVS3-4BC polymorphism (the role of this polymorphism in EPP will be described below). 
Whether this mechanism operates in EPP families has yet to be established. 
More recently, the >50% reduction in FECH activity in symptomatic patients with EPP 
has been ascribed, in the majority of families, to the co-inheritance of a 'low-expression 
allele' in trans to a deleterious allele (Gouya et al. 1996). These authors confirmed that 
symptomatic disease was associated with the inheritance of a specific allele from the 
non-carrier parent in trans to the allele associated with the deleterious mutation. They 
confirmed that this allele resulted in reduced expression of FECH giving <25% normal 
FECH activity in the symptomatic individual with a FECH mutation, in contrast to 50% 
activity in asymptomatic siblings carrying the same mutation. 
Later, they were able to find an association between this 'low-expression' allele and a 
specific haplotype [-251 G; IVS1-23T; IVS2psatA9] which, in turn, led to more accurate 
risk calculation for genetic counseling (Gouya et al. 1999). 
Interestingly, an individual who inherits two 'low-expression' alleles does not show any 
clinical or biochemical evidence of EPP (Gouya et al. 1999; Schneider-Yin et al. 2000). 
They concluded that the inheritance of this 'low-expression' allele is a requirement for 
symptomatic EPP, suggesting that when FECH activity falls below a critical threshold 
excess protoporphyrin IX cannot be cleared by the liver and photosensitivity results 
(Gouya et al. 1999). This mechanism of disease has been observed for hereditary 
elliptocytosis, where the degree of clinical manifestation is increased when the a-
spectrin gene is expressed at a low level in trans to a mutated allele (Alloisio et al. 
















Currently, the modulation of the penetrance of EPP by this wild type 'Iow-expression' 
FECH allele has been found to be directly associated with a single intragenic 
polymorphism (IVS3-48C) that was present in 38/40 French EPP patients investigated 
by Gouya et al in 2002 and confirmed in larger cohorts in 2004 and 2006. 
This hypomorphic allele, which is estimated to be the result of a single mutational event 
that occurred 60 000 years ago (Gouya et aL 2006), was found to have a frequency of 
11% in the French population. The presence of the IVS3-48C polymorphism in intron 3 
prompts the use of a cryptic acceptor splice site 63 bases upstream from the normal 
splice site (Figure 2.5.). This cryptic splice site is used constitutively whether the allele 
carries a "r" or a "C' at this position. However, the ratio between correctly spliced 
mRNA molecules and incorrectly spliced mRNA molecules changes from 80:20 to 
60:40 when the "C" is present Aberrantly spliced mRNA molecules are degraded by the 
nonsense-mediated decay mechanism because a premature stop codon is created. 
Thus, wild type ferrochelatase concentrations are reduced to below a critical threshold 






tagAAAACATTTCTCAGGTTGC TAA .. . 
STOP 
Figure 2.5. Schematic representation of the use of an alternative splice-site in 
the presence of the IVS3-48C polymorphism (Gouya et aL 2002) 
It is interesting that in 1994, Wang et al had suggested an association of a 
polymorphism with the pathogenesis of EPP, the IVS1-23T polymorphism. Henriksson 
et al (1996) confirmed that this IVS1-23T allele occurred more frequently among EPP 
patients than among the normal Finnish population. This polymorphism has 
subsequently been found to be in linkage disequilibrium with the IVS3-48C 











The presence of a hypomorphic FECH allele containing this IVS3-48C polymorphism in 
individuals presenting with EPP, and its role in clinical expression of the disease, has 
been confirmed in a few populations, including people of French (Gouya et at 1999, 
2002), Swiss (Schneider-Yin et aL 2001), North American (Wang et al. 1999; Chen et 
al. 2002; Risheg et aL 2003), Swedish (Wiman et aL 2003), British (Whatley et aL 2004) 
and Japanese origin (Yasui et al. 2002; Onaga e1 al. 2004) as well as one Israeli patient 
(Schoenfeld et aL 2003). 
Recent studies by Gouya et al (2006) have shown that the frequency of this IVS3-48C 
polymorphism differs amongst populations. The highest frequency was observed in 
Japan (43%) and the lowest in West Africa «1%). These authors propose that the 
prevalence of symptomatic EPP in a population would be determined by the frequency 
of the IVS3-48C polymorphism In the respective population (Gouya et aL 2006; Nakano 
et al. 2006). 
Interestingly, only a few black (African-American) EPP cases have been reported to 
date (Todd 1994; Baran and Juhlin 2002; Elliot et at. 2004) and no case of EPP in a 
Black African subject has been reported (Gouya et al. 2006). The prevalence of EPP in 
Japan has not been precisely determined; however, a study of this nature has been 
proposed in the light of the reported high prevalence of the IVS3-48C polymorphism in 
Japan (Nakano et al. 2006). 
The terminology used to describe the inheritance of EPP has been confusing. Thus 
terms such as 'complex mode of inheritance' and 'compound heterozygous disorder' 
(Risheg et al. 2003), 'pseudodominant' (Gouya et al. 2006), 'autosomal dominant' and 
'autosomal recessive' have been used (Cox et al. 1998). However, as mentioned 
earlier, in contrast to a classical autosomal recessive disorder, homozygosity for the 
IVS3-48C polymorphism does not cause disease (Badminton and Elder 2005). Thus it 
is probably best to regard EPP as a 'pseudodominant' condition in which penetrance is 














2.3.2. EPP in the absence of the IVS3-48C polymorphism 
Though co-inheritance of the IVS3-48C allele appears to accompany most cases of 
EPP. cases have been reported where the IVS3-48C allele is absent (Risheg et al. 
2003; Wiman et al 2003). and other genetic, epigenetic and/or acquired factors are 
predicted to playa role in modulating the phenotype. Recessive inheritance is the most 
common explanation for disease expression in the absence of the IVS3-48C 
polymorphism as, even in cases where a second mutation is not identified, it is possible 
that more stringent screening would reveal other FECH variations (Whatley et al. 2004). 
The dominant-negative mechanism described above is a further possibility. 
Hypermethylation or point mutations affecting the SP1 binding site of the FECH 
promoter have also been reported to modulate disease phenotype (Onaga et al. 2004; 
Oi Pierro et al. 2005). Lastly. acquired, late-onset EPP has been described in an 
individual with myelodysplastic syndrome in whom there was deletion of the long arm of 
chromosome 18, which included the FECH gene, in haematopoietic cells with 
subsequent clonal expansion (Aplin et al. 2001). Late-onset EPP has also been 
associated with myelogenous leukemia and myeloproliferative disorder and is likely to 
be the result of acquired somatic FECH mutations in bone marrow (Goodwin et al. 
2006). 
2.3.3. Genetic heterogeneity of EPP 
EPP is characterised by allelic heterogeneity of the FECH gene (Taketani and Fujita 
1995) The Human Gene Mutation database (http://www.hgmd.org) records 88 
mutations identified in the FECH gene to date (15/06/06). Analysis of these mutations 
reveals three main categories: 1) Nucleotide substitutions (38%). which include both 
missense and nonsense mutations caused by single base changes in the coding 
region, 2) Frameshift mutations (32%), from insertions or deletions, that may result in 
premature stop codons and 3) Splice-site mutations (27%), which cause exon-skipping. 
The remaining mutations (3%) include one gross deletion, one complex rearrangement 














Early reports suggested exon skipping to be a common genetic defect in EPP (Wang et 
aL 1993) In particular, the loss of exons 2, 4 or 6 is predicted to cause frameshifts 
resulting in premature stop codons, whereas skipping of exons 3, 5, 7, 8, 9 or 10 would 
not disrupt the reading frame. In reality, the product is likely to be non-functional 
regardless of which exon is skipped, as loss of any of exons 3-11 of FECH resulted in 
an inactive enzyme that lacks a [2Fe-2S] cluster. This is most likely a result of 
significant altering of the structure of the protein so that the cluster cannot be 
coordinated (Sellers et al. 1998) 
As of 2005 ±80% of all identified mutations were 'null-allele' mutations in which either 
no enzyme is produced or the resulting protein is non-functional (Ohgari et al. 2005). 
Mutations are scattered throughout the gene and no confirmed mutation 'hot-spots' 
have been identified for FECH (lmoto et al. 1996; Schneider-Yin et al. 2000). However, 
haplotype analysis of a 'g(+5)-a' transition in exon 1 in 4 American families of European 
ancestry revealed three distinct haplotypes associated with this mutation suggesting a 
'hot-spot' in this region (Wang 1999). 
The disease-causing mutations that have been identified, referred to as primary 
mutations in this dissertation, are largely family-specific. The first report of a FECH 
mutation occurring in more than one family was in Northern Ireland. Todd et al (1993) 
reported a deletion of a single base (40deIG) found in 3 out of 6 families studied, and 
suggested that this was the most common mutation in the UK. A Swiss study reported 
that the mutations identified in their population were mostly shared by more than one 
family (Rufenacht et al. 1998). Recently, specific mutations have been described in a 
number of different countries around the world e.g. IVS3+2T/G in the UK, USA and 
France (Sarkany et al. 1994; Bloomer et al. 1998; Chen et al. 2002; Gouya et al. 2006). 
Two de novo mutations for EPP, 'Ala155-Pro' and '1122delr, were reported by 






















2.3.4. Genetic basis of EPP-related liver disease 
A contentious question is whether liver disease, which is far less common than 
photosensitivity in patients with EPP, is associated with a particular genetic 
predisposition. The onset in adolescence of fulminant hepatic failure in two affected 
siblings with recessive EPP led Sarkany et al (1994) to suggest that liver disease is 
associated with compound heterozygosity. However, this does not seem to be a 
prerequisite, nor a common association for the development of liver disease in EPP 
(Bloomer et al. 1998). Further support for a higher risk of liver disease in recessive 
inheritance of EPP has been provided by Whatley et al (2004) in a study conducted on 
105 randomly selected EPP cases. Other studies have proposed that a 'null-allele' 
mutation in the deleterious FECH allele may also predict hepatic involvement (Chen et 
al. 2002; Schoenfeld et al. 2003). It is also possible that acquired factors may contribute 
to reduced FECH activity during progression of liver disease (Bloomer et al. 1998, 
2006) and researchers may need to investigate loci apart from FECH to explain 
susceptibility to EPP liver disease. Recent investigations include DNA microarray 
analysis of liver tissue from individuals who underwent a liver transplant in order to 
investigate hepatic gene expression (Bloomer et al. 2005). Simifarly, attempts to link the 
'severity' of a mutation to FECH activity and to liver disease have not yielded conclusive 
results. 
A single case in a Japanese patient with EPP and fatal liver failure has been described 
in which it is possible that altered methylation patterns in the FECH promoter region, in 
cis to the IVS3-48C polymorphism, led to further reduced expression of the wild type 
allele (Onaga et al. 2004). Hypermethylation near a transcription initiation site is 
proposed to inhibit gene transcription by inhibiting basal transcription machinery (de 
Smet et al. 1999). Thus, epigenetic inheritance of the hypermethylated promoter, in 
addition to a primary mutation and the IVS3-48C polymorphism, may have been an 
additional factor in the expression of this patient's disease. Indeed, very low levels of 















In general, although attempts have been made to correlate a specific FECH genotype 
with the liver-disease phenotype, with a view to predicting the risk of serious liver 
damage in EPP individuals, the link remains elusive. Thus it appears that detailed 
characterisation of the genetic defect responsible for EPP in an individual cannot 
directly assist in allowing prevention or early detection of liver disease. However, such 
studies are essential for collecting data other information necessary to work towards a 
better understanding of the genotype-phenotype relationship in EPP. 
2.4. EPP - Management 
2.4.1. Photocutaneous sensitivity 
Treatment of EPP skin disease primarily involves measures to limit sun exposure, such 
as topical barrier sunscreens, protective clothing and window filters (Meerman 2000; 
Kauppinen 2005). Narrow band UV B therapy may improve tolerance to sunlight (Baart 
de la Faille et aL 1991; Roelandts 1995). The only systemic medication that is effective 
in EPP for sun protection is J3-carotene (Mathews-Roth 1970; Alemzadeh and Feehan 
2004). The beneficial effects of J3-carotene occur through two probable mechanisms. 
Firstly, it acts as a free radical scavenger, decreasing oxidative damage, and secondly, 
it causes colouration of the skin helping to create a 'light barrier' (Krook and Haeger-
Aronsen 1982). However, the efficacy of this treatment is variable amongst patients 
(Schneider-Yin et aL 2000). 
Anstey (2002) showed that J3-carotene absorbs only weakly at 41 Onm and can therefore 
not be considered an 'optical filter'. Many conventional topical sun creams and lotions 
offer very little, jf any, protection as they do not block visible light of the relevant 
wavelength (Deleo et aL 1976; Mathews-Roth 1977). Tolerance to light depends 
largely on the individual patients, who quickly learn the amount of exposure they can 
withstand (Rufener 1987). They are encouraged to maintain short regular exposures to 













Alternative agents for treatment have been tried. Antihistamines, antimalarials and both 
topical and systemic corticosteroids have been tested in the treatment of EPP, but with 
little success (Deleo et al. 1976). Other systemic treatments include adenosine 
monophosphate, inosine, indomethacin, vitamins C and E, pyridoxine and oral zinc 
(Deleo et al. 1976; Todd 1994). However, none of these were evaluated by controlled 
studies and conflicting results were obtained. A review of both vitamin E (a-tocopherol) 
and l3-carotene treatment concluded that more experimental work needed to be 
conducted to determine the efficacy of a-tocopherol, but that l3-carotene might be 
useful in EPP (Anstey 2002). The potential efficacy of dihydroxyacetone (DHA) that 
results in brown colouring of the skin was discussed by Todd in 1994. Excellent results 
were achieved by Fusaro and Runge (1970) with this treatment in 7 patients and it was 
recommended that DHA be combined with the application of topical sunscreens. 
Terfenadine, an H1 receptor antagonist, inhibited the immediate flare response elicited 
in response to exposure to blue light in seven patients. Although the localised 
'erythemal response' was not altered, they suggested that this might be used in the 
treatment of EPP as it functions via a different mechanism to l3-carotene (Farr et al. 
1990). After the initial report of the use of cysteine to ameliorate photosensitivity in EPP 
patients (Roberts and Mathews-Roth 1993) a 3-year placebo-controlled phase III trial 
provided some evidence for the efficacy of cysteine in increasing the tolerable 
exposure-time of patients to light. It was offered as an alternative to l3-carotene for 
patients who either do not benefit from this treatment, or who are unwilling to develop 
carotenodermia (Mathews-Roth and Rosner 2002). There has been a single report on 
an EPP patient where dietary fish oils (omega-3 marine triglycerides) were beneficial in 
reducing the length of time that the symptoms persisted after exposure (Chakrabarti 
and Tan 2002). 
A second carotenoid, canthaxanthine, has been used to ameliorate EPP, often in 
combination with l3-carotene. Phenoro®, which contains canthaxanthine and l3-carotene, 
was used with some success for approximately 10 years. However, patients were found 
to develop crystalline deposits in the retina after using Phenoro® for a number of years, 














It is unclear whether iron therapy helps or hinders EPP patients. Milligan et al (1988) 
reported four cases of patients treated with oral iron who showed striking deterioration 
in the symptoms and biochemistry of their EPP; withdrawal of therapy was associated 
with improvement. Holmes et al (2006) discuss the place of iron supplementation in the 
management of anaemic patients with EPP (A. Anstey and M. Badminton, Cardiff -
personal communication 2006). The literature is contradictory, with reports both 
supporting (Gordeuk et al. 1986; Mathews-Roth 1974) and refuting (Milligan et al. 1988; 
McClements et al. 1990) treatment In their own patients (Holmes et al. 2006), 6 of 18 
patients receiving iron supplementation reported an increase in symptoms, 2 an 
improvement and 10 were unchanged. 
2.4.2. Liver disease 
EPP patients are encouraged to visit their physician regularly for liver function tests. 
Protoporphyrin IX concentrations should be checked every 6-12 months (Lecha 2003), 
which is essential for the early detection of liver disease, although hepatobiliary 
complications may still go unnoticed until the late stages of disease as patients with 
liver damage may present with normal liver enzymes (Meerman 2000; Kauppinen 
2005). In patients with protoporphyrin-induced liver dysfunction, measures to reduce 
production and enhance excretion of protoporphyrin IX may slow or halt the progress of 
liver disease. These include reducing the blood/plasma protoporphyrin IX concentration 
by plasmapheresis (Do et al. 2002), increasing the haem concentration by iron loading 
or haem arginate infusion or by increasing alimentary excretion of protoporphyrin IX 
with oral sorbents such as activated charcoal cholestyramine (Cox et al. 1998; Frank 
and Doss 1991). Treatment with a-tocopherol in a case of liver cirrhosis appeared to be 
beneficial in treating an EPP patient described by Komatsu et al (2000b). 
Protoporphyrin IX concentrations decreased, suggesting that a-tocopherol may be 














Red blood cell transfusion, to suppress haem synthesis, has not generally been 
accepted as a treatment for EPP (Rufener 1987; Todd 1994). In a study of two patients 
with liver disease, Eichbaum et al (2005) reported that this treatment was more effective 
than plasmapharesis at reducing circulating RBC protoporphyrin IX concentrations, 
although neither prevented progression to liver failure. 
Administration of chenodeoxycholic acid was observed to result in reduced 
concentrations of faecal and biliary protoporphyrin IX, suggesting that this treatment 
may decrease the production of protoporphyrin IX, specifically in the liver (van Hattum 
et al. 1986). Even though EPP patients do not suffer from acute attacks, it is particularly 
important for them to avoid alcohol and cholestatic or hepatotoxic medication, to 
minimise liver damage (Rufener 1987 and Kauppinen 2005). Alcohol was found to 
reduce FECH activity, potentially resulting in greater accumulation of protoporphyrin IX 
and an increase in the risk of liver disease (Doss et al. 2000). When these measures 
fail, liver transplantation becomes the only option (Nordmann 1992; Cox et al. 1998). 
If surgery is required, preparatory steps are necessary to reduce porphyrin 
concentrations and consequent photosensitivity. Plasmapheresis and haem therapy (to 
filter out porphyrins and reduce haem synthesis, respectively) were used to stabilise a 
patient requiring a liver transplant both before and after the transplant (Do et al. 2002). 
Special precautions must be taken to protect individuals from harsh theatre lights. 
These include the use of special filters to block harmful wavelengths and minimise 
exposure of internal organs to the lights (Shehade et al. 1991; Todd and Burrows 1992; 
Yotsumoto et al. 2003). 
2.4.3. General considerations 
In all cases correct and early diagnosis of EPP is essential for effective management. 
All clinical or suspected diagnoses should be confirmed in the laboratory. The mainstay 
of EPP laboratory diagnosis is RBC protoporphyrin IX concentration. This has been 
discussed previously (section 1.2.1, pg. 7). Mutation detection may confirm a diagnosis 
of EPP, and is the only reliable way to identify carriers of a deleterious gene in families 
where the mutation is known (Henriksson et al. 1996). It is now clear that the IVS3-48C 
polymorphism is highly significant in determining clinical expression of EPP. Therefore 
the determination of the IVS3-48C polymorphism status of individuals from EPP families 



















For example, the identification of a non-carrier parent who is homozygous for the IVS3-
48C polymorphism simplifies genetic counselling and the determination of risk as, in 
this case, there is a 50% risk of having an affected child. This is important in cases 
where parents would choose not to have children rather than take the risk of having a 
child affected with EPP. Prenatal diagnosis by determination of the primary FECH 
mutation and IVS3-48C polymorphism status is not considered appropriate, as 
termination of pregnancy is not regarded as justified in a disease where a normal life-
span can be expected (Morris et al. 2002). 
2.5. Animal studies and potential therapies 
2.5.1. Animal models 
In early models, protoporphyria was induced in albino mice by the administration of 
griseofulvin (a FECH inhibitor) followed by repeated exposure to long-wave UV light in 
the 410nm range. Mice presented with thick, waxy lesions that were clinically, 
histologically and microscopically identical to the skin lesions observed in EPP (De 
Matteis and Gibbs 1975; Hbnigsmann et al. 1976). This model has subsequently been 
used to investigate gene expression profiles (mRNA levels) of FECH, ALAS and haem 
oxygenase-1 and is reported as appropriate for studying the pathogenesis of EPP-
associated skin and liver disease (Inafuku et al. 1999; Plbsch et al. 2002; Gant et al. 
2003; Takeshita et al. 2004). 
The first genetically determined mouse model for human EPP was obtained from a 
chemical mutagenesis experiment using ethylnitrosourea (Tutois et al. 1991). The 
mutation was later characterised as a methionine to lysine SUbstitution at amino acid 
position 98 in FECH (80ulechfar et al. 1993). Transmission of the disease was 
recessive, with homozygotes displaying photosensitivity and liver dysfunction with 
jaundice from an early age. FECH activities in the homozygotes were <10% of the 
normal control (Tutois et al. 1991). The severity of the phenotype obtained in this model 
was of limited relevance to the more commonly encountered and less severe 
presentation of human EPP, but it did provide the first mouse model for the study of 
phenotypes associated with liver disease (810ks et al. 2001; Abitol et al. 2005; Davies et 
al. 2005). Indeed, these mice have been further investigated (see section 2.5.2, pg. 36) 
with a view to better understanding the pathophysiology of EPP by performing bone 














Further transgenic mouse models have been generated to analyse the promoter region 
of FECH in order to investigate the regulation of FECH concentrations in erythroid and 
non-erythroid tissues. An extended region 4kb 5'-upstream of the FECH gene was 
found to correspond to a DNase 1 hypersensitive site and is necessary for increased 
expression levels in erythroid tissue (Magness et al. 1998). A second EPP mouse 
model has been established, in which a FECH ex on 10 deletion, a common mutation in 
human EPP, was introduced into the mouse by gene targeting (Magness et al. 2002). 
These mice displayed FECH activity near the threshold for phenotypic expression and 
could be of relevance to human EPP studies by providing insight into the contribution of 
environmental and genetic factors to the expression of the disease. 
A knock-out mouse model for the breast cancer resistance protein (BCRP/ABCG2) 
mouse homologue (Bcrp1) has shown that this protein may protect against dietary-
induced protoporphyria. Mice presented with increased concentrations of 
protoporphyrin IX and displayed photosensitivity when fed with pheophorbide a (a 
chlorophyll break-down product). The authors suggest that BCRP may be involved in 
handling of endogenous porphyrins and, specifically, the clearance of excess 
protoporphyrin IX as this molecule is structurally similar to pheophorbide a (Jonker et al. 
2002). A genetic defect in the BCRP gene may represent another mechanism whereby 
the phenotypic expression of EPP may be modulated in the absence of the IVS3-48C 
polymorphism (Zhou et al. 2005). 
2.5.2. Correction of the FECH deficiency 
Gene therapy, the transfer of wild type FECH genes or cDNA to target cells to correct 
the genetic defect associated with EPP, may be possible in the future. Long-term cure 
of photosensitivity in EPP mice was obtained using pre-selective gene therapy, though 
with no improvement in liver damage (Pawliuk et al. 1999). This method was later 
successfully refined to enable the use of fluorescence-based selection of genetically 
corrected cells, eliminating the need for potentially harmful gene markers (Fontenellas 
et al. 2001). More recently, Richard et al (2001) reported correction of skin 
photosensitivity in the above EPP mouse model using an erythroid-specific lentiviral 















In 2004, Richard et al described a dual gene therapy in which the correction and in vivo 
expansion of deficient transduced hemopoietic stem cells was obtained, resulting in an 
increase in normal RBCs and complete correction of skin photosensitivity, thereby 
improving the efficacy of this procedure stili further. 
There is some evidence that bone marrow transplantation may be beneficial in the 
treatment of EPP (poh-Fitzpatrick et al. 2002). An individual with recessive EPP and 
acute myelogenous leukemia showed marked reduction in circulating protoporphyrin IX 
concentrations, and a concomitant reduction in photosensitivity after receiving bone 
marrow from her brother who was a carrier of only one FECH mutation. In light of this, a 
recent study showed that bone marrow transplantation from wild type mice resulted in 
minimal skin photosensitivity and no liver disease in EPP mice 16-months post-
transplantation (Pawliuk et aL 2005). They showed that normal FECH activity in hepatic 
and dermal cells is sufficient for amelioration of these symptoms and suggest that more 
localised treatment of exposed areas may allow patients to engage in outdoor activities. 
However, this remains controversial (Elder 2005; LeBoulche and Mathews-Roth 2005), 
and further investigation will be necessary to ascertain whether symptomatic relief from 
localised increase in FECH concentration is possible in humans. 
LeBoulche and Mathews-Roth (2005) conclude that "the ideal way to treat EPP is to 
replace or correct the deleterious ferrochelatase gene in haematopoietic stem cells", 
using the methods described by Pawliuk et al (1999) and Poh-Fitzpatrick et al (2002) 
mentioned above. Presently the risks involved in these procedures, however, do not 
warrant their use in diseases such as EPP that are rarely life-threatening. In future we 
anticipate that techniques to reduce these risks will be identified and that gene or bone 



























Aims and Objectives 
The molecular basis of EPP in South African families has not been established to date. 
This is probably because symptomatic EPP is relatively rare, and research has been 
directed towards VP, which is uniquely common in South Africa. Although rare, the 
diagnOSIs and management of this condition, within the South African context, would be 
better facilitated by a systematic characterisation of EPP families. 
3.1. Initial aim: 
The overall aim was to evaluate EPP in a cohort of South African families at a 
molecular (genotypic) level. This involved: 
a) the identification of sequence variations in the FECH gene in EPP subjects, 
to determine which are likely to be responsible for EPP in each family. 
b) the investigation of the IVS3-48C polymorphism, reported to result In 
reduced expression of the FECH allele, and its association with EPP in the 
South African cohort of symptomatic individuals. 
Thus, the initial objectives were: 
i. to assess previously and newly diagnosed symptomatic EPP subjects associated 
with our Centre in Cape Town, and to obtain relevant information and 
biochemical data, where appropriate; 
Ii. to identify FECH sequence variations in EPP subjects and establish family-
specificity, and the likelihood that the variation(s) islare disease-associated; 
III. to employ restriction endonuclease analysis in order to assess the frequencies of 
identified variations, including the IVS3-48T/C polymorphism, in a cohort of 











In the light of results obtained in pursuing the above opjectives, we investigated the 
possibility that the 757_761 delAGAAG FECH mutation identified was the result of a 
single ancestral event. 
3.2. The aim of this additional study was therefore: 
To establish whether individuals heterozygous for the 757 _761deIAGAAG deletion 
shared a common haplotype across FECH and, if so, to determine the prevalence of 
the alleles associated with the haplotype in a control population. 
Thus the objectives were: 
I. to identify microsatellite markers across FECH and complete genotyping of a 
cohort of symptomatic and asymptomatic family members and a matched 
control cohort for these markers; 
II. to construct pedigrees for manual allele segregation determination and 
haplotype analysis for identification of the haplotype associated with the 
757 _761 delAGAAG deletion in each family; 
III. to compare these haplotypes With those associated With the other, distinct 
disease-causing mutations that were identified; 
IV. to assess the frequencies of the alleles associated with the most common 


























Materials and Methods 
4.1. Subject recruitment and control selection 
The Lennox Eales Porphyria Laboratories of the University of Cape Town is the primary 
referral centre for the diagnosis and management of all forms of porphyria in South 
Africa. The index subjects of the EPP families in this study were originally referred to 
this Centre for assessment by Prof Richard Hift (Clinical Director). They were, for the 
purposes of this study, identified from the UCT Porphyria Laboratories database, 
hospital records and correspondence received by the Centre. Where family members 
had not already been screened for EPP, blood samples were obtained and tested 
biochemically. Subsequent to our initial selection, further EPP subjects referred to the 
Centre during the course of the study were included in the EPP cohort on positive 
screening. 
The study received Ethics approval in November 2004 from the UCT Research Ethics 
Committee (408/2004). Inclusion of subjects in the EPP cohort was based on clinical 
and biochemical criteria. The clinical criteria included: a) a history of photocutaneous 
sensitivity beginning in childhood and b) burning, swelling, itching and/or redness of the 
skin after exposure to visible light, often continuing for a number of days. The presence 
of elliptical scarring and thickening of the skin, particularly of exposed areas, was an 
additional indicator for diagnosis of EPP. The primary biochemical criterion was a raised 
erythrocyte protoporphyrin IX concentration exceeding 1000nmollL. 
The EPP cohort, consisting of all symptomatic individuals evaluated, was later extended 
to include available asymptomatic family members and designated the "study cohort" 
DNA samples of control subjects were available in the Porphyria Laboratories as they 
had been collected previously for use in an unrelated study and anonymised. Thus, a 
control cohort of 100 samples was randomly selected out of an ethnically matched 











4.2. Subject and family interview and blood sample collection 
EPP subjects and their families living in the Cape Town region were visited in their 
homes in order to collect samples and subject information. Informed consent (Appendix 
A) from each individual contributing blood samples was obtained in accordance with the 
UCT Ethics Committee which adheres to the Declaration of Helsinki, October 2000. 
Strict regulations for patient confidentiality were adhered to. Subject information 
(Appendix A) was recorded in a password-protected data sheet for sole use by 
individuals directly involved in the project. 
In addition to completing the consent form and subject information sheet, symptomatic 
individuals were subjected to a structured interview using a questionnaire (Appendix 8). 
Individuals residing outside the Cape Town region were asked to visit a pathology 
laboratory where samples were drawn and forwarded to the Porphyria Laboratories. 
The consent form and information sheets were mailed to these subjects for completion 











4.3. Biochemical diagnosis of EPP 
4.3.1. Preliminary red blood cell porphyrin screening 
The fluorescent property of porphyrins provides a rapid screening method for their 
identification in various tissues. including blood. Generally. the higher the concentration 
of porphyrin in the sample, the greater the fluorescence observed. Whole blood 
collected in 5ml EDTA tubes was screened for increased red blood cell porphyrin 
concentration in the presence of UV light (Appendix C). 
4.3.2. Plasma fluorescence scanning 
Plasma fluoroscanning is a sensitive, efficient screening method for detecting increased 
porphyrin concentrations in the plasma and differentiating between the porphyrias (Poh-
Fitzpatrick 1980). The basis of this method is, as above, that of porphyrin fluorescence 
and relies on the property of different porphyrins to fluoresce at different wavelengths. 
Diluted plasma was scanned using a fluorescence spectrophotometer from 580nm to 
700nm and a peak at 630-635nm was indicative of increased protoporphyrin IX 
(Appendix C). The area under the peak represented the protoporphyrin IX concentration 
of the sample. 
4.3.3. Porphyrin quantitative analysis 
Extracted, esterified porphyrins were separated by thin-layer chromatography using 
standard methodology developed and used routinely in the Porphyria Laboratories (Day 
1978; Hift et aL 2004). The method is based on the fluorescence of porphyrins when 
exposed to light with a wavelength of -400nm (Moore et al. 1987). Packed red blood 
cells were esterified by incubation in 5% H2S04 in methanol. Porphyrins were then 
extracted with chloroform as detailed in Appendix C. Porphyrin quantitation was 
performed by photodensitometric fluorescence scanning and compared with standard 
porphyrin mixtures of known concentration. Results were expressed in nmol/L. 
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4.3.4. Determination of free and zinc-chelated protoporphyrin IX concentrations in 
EPP blood samples 
Samples with elevated red blood cell protoporphyrin IX concentrations may contain both 
free and zinc-cheJated protoporphyrin IX. EPP is specifically associated with increased 
concentrations of free protoporphyrin IK The proportion of free protoporphyrin IX to 
zinc-chelated protoporphyrin IX in a sample was determined by extraction with acetone, 
as described by Hart and Piomelli (1981). This method reliably distinguishes between 
free and zinc-chelated protoporphyrin IX based on their distinct emission wavelength 
(Appendix C). 
4.4. DNA isolation 
Molecular methods used to characterise genetic factors in disease generally depend on 
the extraction of high-quality DNA. Isolation of DNA is based on: 1) lysis of the cell 
membrane and the nuclear envelope; 2) removal of contaminating molecules e.g. 
proteins, and 3) precipitation of DNA using alcohol (Jones et al. 1994) 
Blood samples collected in 5ml EDTA tubes were initially stored at 4"C and processed 
as soon as possible. High-purity genomic DNA isolations were performed Llsing the 
Wizard Genomic DNA purification kit. The protocol, as supplied in the kit, was followed, 
with minor modifications as detailed in Appendix D. The isolated DNA was quantified, 
and the purity determined. Stock DNA solutions and remaining blood samples were 
stored at -70G C. 
An isoamyl alcohol:chloroform "clean-up" of previously isolated and stored DNA 











4.5. Analysis of the FECH gene 
4.5.1. Fragment amplification by polymerase chain reaction 
The objective of PCR is to generate large quantities of a specific DNA fragment in vitro 
for further analysis. It is based on the complementarity of DNA that allows copies of a 
single-stranded DNA fragment to be made in the presence of a polymerase. 
Synthesised primers complementary to the 5'- and 3'-ends of the fragment provide the 
free 3'-OH groups for the addition of deoxynucleoside triphosphates (dNTPs) 
complementary to the template strand, and the start and end-points for amplification, 
respectively. 
The chromosome 18 genomic DNA sequence (NT _025028) on which the FECH gene 
lies, as well as the protein (P22830) and mRNA (NM_000140) sequences, were 
obtained from the National Centre for Biotechnology Information (NCBI) database 
(http://www.ncbi.nlm.nih.gov). Annotation of the gene was performed using the 
annotation program ANN01V9 (designed by Dr George Rebello, Division of Human 
Genetics, UCT) 
Primers for the amplification of each of the 11 exons of FECH were designed using the 
Primer3 software package (http://www-genome.wi.mit.edu/cgi-bin/primer/ 
primer3_www.cgi). All fragments were between 250-350bp in length, included the 
intron-exon boundaries and, where possible, were placed 60bp into the intron on either 
side of the exon. The criteria for primer selection are listed in Appendix E. The 
annealing specificity of newly designed primers was evaluated by searching for 
genome-wide sequence similarity using the standard nucleotide NCBI BLAST (Basic 
Local Alignment Search Tool) (http://www.ncbi.nlm.nih.gov/blast). 
Optimum annealing temperatures (Table 4.1) were determined using a temperature 
gradient of 51-65"C on the Robocycler Thermal Cycler. Amplification of all 11 FECH 
exons was subsequently performed. peR reactions were set up as described in 
Appendix E. PCR amplification for the majority of FECH exons consisted of an initial 
cycle of denaturation at 95°C for 1 min (stage 1), followed by 35 cycles of denaturation 
for 30 sec at 95"C, annealing at Ta (Table 4.1) for 30 sec and extension at 72"C for 30 












Table 4.1. Summary of primer sequences and melting temperatures for amplification of 
the exons of FECH, and resultant fragment sizes 
PCR Primer sequence Primer Product *Ta 
fragment {forward and reverse) length {b~) size {b~} rCl 
Exon 1 5'-gagcgggcttctagctca-3' 18 
5'-cgcgacagacccacttac-3' 18 349 59 
Exon 2 5'-atgctctgaggacctctt-3' 18 
5'-ctattggtgtctgcatcg-3' 18 260 53 
Exon 3 5'-agagtccaccctggaaga-3' 18 
5' -gctgctgtttaaccattaccag-3' 22 306 55 
Exon 3c 5'-CTCATGACACTTCCTATTCAGCAg-3' 24 
5' -gctgctgtttaaccattaccag-3' 22 145 53 
Exon 4A 5'-caagagagctggctattgtc-3' 20 
5'-TTCA TCCAGCAGCTTCAC-3' 18 297 57 
EXon 48 5'-AGAGCAGTACCGCAGGAT -3' 18 
5'-gataacgcctggagaccta-3' 19 267 55 
Exon 5 5'-gttctttgttctgggcattg-3' 20 
5'-tccttcccttcagtacttagac-3' 22 311 57 
Exon 6 5'-gcagttacctgctttgaact-3' 20 
5'-agaaggacatccacaaacc-3' 19 296 53 
Exon 7 5'-ttgagggttgctctgagat-3' 19 
5'-aatggaagctggacccat-3' 18 300 53 
Exon 7c 5'-ttgagggttgctctgagat-3' 19 
5'-tacgtaagaacattttctgggat-3' 23 235 53 
Exon 8 5'-attggtgcaggagacaga-3' 18 
5' -gttatggaagagcctgacc-3' 19 342 57 
Exon 9 5'-aggggtactacagaccgtca-3' 20 
5'-gacaccgtacatgcaaac-3' 18 348 57 
Exon 10 5' -ccttttctcatttgattcag-3' 20 
5' -ctgcaagagtttctcagagg-3' 20 148 55 
Exon 11 5'-ggaaaggaagatgctgtaga-3' 20 
5'-CGGAGGTA TCTGGAGGTT -3' 18 350 55 
Note: *T a = Annealing temperature 
Exonic sequences given in uppercase characters 
Exon 3c and 7c denote primer sequences designed to create restriction sites for 











Only 30 cycles were required for stage 2 of the PCR reaction for amplification of FECH 
exons 7 and 9. Amplification of FECH exon 1 required the addition of 2% dimethyl 
sulfoxide (DMSO) to the reaction mixture as the region is particularly GC-rich. 
4.5.2. Polyacrylamide gel electrophoresis (PAGE) 
Separation, identification and purification of DNA fragments may be achieved by 
agarose or polyacrylamide gel electrophoresis (PAGE). DNA is separated primarily on 
the basis of size; however conformational variations do affect the migration of DNA 
through polyacrylamide gels, and will be discussed later (section 6.1.1). PAGE is most 
effective for separating small fragments, as these gels have a higher resolving power 
than agarose gels. Polyacrylamide gels are formed by polymerisation of monomers of 
acrylamide to produce long chains in the presence of free radicals. These become 
cross-linked by N,N'-methylenebisacrylamide and the porosity of the gel is determined 
by the extent of cross-linking and the length of the chains (Sam brook et al. 1990). An 
electric field is set up across the gel and negatively charged DNA fragments move 
through the pores of the gel in the direction of the current. Larger fragments are 
retarded, while smaller fragments can move more quickly through the gel, allowing 
separation of these fragments. Visualisation of these fragments is achieved by staining 
the gel with ethidium bromide (EtBr). This dye becomes intercalated into the DNA helix 
and fluoresces when exposed to UV light (Sharp et al. 1973). 
PCR products are routinely resolved by PAGE in the Porphyria Laboratories (Appendix 
F). A 100bp DNA ladder and a negative control (blank) for each amplified exon were 












4.6. Investigation of the IVS3-48T/C polymorphism 
4.6.1. Ita I Restriction endonuclease analysis 
Restriction endonuclease analysis may be used for rapid screening of a cohort for 
previously described sequence variations. This method is based on the ability of certain 
enzymes to recognise and cleave specific palindromic sequences (restriction sites) in 
double-stranded DNA. Restriction endonuclease analysis is therefore applicable to 
variations that either create or abolish restriction sites by providing a base that either 
completes or interrupts the recognised sequence. Digestion of genomic DNA with an 
appropriate enzyme that cleaves the DNA at such a restriction site will provide 
information as to whether the variation is present at that site or not, by observing the 
number of restriction fragments. 
PCR products amplified for exon 4 (amplification fragment 4A) were subjected to Ita I 
restriction endonuclease analysis (Appendix G) after confirming that this enzyme was 
appropriate (Webcutter3; www.carolina.com). The digestion products were separated 
using PAGE as described in Appendix F. A single undigested exon 4A PCR product, a 
positive control and two molecular weight markers, the 100bp DNA Ladder and 25bp 
DNA Step Ladder, were resolved on the same gel. Gels were visualised by silver 
staining (Appendix G). Samples in the matched control cohort were screened for this 
polymorphism using Ita I restriction endonuclease analysis. This allowed the 
determination of the frequency of the IVS3-48C polymorphism in the control population. 
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4.7. Mutation detection and screening 
4.7.1. Single-stranded conformational polymorphism analysis 
An effective method for mutation detection within specific exonic fragments is single-
stranded conformational polymorphism (SSCP) analysis (Appendix H). Double-stranded 
DNA fragments are denatured and separated using a MOE (Mutation Detection 
Enhanced) PAGE system. Mobilities of distinct fragments differ because of the different 
conformations assumed by single-stranded fragments. Sequence variations therefore 
result in unique banding patterns on the gel that distinguish mutant from wild type 
fragments. As the sensitivity of SSCP decreases with increasing fragment length, it is 
important that amplification fragment length be taken into consideration (Orita et al. 
1989; Sheffield et al. 1993). In our experience, variations have been detected in 
fragments s350bp using this method. 
Amplification fragments for exons 1-11 of FECH were screened by SSCP analysis for 
sequence variations. Three controls were included on each gel as well as a previously 
tested positive control where possible. The analysis was performed in both the absence 
and presence of 10% glycerol, and the running conditions are described in Table 4.2. 
Table 4.2. SSCP running conditions 
Fragment size 
Voltage (V) 
Running time (h) 
(bp) +glycerol -glycerol 
260 - 290 270 17 15 
290 - 320 300 19 15.5 
320 - 360 350 23 17 
Banding patterns were visualised by silver staining as described in Appendix G, but 
staining times were increased to 20 min (solution 1) and 10 min (solution 2) for the 











4.7.2. Direct sequencing 
Direct sequencing of a DNA fragment allows the determination of the precise base 
composition of the fragment. It is based on PCR amplification, gel electrophoresis and 
fluorescent labeling of dideoxynucleoside triphosphates (ddNTPs) that lack a 3'-OH 
group. A PCR reaction is carried out using either the forward or reverse primer and 
includes ddNTPs producing amplification fragments of differing lengths, depending on 
where each specific ddNTP is incorporated. Electrophoresis of fragments through a 
polyacrylamide gel or capillary matrix separates the fragments according to size, and 
the termination base of each fragment is "read" by laser as it migrates, giving the exact 
sequence of the fragment. 
Direct sequencing was carried out for aI/ samples that exhibited a distinctive banding 
pattern on SSCP analysis. Prior to sequencing, a DNA "clean-up" of each sample was 
performed. For those amplification fragments not requiring further manipulation, the 
"clean-up" was performed directly using a GFX PCR DNA and gel band purification kit 
as described in Appendix I. Samples that could not be purified directly from the PCR 
product were subjected to agarose/polyacrylamide gel electrophoresis (Appendix I) and 
the relevant band excised and purified (Appendix I). Direct sequencing was carried out 
by the University of Stellenbosch Core DNA Sequencing Facility using the ABI 3130XL 
Genetic Analyser Big Dye Terminator vs 3.1 kit, on the ABI PRISM 3130XL automated 
sequencer (PE Applied Biosystems). Sequencing was performed in both the forward 














4.7.3. Isolation of the mutant allele for sequencing 
In order to further characterise the primary mutation (356_362deITICAAGA) identified 
in exon 4 for sample EPP5.1, isolation of the mutant allele was required. This was 
achieved using the endonuclease Hint I which digested the wild type allele but not the 
mutant allele for amplification fragment 4A as the deletion abolishes the restriction site. 
The PCR reactions for the amplification of fragment 4A for sample EPP5.1 was as 
described previously (Appendix E). The template DNA was increased to 100ng and 35 
cycles of amplification were employed. The restriction endonuclease analysis was 
performed as described for Ita I in Appendix G. The full PCR reaction (50111) was 
digested with 8U of Hint I. Digests were incubated at 37°C overnight PAGE (Appendix 
F) at BOV for 4 h was performed to separate digestion products. DNA from gel bands 
that were likely to represent the mutant allele alone was isolated from polyacrylamide 
using the Qiaex II gel extraction kit as detailed in Appendix I. Recovered DNA for 
sample EPP5.1 was re-amplified by PCR (Appendix E). New amplification products for 
sample EPP5.1 were separated by PAGE (Appendix F) and samples that appeared to 
be free of heteroduplexes were purified for direct sequencing (Appendix I). 
4.7.4. Restriction endonuclease analysis for identified sequence variations 
The principle of restriction enzyme analysis has been outlined in section 4.6.1. PCR 
amplification fragments of FECH exons 2, 3, 4, 7, 9 and 11 from the study and control 
cohorts were subjected to appropriate restriction endonuclease analysis (Appendix G). 
This included screening for identified sequence variations (IVS1-23CfT, R96Q, 
IVS3+2T>G, 356_362deITTCAAGA, 757 _761deIAGAAG, IVS7+1G>A, P266P, P307P 
and IVS1 0-61 G/A) and the initial screening for the known polymorphism (IVS3-4BT/C) 
with Ita I as described above (section 4.6). Recommended conditions for each 
endonuclease were optimised (Table 4.3). When the sequence variation identified did 
not fall within a recognisable restriction site, primer sequences were selected to create 
one. The insizer on zeon program (http://zeon.well.ox.ac.uk/git-bin/insizer) was used to 
design these. Fragments amplified using these primers are denoted 3c and 7c in Table 
4.1 and endonucleases used to screen for these changes are indicated by an asterisk 














Alw26 I and Bts I digests required the addition of 1 % BSA (Promega). Endonuclease-
digested products were separated using PAGE as described in Appendix F and section 
4.5.2. Electrophoresis was performed at 100V for 3-4 h. Mba II, CacB I and Alw26 I 
digests were visualised by EtBr staining as described in Appendix F to reduce 
ambiguous results obtained from incomplete digestion. Staining time was extended to 
20 min to accommodate lower DNA concentrations. The remainder of the gels were 
visualised by silver staining (Appendix G). The frequency of each of the variations 
identified in the study and control cohorts was determined. Probability (p) values 
comparing the EPP to the control cohorts were calculated using Yates chi-squared test 
on the Statistica-7 software package (University of Cape Town, ICTS). 
Table 4.3. Summary of restriction endonucleases used for mutation screening 
Sequence Exonl Restriction [E] Incubation 
Restriction site Supplier 
variation intron enz~me (U) Ti (OC) t {h) 
IVS1-23CIT 1 Cac81 5'-GCN'NGC-3' 3 37 O/N New England 
Biolabs 
R96Q 3 Alw26 I 5'-GTCTCN,-3' 2 37 O/N MBI Fermentas 
IVS3+2T>G 3 *Bts I 5'-GCAGTGNN-3' 2 55 O/N New England 
Biolabs 
IVS3-48T/C 3 Ita I 5'-GCNGC-3' 37 2 Roche 
3 Fnu4 Hi 5'-GC'NGC-3' 37 2.5 New England 
Biolabs 
356_362del 4 Hinfl 5'-GANTC-3' 1.5 37 O/N Promega 
TTCAAGA 
P266P 7 Hsp92 II 5'-CATG-3' 1.5 37 O/N Promega 
IVS7+1G>A 7 *Rsa I 5'-GTAC-3' 3 37 O/N Promega 
757_761 del 7 Mba II 5'-GAAGA(N)8-3' 2 37 2 Promega 
AGAAG 
P307P 9 BstXI 5'-CCANNNNN'NTGG-3' 2 55 O/N Prom ega 
IVS10-61G/A 10 BsmFI 5' -GGGAC( N), 0-3' 1.5 65 O/N New England 
Biolabs 
*Modified restriction enzyme site [E) = Endonuclease concentration 











4.8. Haplotype analysis 
Microsatellite markers (short tandem repeat nucleotide units - see 6.2) in the immediate 
vicinity of a gene are likely to be inherited as a single unit. Genomic regions between 
these markers can therefore be investigated for association with disease (linkage 
analysis) or to investigate the presence of a founder mutation in a population. Affected 
individuals with a mutation at the same locus, or those carrying a mutation resulting 
from a single ancestral event, will have the surrounding sequence in common. The 
smaller the region between two microsatellite markers, the less the chance that 
recombination has occurred in the region and, in the case of a founder mutation, the 
more likely it is to be shared between mutation carriers. Microsatellite markers vary with 
respect to their repeat length and can therefore be distinguished by PCR amplification 
of the sequence because of the different fragment sizes obtained. 
4.8.1. Microsatellite selection, design and amplification 
Bioinformatics is a fundamental part of both the design and initial stages of a study such 
as this. Essential information regarding genes of interest and flanking regions may be 
obtained, allowing accurate design of primers, microsatellite markers and other 
components necessary for genetic analysis. 
Published microsatellite markers D18S381 and D18S858 were identified from the NCBI 
database (http://www.ncbi.nlm.nih.gov). Interrogation of the Genome Database 
(http://www.gdb.org) revealed that these markers were unsuitable in repeat sequence 
(mixed, interrupted repeat) and repeat length, respectively. Another published marker 
(X69298) submitted by Whitcombe and Cox in 1992 lies within the gene, and has a 
maximum heterozygosity of 0.68. A Clustalw multiple sequence alignment of the given 
amplification fragment with the FECH pseudogene on chromosome 3 revealed high 
homology with a region of this gene. Primers were designed within regions of least 
similarity, but neither this, nor extensive PCR optimisation, could increase specificity for 
this marker. Thus, alternative microsatellite markers were chosen. A search was 
conducted for all (CA)11 dinucleotide repeats within 300kb either side of the FECH gene 
using the Tandem Repeats Finder program vs 2.02 (Gary Benson, Department of 
Biomathematical Sciences, Mount Sinai School of Medicine). Criteria for the selection of 
the (CA)n dinucleotide repeats to be used as polymorphic markers were as follows: the 













GC-content and complex repeats), and proximity to FECH. Primers resulting In a 
fragment smaller than 360bp, containing the repeat sequence, were designed for each 
marker using the software, Primer3 (see section 4.5.1). Primers utilised are shown in 
Table 4.4. The criteria for primer selection was as described in Appendix E A map of 
the relative positions of the dinucleotide (CA)n repeat microsatellite markers, as 
obtained from the Ensembl website (httpllwww.ensembLorg), is given in Figure 5.9 
(section 56.1). 
Table 4.4. Summary of primer sequences, melting temperatures and minimum 
fragment sizes for amplification of microsatellite markers surrounding FECH 
Marker Primer sequence 





R1: 5'-cacaaatagctgggcctacag-3' 21 
FECH-MM2gt *F3: 5'-cctctaacttcagatgacacc-3' 
R3: 5' -acagagtgagatgtgagatcc-3' 
FECH-MM3gt "F2: 5'-gacttgtggacacatcactc-3' 
R2: 5'-ttcaccaggtgtagtggac-3' 















Forward primer sequences were labeled with a fluorescent tag (5' 6-FAM) while the 
reverse was unlabelled. The peR reaction for amplification of these exons was carried 
out as described in Appendix E and section 4.5.1. Annealing temperatures (Ta) were as 
listed in Table 4.4 and stage 2 consisted of 30 cycles of amplification. PCR was 
performed using the hot-top facility on the thermal cycler in the absence of mineral oil, 
as this was a requirement for sample analysis using the ASI PRISM 3100 automated 
sequencer. PCR amplification products were subjected to PAGE (Appendix F) to 
visually determine the dilution factor to be used for each sample. Samples used for 
PCR optimisation were subjected to agarose gel electrophoresis to determine the 











4.8.2. Marker genotyping (allele identification and assignment) 
A cohort of 83 individuals, consisting of EPP subjects and family mernbers (the study 
cohort), and 50 controls were genotyped for the selected microsatellite markerso DNA 
was unavailable for individual EPP803 for haplotype analysiso Genotyping was 
performed on the ASI PRISM 3100 automated sequencer (Wenz et aL 1998)0 Results 
were analysed using the ABI PRISM GeneMapper software vs 3000 
4.8.3. Pedigree construction 
Pedigrees were constructed for each of the families using Cyrillic Pedigree Editor vs 
2002 (Chapman CJ 19930-1996, Cherwell Scientific Publishing Ltd Oxford, UK)o 
Haplotypes were constructed manually for all pedigrees in which chromosome phase 
could be determinedo Where parental genotypes were not known, the most probable 
haplotypes were inferredo Probability (p) values comparing haplotype allele frequencies 
in the EPP and control cohorts were calculated using Yates chi-squared test on the 
VasserStats: web site for statistical computation (http://facultyovassaLeduliowry/ 
VassarStatso htm 1)0 
56 


























5.1 Subject recruitment and control selection 
We investigated 28 symptomatic EPP subjects, defined as subjects with positive 
biochemical evidence of EPP and a convincing history of photosensitivity, representing 
17 apparently unrelated families. Of these families, 14 had previously been identified 
and were recorded in the UCT Porphyria Database. A further 3 families were identified 
during the course of this study. 
An additional 58 asymptomatic family members, mostly siblings or parents of the 
symptomatic individuals, were recruited for study. In 2 families, 3 generations were 
available for study. Our study cohort therefore had a total of 86 subjects, of whom 28 
were symptomatic (EPP cohort), and for which 84 DNA samples were available. 
As the primary aim of this investigation was to characterise the South African EPP 
cohort at a molecular level, the results of genetic analyses will be presented first, 
followed by the clinical information and biochemical data for the study cohort. 
5.2. DNA Isolation 
DNA (200 - 1000ng/lll) with a purity of 75-95% was obtained for the majority of 
samples; the minimum purity achieved being >65%. Prompt handling of blood samples 
gave the highest yields, and required fewer repetitions of critical steps in the protocol. In 
some cases, previously stored DNA required a "clean-up" purification, which resulted in 











5.3. Analysis of the FECH gene 
5.3.1. FECH exon amplification 
Amplification of the coding region of FECH was achieved for all samples in the EPP 
cohort. For each exon, we encountered a few samples from the control and study 
cohorts which failed to amplify adequately, in most cases as a result of poor quality 
DNA. The number of samples suitable for analysis for each exon ranged from 77 to 96 
for the control cohort and from 66 to 84 for the study cohort. 
Highly specific PCR products of good intensity, as observed on PAGE, were obtained in 
all cases except for exon 1. The high GC-content of the sequence surrounding exon 1 
made primer selection difficult, and weak amplification was only achieved with the 
addition of 2% DMSO. All further attempts to improve this amplification proved 
unsuccessful. 
Heteroduplex formation was observed on amplification of a number of samples from the 
study cohort for exons 4 and 7 (Figures 5.1 and 5.2). This was useful as a first-line 
screening for heterozygous deletions in these exons. Lanes 2-6 (Figure 5.1) and lanes 
2-5 (Figure 5.2) show samples that were later proven to be heterozygous for a minor 
deletion. Lane 7 (Figure 5.1) and lane 6 (Figure 5.2) contain homozygous wild type 
samples for the respective exons. Gel bands representing PCR amplification products 
did not always correspond to marker bands of the same size, as seen in Figures 5.1, 
5.2 and subsequent gel figure . In each case the PCR fragment was confirmed to be 
correct by direct sequencing, and the anomaly, an artifact induced by the use of PAGE, 


















Figure 5.1. PAGE (6%) of PCR amplification fragments for FECH exon 4 
visualised by EtBr staining. Heteroduplexes observed in lanes 2-6 
Lane 1 - 1 OObp DNA Ladder; Lane 2 - Subject EPP5.1; Lane 3 - EPP5.1; 
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Figure 5.2. PAGE (6%) of PCR amplification fragments for FECH exon 7 
visualised by EtBr staining. Heteroduplexes observed in lanes 2-5 
Lane 1 - 100bp DNA Ladder; Lane 2 - Subject EPP12.1; Lane 3 - EPP12.1 ; 
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5.3.2. Mutation detection 
Previously amplified samples from EPP subjects for the 11 FECH exons were 
successfully subjected to SSCP analysis. The initial screen, which excluded glycerol in 
the MDE gel mixture, revealed conformational variations in exons 4A, 7, 9 and 11. The 
addition of 10% glycerol to the gel mixture on subsequent analyses allowed detection of 
these same variations, with slightly different banding patterns, and additional mobility 
shifts in exons 2, 3, 48, 5, 7 and 9. For example, SSCP analysis of exon 7 with glycerol 
produced 6 distinct banding patterns, whereas only 3 distinct banding patterns were 
observed on analysis in the absence of glycerol. 
Conformational variations were not observed in the other exons under these conditions. 
In the case of exon 4B and exon 5, direct sequencing (section 5.3.3 below) did not 
identify a sequence variation despite the conformational change. 
SSCP analysis results for FECH exon 1 were inconclusive as a result of weak peR 
amplification. Although a single band was observed for each sample on PAGE, a smear 
was repeatedly obtained on SSCP analysis and banding patterns could not be 
distinguished. 
5.3.3. Direct sequencing 
Representative samples for each amplification fragment that illustrated a mobility shift 
were sequenced. Ten variations were identified. These included the known IVS3-48T/C 
polymorphism, and four additional previously identified polymorph isms (R96Q, P266P, 
P307P and IVS1-23CIT), which are reported to have no effect on FECH expression or 
activity (rs1041951, rs536765, rs536560, rs7243988 and rs577152). 
Sequence analysis corresponding to the remaining 5 mobility shifts, identified 4 primary 
(likely disease-causing) mutations in 15 of our 17 families, and one novel variation 
described below. Figures 5.3A, 5.4A and 5.5A show the various banding patterns 
observed on SSCP analysis of exons 3, 4 and 7, respectively. Sequencing 
ielectroPherograms for the primary mutation/s observed in each exon that correspond to 















Wild type: A G A A G T GAG A T 
Mutant: A G A A G G GAG A T 
B 
Figure 5.3. Mutation detection and identification: FECH exon 3 
A) SSCP analysis indicating a mobility shift in lane 3 
Lane 1 - EPP3.7 and Lane 2 - EPP9.4: Homozygous IVS3+2T; 
Lane 3 - EPP13.1: Heterozygous IVS3+2T>G 
B) Direct sequencing (forward primer) for EPP13.1: IVS3+2T>G mutation 
2 3 4 Wild type: C A A GAT TeA A G A 
Mutant: C A A GA G C A A T A C 
A B 
Figure 5.4: Mutation detection and identification: FECH exon 4 
A) SSCP analysis indicating mobility shifts in lanes 1, 2 and 4 
Lane 1 - EPP4.1: Heterozygous IVS3-48T/C; 
Lane 2 - EPP5.1: Heterozygous 356_362de1TTCAAGA deletion and IVS3-48T/C; 
Lane 3 - EPP6.1: Homozygous IVS3-48T and does not carry the deletion; 
Lane 4 - EPP6.2: Genotype as for lane 1 












Wild type G T C T G T A A G T 








Figure 5.5. Mutation detection and identification: FECH exon 7 
A) SSCP analysis showing mobility shifts in lanes1-3 
Lane 1 - EPP6.1: Heterozygous 757_761 deIAGAAG, P266P; 
Lane 2 - EPP6.2: Heterozygous P266P; 
Lane 3 - EPP7.1: Heterozygous IVS7+1 G>A; 
Lane 4 - EPP7.2: Homozygous wild type 
B) Direct sequencing (forward) for EPP7.1: IVS7+1 G>A 











Unexpectedly, the same 5bp deletion in exon 7 (Figure 5"5C) was identified in 12 of our 
families" We refer to this primary mutation as 757 _761deIAGAAG* which probably 
corresponds to a previously reported mutation (Henriksson et aL 1996)" However, as it 
was not possible to determine the exact point of deletion of this mutation (section 5"3.4 
below), we could not confirm that the position of these two deletions is identical, 
although it is likely" 
Three family-specific primary mutations were identified: 
• a novel 7bp deletion in exon 4 (356_362deITTCAAGA·) (Figure 5.48) 
• a previously identified splice-site mutation: IVS7+1 G>A 
(Nakahashi et aL 1993, Figure 5"58) 
• a previously identified splice-site mutation: IVS3+2T>G 
(Sarkany et aL 1994, Figure 5"38)" 
The remaining mobility shift observed corresponded to a second novel variation (lVS 10-
61G/A), identified in intron 10" We found this to be a common polymorphism with a 
frequency of 13% in our control cohort" Tables 5" 1 and 5.2 summarise the variations 
identified in our South African EPP cohort" 
5.3.4. Isolation of mutant alleles for sequencing 
Further characterisation of the two deletions (356_362deITTCAAGA and 
757 _761deIAGAAG) identified in this study was required to determine their exact 
positions. The most conclusive way to determine this would be to obtain the sequence 
of the mutant allele alone. In the case of exon 4A (EPP5.1), complete digestion of the 
normal allele was obtained by incubation of the sample with the restriction 
endonuclease Hint I (section 4.7.4)" Isolation and re-amplification of the mutant allele 
alone allowed sufficient product to be purified for sequencing (Figure 5.6A) 
The point of deletion cannot be determined because of the repetitive nature of the surrounding sequence The name 
therefore corresponds to the most 3' set of possible deleted bases as per naming conventions suggested by den Dunnen 




















Unfortunately, due to the nature of the sequence surrounding the deletion, the 
sequencing results (Figure 5.68) were still ambiguous and the exact position of the 
deletion could not be determined. Hence the deletion was named as per den Dunnen 
and Antonarakis (2001). Isolation of the mutant allele for exon 7 (EPP2.1) was 
unsuccessful. 




B Mutant: A ACe C C C A A GAG C A G T Ace G C 
Figu re 5.6. Characterisation of 356_362de1TTCAAGA deletion 
identified for EPP5.1 (fragment 4A) 
A) PAGE of re-amplified PCR products after Hinfl digestion 
Lane 1 - 1 OObp DNA ladder; Lane 2 to 13 - amplification products of 
the mutant allele alone; Lane 14 - undigested sample 













5.4 Investigation of the IVS3-48T/C polymorphism 
Exon 4A amplification products for the study cohort and a matched control cohort were 
screened using Ita I restriction endonuclease. We confirmed the suitability of Ita I with 
the Webcutter3 program (Appendix G). Direct sequencing confirmed the presence of 
the IVS3-48C polymorphism (NCBI database: rs2272783) in sample EPP2.1 (Appendix 
G), and we subsequently used this sample as a positive control for IVS3-48T/C 
polymorphism heterozygosity. 
Figure 5.7 shows Ita I restriction analysis on a 6% polyacrylamide gel. The undigested 
exon 4A amplification fragment was 297bp in size. Samples homozygous for the IVS3-
48T allele had a single Ita I cutting site on digestion (product size: 286 + 11 bp). The 
presence of the IVS3-48C polymorphism, however, created an additional cutting site 
(product size: 169 + 117 + 11 bp). We were able to distinguish heterozygous samples by 
the presence of three bands on the gel (286 + 169 + 117bp). The 11 bp fragment was 
not visible as the band becomes too diffuse during electrophoresis due to its small size. 
The bands observed at approximately 600bp in lanes 12, 13, 14 and 17 are the result of 
heteroduplex formation as described for the PCR amplification of these samples 
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Figure 5.7. PAGE (6%) of FECH exon 4A amplification products after Ita I 
restriction analysis, visualised by silver staining 
Lane 1 - 25bp Step DNA Ladder; Lane 2 - EPP14.1; Lane 3 - EPP14.2; 
Lane 4 - EPP14.3; Lane 5 - EPP14.4; Lane 6 - EPP14.5; Lane 7 - EPP15.1; 
Lane B - EPP15.2; Lane 9 - EPP15.3; Lane 10 - EPP15.4; Lane 11 - EPP15.5; 
Lane 12 - EPP5.1; Lane 13 - EPP5.2; Lane 14 - EPP5.3; Lane 15 - EPP5.4; 
Lane 16 - EPPS.5; Lane 17 - EPP5.6; Lane 18 - EPP2.1 (positive control); 
Lane 19 - EPP14.1 (u ndigested); Lane 20 - 100bp 0 NA Ladde r 
Lanes 2 t 3, 6, 7, B. 12, 1 3, 15, 16 and 18: Heterozygous IVS3-4BT Ie polymorph is m 
Lanes 4,5.9, 10, 11, 14 and 17: Homozygous IVS3-48T allele 
The IVS3-48C polymorphism was present in 15/17 families (88%) and in 22/28 
members of the EPP cohort (a frequency of 39%: 22/56 chromosomes). The frequency 
of the IVS3-48C polymorphism in the study cohort was 27% (45/168 chromosomes). In 
contrast, the IVS3-4BC polymorphism was found to have a frequency of 90/0 (16/180 
chromosomes) in the control cohort. Table 5.0 lists the respective frequencies of the 
IVS3-48T/C genotypes observed for each of the cohorts. 
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5.5. Restriction endonuclease analysis for identified sequence variations 
Screening for all sequence variations identified in the EPP cohort, including previously 
identified common polymorphisms, was performed using the appropriate restriction 
endonucleases to determine their frequencies in the EPP cohort, the study cohort and 
the control cohort, respectively. 
5.5.1. Determination of the frequencies of the common polymorphisms identified 
Figure 5.8 compares the single nucleotide polymorphism (SNP) frequencies in the EPP 
cohort with those in the control cohort. In the EPP cohort, the frequencies of the most 
commonly encountered SNPs (IVS3-48C and IVS1-23T) both equaled 39%. The IVS3-
48C polymorphism had the lowest frequency in the control cohort (9%) as mentioned 
above, whereas the IVS1-23T polymorphism was more common in this cohort at 22%. 
The other SNPs identified had lower frequencies in the EPP cohort than in the control 
cohort. 
50 
45 I Control cohort 
40 I EPP cohort 
35 










IVS1-23T R96Q IVS3-48C P266P P307P IVS10-61A 
Single nucleotide polymorphism (SNP) 
Figure 5_8_ Frequencies of SNPs in the EPP and control cohorts 
Table 5.1 provides a summary of the common polymorphisms identified in the South 











5.5.2. Determination of the frequencies of the primary mutations identified 
Three of the 4 primary mutations identified by SSCP analysis and direct sequencing, 
356_362deITTCAAGA, 757_761de1AGAAG and IVS7+1G>A were absent in our control 
cohort, confirming a frequency of <1 % (150 chromosomes screened) characteristic of 
disease-associated mutations (Table 5.2). The frequencies of these mutations in the 
EPP cohort were 4% and 2% for the family-specific mutations (356_362deITTCAAGA 
and IVS7+1G>A) respectively, and 30%) for the 757 _761deIAGAAG deletion. When 
calculated as a frequency within the study cohort the frequencies were 5% and 4% for 
the family-specific mutations (356_362deITTCAAGA and IVS7+1 G>A) respectively, and 
35% for the 757 _761deIAGAAG deletion. The fourth primary mutation, the IVS3+2T>G 
splice-site mutation, has not as yet been investigated. 
69 










Table 5.1. FECH common polymorphisms in South African EPP cohort 
Cohort frequencies (')/0) 
SNP *p Effect References 
IVS1-23T Skipping Nakahashi et aL 1992: 
(39) (38) (22) 
[Wang et aL 1 
R96Q 4/56 111136 25/192 0.34 None SNP (rs1041951) 
(7) (8) (13) 
IVS3-48C 22156 45/168 16/180 <00001 Gouya et al. 2002 
(39) (27) (9) 
SNP (rs2272783) 
P266P 7/56 25/160 36/154 0.125 None SNP (rs536765) 
(13) (16) (23) 
P307P 8/56 26/132 49/178 0,067 None SNP (rs536560) 
(14) (20) (28) 
IVS10-61A 2/56 6/132 24/180 0,073 Unknown Novel polymorphism 
(4) (5) (13) 











Table 5.2. FECH primary mutations identified in the South African EPP cohort 
Primary 
I 
Cohort Frequencies (%) Reported 
Sequence 
relationship to References mutation 
EPP Study Control alteration 
liver disease 
IVS3+2T>G I NO NO NO Exon 3 skipping Present 
Sarkany et al. 1994: 
Bloomer et al. 1998: 
Chen et al. 2002 
I 356_362del 2/59 4/168 0/176 Premature stop ND Novel 
TTCAAGA codon (4) (2) (0) 




codon Chen et al. 2002 
(17) (0) 
IVS7+1G>A 1/56 3/156 0/163 Exon 7 skipping None 
Nakahashi et ai. 1993 
(2) (2) (0) 











5.6. Haplotype analysis 
5.6.1. Microsatellite selection, design and amplification 
The 757 _761deIAGAAG deletion was identified in 17 symptomatic individuals (deletion 
subgroup) from 12 families in our cohort. In order to investigate this further, we 
undertook haplotype studies to determine whether a common ancestral allele is present 
in these families. Online genetic databases were consulted in order to annotate 
chromosome 18 genomic sequence with regard to FECH. Three microsatellite markers 
(FECH-MM1 ac, FECH-MM2gt and FECH-MM3gt) were selected on the basis of their 
repeat length, surrounding sequence and proximity to FECH, to follow allele 
segregation. A map of the relative positions of the markers to the 757 _761deIAGAAG 
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Not to scale 
Figure 5.9. Schematic representation of the FECH gene on chromosome 18 showing published (underlined) and 
newly-designed (red) microsatellite markers. FECH exons are numbered 1-11 and the chromosomal positions for the 
start and stop codons are given in brackets. Genetic distances for published microsatellite markers were obtained from 
the Centre for Medical Genetics website (http://research .marshfieldclinic.org/genetics/map_markers) and are given in 
centimorgan (cM). Chromosomal positions of all markers are supplied in brackets. Physical distances of newly-



















Amplified samples used for PCR optimisation (T1) were subjected to agarose gel 
electrophoresis after PCR amplification to determine the specificity of the primers 
(electrophoresis of FECH-MM 1 ac is shown in Figure 5.10). A bright, single band was 
observed for each marker, indicating that primer specificity was optimal. Samples 
amplified under these conditions were used for genotyping. 






300bp ± 3500p 
B 
Figure 5.10. Visualisation and optimisation of microsatellite marker FECH-MM1 ac 
amplification products by (A) polyacrylamide (6%) and (8) agarose (2%) gel 
electrophoresis, visualised with ethidium bromide staining. 
A) Lane 1 - 1 OObp DNA Ladder; Lane 2 - EPP1 .1; Lane 3 - EPP2.1 ; Lane 4 - EPP2.2; 
Lane 5 - EPP2.3; Lane 6 - EPP2.4 
8) Lane 1 - 1 OObp DNA Ladder; Lanes 2 to 7 - Test sample (T1) amplified using a 
temperature gradient (51- 61 Oe) 
5.6.2. Marker genotyping and pedigree construction 
The study cohort and 50 randomly selected matched controls were genotyped for the 
three microsatellite markers (FECH-MM1 ac, FECH-MM2gt and FECH-MM3gt). Each 
marker gave a distinct profile on the ASI PRISM 3100 automated sequencer that 
allowed assignment of alleles according to size in base pairs. As these marker profiles 
were representative of dinucleotide repeat sequences, a size change of two base pairs, 
or multiples thereof, indicated a new allele, and a new allele number was assigned 
accordingly. Marker FECH-MM1ac was more complex to analyse in that, in addition to 
the dinucleotide repeat sequence, it contained a short trinucleotide repeat region. 
Alleles of only one base pair difference were observed, indicating that this region was 
also unstable. Care was taken in assigning allele numbers for this marker as profiles 
were difficult to interpret and even a slight offset between runs caused profile peaks to 











Fragments were allocated into "bins" by the genotyping analysis program according to 
their size - those that are close in size, e.g. those differing by only a single base, are 
sometimes difficult to assign correctly. Thus reference samples were used to delineate 
fragment sizes and allow the correct alleles to be determined. 
Genotyping results confirmed that the three newly-designed microsatellite markers were 
highly informative (Table 5.3). Maximum heterozygosity was 290% and marker FECH· 
MM2gt was the least heterozygous. 
Table 5.3. Informativity of microsatellite markers 
Microsatellite Marker size range I *Numberof Maximum , 
marker (bp) alleles heterozygosity 
FECH"MM3gt 297-325 15 0.93 
FECH-MM1ac 326-358 17 0.94 
FECH-MM2gt 205-223 10 0.90 
*268 chromosomes screened 
Table 5.4 summarises the genotyping results for the probands of the 12 families in 
which the 757 _761deIAGAAG deletion segregates as a familial trait In each case, only 
marker genotypes for the allele associated with the 757 _761deIAGAAG deletion are 
given except for EPP6.1 and EPP17.1, where allele phase could not be determined, 
and both sets of genotypes are included The two symptomatic siblings from family 
EPP2 (EPP2.1 and EPP2.2) are both included in the table as they carry distinct 
haplotypes as a result of a recombination event in the current generation. In each of the 
other families, symptomatic siblings had the same set of genotypes for the allele 
associated with the 757 _761deIAGAAG deletion. The most common haplotype 
obselVed [4;C;8;G] was present in at least 15/17 (88%) of the deletion subgroup. A 
complete haplotype [4;C;8;G;4] was observed in at least 8/17 (47%) of this subgroup 
and other samples only differed in the FECH-MM2gt allele. Corresponding genotypes 
(highlighted in bold type) for samples EPP6.1 and EPP17.1, where phase is unknown, 











Table 5.4. Haplotype analysis of the FECH locus for families in which the 
757 _761deIAGAAG deletion segregates as a familial trait (+ = present) 
FECH- FECH- FECH-
Subject MM3gt IVS1-23CIT MM1ac 757J61delAGAAG IVS10-61G/A MM2gt 
2.1 4 C 8 -+ G *7 
-'-'-'-'-'-'-'-'---'_._.-._._-_._._.-.- - -'-'-'-'-'-'-'-'- -.-.- .-.-.-.-.-.-.-.-.-.-.-
2.2 4 C 8 + G 4 
4.1 4 C 8 + G 4 
9.1 4 C 8 + G 4 
10.1 4 C 8 + G 4 
12.1 4 C 8 + G 4 
15.1 4 C 8 + G 4 
16.1 4 C 8 + G 4 
_.-:._--.- .. "- -'-'-'-'-'-'- -.-'-'-'-'-'-'-'-'-'- _.- - _._._._.- -.-.-.-.-.-~-"-.- _._._.-
1.1 4 C 8 + G 7 
3.1 4 C 8 -+ G 2 
14.1 4 C 8 + G 2 
6.1 4/4 C 8/16 + G/A 4/7 
17.1 4/3 CfT 8/1 i- G 4/3 
Column 1 lists the i dividual subjects and the other columns record the genotype of each marker 
(microsatellites and polymorphisms) associated with the 757_761 delAGAAG deletion. 
Further support for the significance of the common haplotype observed for subjects 
carrying the 757_761de1AGAAG deletion comes from the observation that this 
haplotype is not associated with any of the family-specific mutations identified in our 
EPP cohort (Table 5.5). Subject EPP16.1 contrasts the common haplotype with those 















Although the SNPs correspond, the marker alleles are not consistent with those of the 
common haplotype. The range of marker FECH-MM2gt alleles is as observed in the 
above table. 
Table 5.5. Haplotype analysis of the FECH locus for families in which the 
757 _761deIAGAAG deletion is absent (+ = present; - = absent) 
FECH- FECH- FECH· 
Subject MM3gt IVS1-23Crr MM1ac 757_761de1AGAAG IVS10-61G/A MM2gt 
I 
16.1 4 c 8 + G 4 j 
5.1 6 c 1 G 2 
7.1 6 c 11 G 4 
13.1 1 c 12 G 7 
Genotyping of a randomly-selected, matched control cohort was performed in order to 
determine the frequency of each of the alleles identified and particularly those alleles 
associated with the 757 _761deIAGAAG deletion, namely allele 4 for FECH-MM3gt, 
allele 8 for FECH-MM1ac and allele 4 for FECH-MM2gt (Table 5.5). All three alleles had 
low frequencies in the control cohort with allele 8 of FECH-MM1ac being the highest at 
22%. Allele 4 of marker FECH-MM3gt and allele 4 of marker FECH-MM2gt had 
frequencies of only 11 % and 10%, respectively in the control cohort. 
A subset of 28 asymptomatic family members was used as a more closely matched 
control group (family control cohort) in order to assess the same allele frequencies. 
There is strikingly little difference between these frequencies and those obtained for the 
general control cohort. Allele 8 for FECH-MM1 ac and allele 4 of marker FECH-MM3gt 
were present at 18% and allele 4 of marker FECH-MM2gt was at a frequency of 7% in 
this subset. The other FECH-MM2tg alleles associated with the 757_761 delAGAAG 
deletion in the deletion subgroup, namely alleles 2 and 7, constitute 46% of the alleles 
observed in the random control cohort. The low frequencies of these alleles when 
compared to the EPP cohort suggest that the common haplotype is more prevalent than 











Table 5.6. Allele frequencies for the most common marker alleles associated with the 
757 _761deIAGAAG deletion 
Allele frequencies (%) 
Marker Deletion Random Family *p 
control control 
FECH-MM3gt - 4 20/34 (59) 11/100(11) 10/56 (18) <0.0001 
FECH-MM1ac - 8 22/34 (65) 18/82 (22) 10/56 (18) <0.000'1 
FECH-MM2gt - 4 11/34 (32) 10/100 (10) 4/56 (7) 0.0047 
*p values compare allele frequency in the deletion subgroup and random control cohort and are 
2 calculated by X analysis (Yates) 
Pedigrees for all 17 families were constructed, and genotyping results included on the 
pedigrees for haplotype analysis (Appendix K). At least two generations were present 
for the majority of families, aI/owing phase determination of alleles. Two examples of 
pedigrees (Figure 5.11 - EPP2 and Figure 5.12 - EPPS) are shown, demonstrating 
allele segregation in two generations. EPP2 illustrates the general mode of inheritance 
of alleles associated with the primary and secondary (IVS3-4SC) mutations confirmed in 
13 of the 17 EPP families. This pedigree also shows a single intra-familial 
recombination event (EPP2.1). The pedigree EPPS shows the atypical presentation of 
EPP in this family as the disease is inherited in a highly penetrant fashion. The IVS3-
4SC polymorphism is absent and genotyping results did not reveal a single allele 
shared by all symptomatic individuals. A primary mutation was not identified in FECH 
for this family and haplotype analysis shows no linkage to FECH as the major EPP-
associated locus in this family. The haplotype [4; T; 6; 3] was identified in three of the 
symptomatic individuals who also appear to have a more severe phenotype, and it is 





























EPP2.1 EPP2.2 EPP2.4 EPP2.6 
3 4 3 
I ~ 
4 7 4 It T C T C C C 1 8 1 8 17 8 G G G G G G 6 7 6 1 7 1 
Figu re 5.11. Pedigree of Family EPP2 illustrating the general mode of inheritance of alleles 
associated with the primary: 757 J61 delAGAAG (red bar) and secondary: IVS3-4BC (blue 
bar) mutations. Squares represent males and circles represent females. Symptomatic 
individuals are represent d by filled symbols while clear symbols represent asymptomatic 
individuals. Primary and secondary mutation carriers are indicated by symbols that are half-












No sample No sample 
II 
~ - '-----J LJ ... No sample EPP8.2 EPP8.8 EPP8.7 EPP8.6 
FECH-MM3tg 




UI~ IVSl-23CiT e . e FECH-MM1ac 1 _ 8 1 16 IVS10-61G/A G G G G FECH-MM2tg 4 2 2 4 
III 
LJ .. .. V .. 
EPP8.9 EPP8.1 EPP8.4 EPP8.3 EPP8.5 
FECH-MM3tg 61 ~ 10 ~Ir 'g II ~ nl~ IVS1-23CiT (e) (T) FECH-MM1ac 11 8 11 1 16 6IVS10-61G/A G G G G G G FECH-MM2tg 5 2 5 4 4 3 
Figure 5.12. Pedigree of Family EPP8 showing atypical presentation of EPP in this family as the disease is inherited in a highly penetrant fashion 
(patterns differentiate haplotypes). Squares represent males and circles represent females. Symptomatic individuals are represented by filled 
symbols while clear symbols represent asymptomatic individuals. Inferred genotypes are given in brackets. A line through a symbol indicates a 











5.7. Clinical features 
5.7.1. Patient presentation and perception of their disease 
Six families (40 subjects) were visited in their homes and blood samples collected. The 
questionnaire was completed by 16 of the 28 symptomatic individuals and the results 
are summarised in Table 5.7. We observed a slightly higher proportion of male 
symptomatic individuals compared to female [17:11 (60.7%)] (95% GI, 40.7 to 77.8%). 
5.7.1.1. Age 
The mean age of symptomatic individuals was 32.7 years (range: 13-79 years). The 
age of onset of EPP was predominantly between 9 months and 6 years, although 
symptoms were first observed in individuals up to the age of 10. The majority (56%) 
were diagnosed between 5 and 13 years. However, some children were younger, and 
two individuals were only diagnosed at 26 and 31 years, respectively. Two individuals 
were unsure of the age of onset of symptoms and diagnosis 
5.7.1.2. Precipitants 
The majority of patients (75%) were affected only by direct sunlight and/or the reflection 
thereof. However, 19% said that fluorescent lights affected them after exposure to 
sunlight. In addition, one individual was sensitive to incandescent light after exposure to 
sunlight while another was sensitive to all types of light. The amount of exposure to light 
that could be tolerated varied and differed seasonally. Most individuals (94%) were 
more severely affected in summer, and 69% could tolerate at most 30 min of sunlight 
provided that no recent previous exposure to sunlight had occurred. Up to 4 h of 
sunlight could be tolerated by 38% of the individuals if they stayed in the shade, or if it 
was a cool day in early summer. In winter, the maximum exposure time ranged from 2 
to 8 h. However, one individual claimed to be more severely affected in the winter 
months, and not more than 30 min of sunlight could be tolerated. The length of time 
symptoms persisted depended on the amount of sun exposure and could be up to a 













5.7.1.3. Signs and symptoms 
The general description of the sensation experienced after exposure to light included a 
burning, tingling pain often accompanied by heat. Swelling and redness of the exposed 
areas were described by 31% and 19%, respectively. Only one subject described the 
sensation as itchy, as opposed to a burning pain, and two individuals mentioned the 
appearance of a rash. Scarring on the hands and face, and thickening of the skin on the 
knuckles and bridge of the nose, was described by 69% and 56% of the patients, 
respectively. 
5.7.1.4. Precautionary measures and symptom alleviation 
The major precautionary measures taken by patients were avoiding sunlight (94%) and 
wearing protective clothing (81%). Ice, cold water or compresses, and cold, wet cloths 
were the most common means utilised to obtain symptomatic relief from the burning 
pain. Other methods include medication, staying in the shade or complete darkness, 
physically rubbing affected areas, e.g. the hands, to soothe the pain and applying body 
lotion. 
5.7.1.5. Liver disease 
With regard to liver disease, two individuals had gallstones and one had been 
investigated for a liver complaint. None had however been diagnosed as having EPP-
associated liver disease, although patients were not intensively investigated in this 
study as this was not the purpose of the project. One deceased member of a single 
family (EPP8) had earlier been documented as having EPP-associated liver disease. 
5.7.1.6. Family history 
Of the 16 symptomatic subjects who completed the questionnaire, 6 subjects, 
representing 3 families, reported a previous family history of photosensitivity (38%). 
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Table 5.7. SUbject perspective of the disease EPP 
No. Question 
1. Do you suffer from any undue 
photosensitivity? 
Most common response (%) Other responses (%) 
Yes, very sensitive: 16/16 (100) None: 0/16 (0) 
Which of these (or other) types of light seem to have the most severe effect on your skin? 






Other types of light? 
Can you describe the sensation you 
experience after exposure to light? 
Can you give an indication of the maximum 
tolerance you have to light exposure? i.e. 
how long can you spend in the sun without 
experiencing any symptoms? 
No: 13/16 (81) 
No: 14/16 (88) 
Burning: 13/16 (81) 
Pain: 7/16 (44) 
Heat: 6/16 (38) 
Tingling: 6/16 (38) 
Swelling: 5/16 (31) 
Summer: 
Up to 30 min: 11/16 (69) 
Winter: 
More tolerance: 9/16 (56%) 
And reflection thereof: 2/16 (13) 
Only after exposure to sunlight: 3/16 (19) 
All other types of light: 1/16 (6) 
Incandescent (after exposure): 1/16 (6) 
Redness: 3/16 (19) 
Irritating: 3/16 (19) 
Rash: 2/16 (13) 
Itching: 1/16 (6) 
Blisters: 1/16 (6) 
Summer: 1-2 h: 2/16 (13) 
Less tolerance (not specified): 3/16 (19) 
Early summerlshade: 1-4 h: 4/16 (25) 
Winter: 2-8 h: 4/16 (25) 











No. Question Most common response (%) Other responses (%) 
7. Does the length of exposure, type of light etc More severely affected in summer One patient suffers more in the winter sun: 
that you are sensitive to vary during the year months: 15/16 (94) 1/16(6) 
or is the severity of symptoms constant 
throughout the year? 
8. For what length of time do the symptoms 12 h-2 days: 10/16 (63) 3-5 days: 5/16 (31) 
persist? More than a week: 1/16 (6) 
9. How do you attempt to relieve the symptoms Ice Medication: 3/16 (19) 
described above? Cold water Shade/darkness: 3/16 (19) 
Cold, wet cloths Body lotion: 2/16 (13) 
Compresses etc: 14/16 (88) Rubbing, sleep or a fan: 1/16 (6) 
10. Do you experience any other physical Yes: 10/16 (63) Bruising, brittle or fragile skin: 3/16 (19) 
symptoms after light exposure or that you Anaemia and low platelet count: 3/16 (19) 
think may be attributed to porphyria? Slow wound healing: 2/16 (13) 
Fatigue: 1/16 (6) 
Nausea, anxiety: 1/16 (6) 
Insomnia: 1/16 (6) 
11. What specific precautions do you take to limit Avoid sunlight: 15/16 (94) Sun cream: 3/16 (19) 
exposure to sunlight or to protect yourself Protective clothing: 13/16 (81) Umbrella: 1/16 (6) 












12. Have you noticed any scarring or thickening 
of your skin? 
13. In which areas is this most apparent? 
14. At what age did you/a family member first 
become aware of the photosensitivity? 
15. At what age were you diagnosed? 
16. Can you describe the level at which you find 
the disease debilitating? i.e. to what extent 
does it affect your lifestyle? 
17. Have you ever suffered from gall stones? 
18. Have you ever been investigated for a liver 
complaint? 
19. Is there a previous family history of 
photosensitivity? 
Most common response (%) 
Scars 11/16 (69) 
Thickening of the skin: 9/16 (56) 
Hands and knuckles: 14/16 (88) 
Face (nose, lips ears): 9/16 (56) 
9 months-6 years 9/16 (56) 
5-13 years: 9/16 (56) 
Moderately/severely: 12/16 (75) 
Socially: 8/16 (50) 
Lifestyle: 5/16 (31) 
No: 14/16 (88) 
No: 15/16 (94) 
No: 10/16 (63) 
Other responses (%) 
None: 3/16 (19) 
Feet 4/16 (25) 
Neck, arms and elbows: 3/16 (19) 
7-10 years: 5/16 (31) 
2 unsure 
9 months-4 years: 3/16 (19) 
26 and 31 years: 2/16 (13) 
2 unsure 
Minimal/mildly: 4/16 (25) 
Career: 4/16 (25) 
Worse when younger: 4/16 (25) 
Sport: 2/16 (13) 
Yes 2/16 (13) 
Yes: 1/16 (6) 
Parent: 4/16 (25) 











5.7.2. Biochemical diagnosis of EPP 
5.7.2.1. Preliminary red blood cell porphyrin screening 
All 28 symptomatic EPP subjects screened positive for increased red blood cell 
porphyrins (data not shown). 
5.7.2.2. Plasma fluorescence scanning 
Blood samples from 23 of the 28 symptomatic EPP subjects, were subjected to plasma 
fluorescence scanning. Of these, 19 had a plasma porphyrin peak ranging between 
625nm and 632nm whereas the remaining 4 did not (Table 5.8). Depending on the 
amount of fluorescence observed, plasma protoporphyrin IX concentrations were noted 
as +/-, + or ++, indicative of low to high concentrations of plasma protoporphyrin IX. 
None of the 46 asymptomatic family members scanned exhibited a plasma porphyrin 
peak. 
5.7.2.3. Porphyrin quantitative analysis 
Table 5.8 shows the red blood cell protoporphyrin IX concentrations in the study cohort 
as determined by quantitative thin-layer chromatography. All 28 symptomatic EPP 
subjects had raised protoporphyrin IX concentrations with a mean of 15843nmoilL 
ranging from 2730nmoi/L to 50000nmo1lL. In all cases this was above the 1000nmoilL 
control reference range routinely used in our laboratory. Of these, 25 had 
concentrations above 4000nmoilL used by certain other international laboratories. In 
addition, 24 asymptomatic individuals in the study cohort had concentrations above 
1000nmol/L. In addition, Table 5.8 records the disease status (symptomatic or 
8,:,;yrnptomatJc) and carrier status (for the IVS3-48C polymorphism and the primary 














Table 5.B. results disease status, carrier status 
respect to disease-associated variations, plasma scanning results and RBC protoporphyrin IX concentrations 
Subject 
(I;: Proband) 

























IVS3-48C Primary mutation 
+- 757_761 delAGAAG 
+- 757 _761deIAGAAG 
.,... -




""Plasma porphyrin RBC protoporphyrin IX (nmoIlL) 
scan (Normal = <1000) A 
625nm '+-/- 23723 






630nm +/- 5160 















Subject Disease Carrier status *Plasma porphyrin RBC protoporphyrin IX (nmoI/L) 
(I = Proband) status IVS3-48C Primary mutation scan (Normal = <1000) A 
EPP 3.1 (I) Symptomatic +- 757 _761deIAGAAG Not done 23200 
EPP 3.2 Symptomatic +- 757_761 delAGAAG 630nm ++ 50000 
EPP 3.3 Asymptomatic +- Normal 520 
EPP 3.4 Asymptomatic 757_761 delAGAAG Normal 750 
EPP 3.5 Asymptomatic +- Not done 892 
EPP 3.6 Asymptomatic Normal 263 
EPP 3.7 Asymptomatic Normal 633 
EPP 4.1 (I) Symptomatic +- 757_761 delAGAAG 630nm +/- 23733 
EPP 4.2 Symptomatic +- 757 _761deIAGAAG Normal 23800 
EPP 4.3 Asymptomatic +- Normal 800 
EPP 4.4 Asymptomatic -t-- Normal 525 
EPP 4.5 Asymptomatic 757 761 delAGAAG Normal 5612 
EPP 4.6 Asymptomatic +- Normal 10177 
EPP 4.7 Asymptomatic Normal 1600 
EPP 5.1 (I) Symptomatic +- 356_362de1TTCAAGA 625nm + 7200 
EPP 5.2 Symptomatic +- 356_362deITTC.AAGA 625nm + 3500 
EPP 5.3 Asymptomatic 356_362de1TTCAAGA Normal 670 
EPP 5.4 Asymptomatic +- Normal 250 
EPP 5.5 Asymptomatic +- Normal 257 














































IVS3-48C Primary mutation 
delAGAAG 
+-















*Plasma porphyrin RBC protoporphyrin IX 
scan (Normal = <1000) 
No new sample 12027 (old sample) 
No new sample 3917 (old sample) 
No new sample 7876 (old sample) 






630nm + 11083 
No new sample 5912 (old sample) 
625nm +/- 9343 
Normal 8138 














(I = Proband) 











EPP 11.1 (I) 
EPP11.2 






















EPP 13.1 (I) Symptomatic 
EPP 13.2 Asymptomatic 
EPP 13.3 Asymptomatic 
EPP 13.4 Asymptomatic 
Carrier status 















Unknown (no DNA) 
+ - 757_761de1AGAAG 
757 _761 deIAG,AAG 
757_761 delAGAAG 




*Plasma porphyrin RBC protoporphyrin IX (nmollL) 












No new sample 















7553 (old sample) 





630nm +/- 19283 
Normal 385 
Normal 870 











Subject Disease Carrier status *Plasma porphyrin RBC [rotoporphyrin IX 
(I = Proband) 








































--r- = Heterozygous for the IVS3-48TiC n",vmnmh 
= Homozygous for the IVS3-48T a!1ele 
++ = Homozygous for the IVS3-48C allele 




























EPP Resoective EPP families 
? Disease status unknown or uncertain 
1\ See section 6.5.2 
concentration 



























5.7.2.4. Determination of free and zinc-chelated protoporphyrin IX concentrations 
in blood samples from EPP subjects 
Analysis of whole blood samples from EPP subjects to determine the free and zinc-
chelated protoporphyrin IX concentrations was performed by fluorescence spectrometry 
(Table 5.9). Free protoporphyrin IX concentrations were higher than zinc-chelated 
protoporphyrin IX concentrations in 20 of the 23 EPP subjects tested, while 3 subjects 
in family EPP8 (EPP8.1, EPP8.4 and EPP8.S) had zinc-chelated protoporphyrin IX 
concentrations that were up to two-fold higher than the free form Samples were 
unavailable for testing for S further subjects. 
Table 5.9. Summary of zinc-chelated and free protoporphyrin IX concentrations in 
blood samples from EPP subjects. Results in relative fluorescent units (RFU) 
Subject Zinc-chelated protoporphyrin IX 
(RFU "em 588nm) 
Free protoporphyrin IX 
(RFU "em 632nm) 
Control (n::::: 5) Range: 14-54 Range: 1-32 
----------------------------------------------------------~-~------------------------. 
EPP 1.1 50 479 
















EPP 4.2 24 43 
--------------------------------------------------------~-----------~----------------, 










EPP 7.1 102 523 


































Zinc-chelated Protoporphyrin IX 











Free Protoporphyrin IX 




































The significant advances that have been made in the past five years to explain the 
inheritance pattern observed in EPP have led to a new interest in determining the 
genetic status of EPP subjects in various population groups. No other studies of this 
nature in EPP subjects in South Africa have been reported to date. This discussion will 
be presented in keeping with the results section. Genetic analyses will be discussed 
first, followed by the clinical information and biochemical data. 
6.1 Analysis of the FECH gene 
6.1.1. Methodologies 
In this study, the use of PAGE to visualise amplified PCR products was useful as a first-
line screening method for the two heterozygous deletions identified. PAGE exploits the 
potential of acrylamide to distinguish between hetero- and homoduplexes. 
Heteroduplexes may arise during the final stages of PCR amplification of genomic DNA 
where two different alleles for the fragment of interest are present (Upchurch et al. 
2000; Thompson et al. 2002). Heteroduplexes migrate more slowly than their 
corresponding homoduplexes as a result of a more open double-stranded configuration 
surrounding the mismatched bases. Heteroduplex formation was seen on analysis of 
the amplification product of exon 7 for subjects carrying the 757_761 delAGAAG 
deletion and of exon 4A for subjects carrying the 356_362deITTCAAGA deletion 
(Figures 5.1 and 5.2). Any possible confusion of heteroduplex bands with non-specific 
priming was resolved by including wild type control DNA samples for PCR optimisation. 
The presence of multiple amplification bands such as these is only an indicator of a 
possible sequence variation and products were still subjected to SSCP analysis and 
sequencing for verification and identification. Heteroduplex formation has been 
observed previously on analysis of the FECH gene when a heterozygous deletion of 











One difficulty associated with the separation of nucleic acids by PAGE is the incorrect 
sizing of fragments as they are not only separated according to size but also 
conformation. Some amplification fragments separated on acrylamide do not migrate 
with the expected molecular weight marker fragment because of "conformational 
bending of the helix duplex" (Marini et al. 1982; Lareu et al. 1998). Sequencing is then 
necessary to determine whether the correct fragment has been amplified or not. 
Single stranded conformational polymorphism analysis is a relatively efficient, cost 
effective method for mutation detection. An 80% mutation detection rate for SSCP has 
been reported for fragments ±200bp (Hayashi 1992; Sheffield et al. 1993) and 
mutations that are not revealed under specific running conditions may be detected by 
altering such conditions. In our study, the addition of 10% glycerol to the SSCP gel 
allowed detection of variations that were otherwise not observed. The sensitivity of this 
method for mutation detection was demonstrated by the analysis of FECH exon 7. Six 
distinct banding patterns were observed on the gel (4 of these are shown in Figure 
5.5A) representing combinations of 3 variations, namely 757_761deIAGAAG, 
IVS7+1G>A and P266P. The latter is a polymorphism and both the homozygous and 
the heterozygous states were observed in this set of samples. 
6.1.2. Characterisation of the EPP cohort 
One of the objectives of this study was to ascertain the prevalence of the FECH IVS3-
48C polymorphism in the South African EPP cohort. This polymorphism was present in 
15 of the 17 EPP families in this study and in 9% of the matched control cohort. This 
high prevalence in the EPP cohort strongly supports a role for this polymorphism in 
modulation of the penetrance of EPP, as proposed by Gouya et al (2002), in population 
groups exhibiting this polymorphism. This result was not entirely unexpected in that all 
these families are of European ancestry. The IVS3-48C polymorphism will be further 
discussed where relevant. The absence of the IVS3-48C polymorphism in one family 
(EPP8) demonstrates that other mechanisms must exist for the clinical expression of 
EPP as has been reported on a few previous occasions (Aplin et aL 2001; Onaga et at 
2004, Oi Pierro et aL 2005; Goodwin et al. 2006). We were unable to detect any 
disease-associated mutations in the FECH gene for this family. Compound 
heterozygosity is therefore not a likely mechanism of disease in this case. In addition, 
heterozygosity for certain polymorphisms across FECH was demonstrated, excluding 
the possibility of a whole gene deletion. 
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6.1.2.1. FECHprimary mutations and polymorphisms identified 
The South African EPP cohort is characterised by some allelic heterogeneity. Of the 10 
variations observed in the cohort, only 4 are likely to be disease-causing, the rest being 
common FECH polymorphisms. The low allelic heterogeneity can be explained by the 
observation that 71 % (12117) of the families in our cohort carry the same FECH 
mutation namely, 757_761 deIAGAAG. This probably corresponds to a previously 
reported 5bp deletion in exon 7 (751deIGAGAA) described in Finland by Henriksson et 
al (1996), and subsequently observed by Chen et al (2002) and Gouya et al (2006) 
(c751deIGAGAA and c757deIAGAAG) in the USA and France, respectively. The 
difficulties encountered when a single mutation is assigned multiple names, highlights 
the importance of the adoption of a common nomenclature for sequence variations so 
as to facilitate easier mutation tracking around the world. The 757 _761deIAGAAG 
deletion results in a frameshift, producing a truncated protein of 321 amino acids. 
The other three disease-associated sequence variants identified were family-specific, 
and included one novel deletion (356_362 deITTCAAGA) , and 2 donor splice-site 
mutations, IVS3+2T>G, previously identified in the UK, USA and France (Sarkany et al. 
1994; Chen et al. 2002 and Gouya et al. 2006) and IVS7+1 G>A, previously identified in 
Japan and France (Nakahashi et al. 1993 and Gouya et al. 2006). 
We predict that the 356_362de1TTCAAGA deletion results in a frameshift and a 
truncated protein of 141 amino acids. Although characterisation of this mutation at 
mRNA or protein level was not performed as part of this study, it is likely to be the 
disease-causing mutation in this family as the resulting transcript is not expected to 
produce a functional FECH protein. Furthermore, the deletion was identified in both the 
mother and grandmother of the proband, who were asymptomatic as they were 
negative for the IVS3-48C polymorphism. 
The IVS3+2T>G splice-site mutation is reported to result in exon 3 skipping (deletion of 





















The IVS7+1 G>A mutation results in skipping of the 99bp of exon 7 with the loss of 
amino acids 236-268 in the final protein product (Nakahashi et al. 1993). Although the 
skipping of this exon does not result in a frameshift, the transcript is likely to produce an 
inactive enzyme presumably as a result of significant structural variations (Sellers et al. 
1998). 
A single novel polymorphism was identified in our South African EPP cohort, namely 
IVS1 0-61 G/A (frequency: 4%). It was found to have a prevalence of 13% in the 
matched control cohort and does not appear to be disease-associated (p = 0.073). The 
prevalence of the other previously identified polymorph isms (Ta ble 5.1) ranges from 9-
28% in the control cohort. The IVS3-48C polymorphism was significantly associated 
with EPP in our cohort (p<0.0001) as observed in other populations. 
6.1.2.2. Inheritance of disease-associated alleles 
Seventeen symptomatic subjects from 12 families in our South African EPP cohort carry 
the 757_761de1AGAAG deletion. Of the 17, 12 subjects from 8 of the 12 families were 
confirmed to have inherited the IVS3-48C polymorphism in trans to the primary 
mutation. Asymptomatic carrier parents and siblings of symptomatic individuals from 
these 8 families, in contrast, had an IVS3-48T allele in trans to the mutant allele. It is 
probable that the polymorphism is similarly inherited in three other families and 
haplotype analysis (section 5.6) supports this for two of these (EPP1 and EPP10). 
However, as both parental DNA samples were unavailable for phase determination of 
chromosomes in the third family (EPP17), one cannot definitively conclude that the 
polymorphism is inherited in trans to the primary mutation. 
One seemingly symptomatic individual in family EPP6 carries the 757 _761de1AGAAG 
deletion but lacks the IVS3-48C polymorphism. Surprisingly, his apparently 
symptomatic brother is positive for the IVS3-48C polymorphism but negative for the 
primary mutation. Unfortunately we were unable to obtain repeat blood samples from 
these two brothers for confirmatory testing and there was a paucity of clinicallfamily 
data accompanying the original blood samples on which our diagnoses were made. 
Based on the genotyping results, neither subject would be predicted to exhibit 
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The IVS 1-23T polymorphism has previously been reported as potentially disease-
associated (Nakahashi et al. 1992) despite the acknowledgement that it is a common 
polymorphism (Wang et al. 1994; de Rooij et al. 1996). This was found to be true 
indirectly, in that the functional disease-associated IVS3-48C polymorphism, which was 
subsequently identified, is in linkage disequilibrium with the IVS1-23T polymorphism 
(Gouya et al. 1999). Our results confirm that these polymorph isms are in linkage 
disequilibrium (Lewontin (1964) D' = 1; [IVS1-23C; IVS3-48C] allele absent in the 
cohort). A single asymptomatic individual carries an [IVS1-23T; IVS3-4BT] allele in trans 
to the 757 _761 delAGAAG deletion, excluding a direct association of the IVS 1-23T 
polymorphism with disease expression, and providing additional support for the role of 
the IVS3-4BC polymorphism in disease expression. 
The above inheritance pattern, i.e. coinheritance of the IVS3-4BC polymorphism in trans 
to the primary mutation, was also observed in the 3 other families in which we identified 
distinct primary mutations (EPP5, EPP7, EPP13). Thus, in total, 11 of 17 families 
followed the expected mechanism for disease expression as described by Gouya et al 
(2002). In 3 further families the same mechanism is likely to be operational, although 
not confirmed, as both the IVS3-48C polymorphism and a specific primary mutation are 
present. Disease expression in 1 family (EPP6) cannot be explained with the current 
results, despite the presence of a primary mutation. Furthermore, there were 2 families 
in which we were unable to detect the primary mutation responsible for EPP in the 
symptomatic individual. The IVS3-4BC polymorphism is present in one of these families 
(EPP11) but is absent in all 5 symptomatic individuals in the other family (EPPB). 















6.1.3. Screening for identified sequence variations 
Restriction endonuclease analysis provided a fast, reliable method of screening for 
previously identified sequence variations, including those identified in this study, that 
are common in the population. For example, the prevalence of the 757 _761deIAGAAG 
deletion in our cohort suggests that it is likely to be present in other South African EPP 
families, Thus, the most valuable application of Mbo II restriction analysis was to initially 
screen newly identified families for this mutation. Those found to be positive were 
excluded from further unnecessary and time-consuming mutation detection. 
In addition, restriction endonuclease analysis was effectively used to determine the 
prevalence of observed sequence variations in the study and control cohorts (Tables 
5.1 and 5.2) and to confirm that the 4 suspected primary mutations identified were 
absent in more than 150 normal control chromosomes. 
An important application of restriction endonuclease analysis is to identify asymptomatic 
carriers, This is necessary for genetic counseling of family members where the family-
specific mutation has been identified. In the context of EPP, accurate risk assessment 
involves screening for both the primary mutation and the IVS3-4BC polymorphism. The 
risk of having a child affected with EPP, when one parent is a mutation carrier and the 
other has either the IVS3-48C polymorphism or a second FECH mutation, is 25% with a 
50% chance of being a carrier of one of the disease-associated alleles. The risk 
decreases significantly when the spouse of a primary mutation carrier does not carry 
the IVS3-48C polymorphism. Gouya et al (2006) have suggested that the prevalence of 
EPP in a population is related to the prevalence of the polymorphism in that population. 
For example the prevalence of the IVS3-4BC polymorphism in West Africa is <1 % and 
few cases of symptomatic EPP have been reported in Black Africans. It is therefore 
probable that, although EPP is rare in South Africa, the number of 757_761de1AGAAG 
mutation carriers is higher than documented in this study because symptomatic disease 

















6.2. Haplotype analysis 
The prevalence of the 757_761 delAGAAG deletion in a subset of the South Africa EPP 
cohort, and the fact that they are all Afrikaans-speaking individuals, is suggestive of a 
common ancestor. In the light of previous reports of this mutation in this population it is 
most likely that the founder was an immigrant from Europe (Henriksson et al. 1996; 
Gouya et al. 2006). It was not possible to establish a common genealogy for these 
families but it was considered worth further exploration. 
Thus, in order to investigate the possibility of a single ancestral event for the 
757 _761deIAGAAG deletion, we assessed the genomic sequence to identify 
microsatellite markers for haplotype analysis. Microsatellite markers account for ±3% of 
the human genome and have an average density of ±1 in 2kb (Lander et al. 2001; 
Chang et al. 2005). They are generally unstable although they remain stable in 
pedigrees because of a relatively low germ line mutation rate (1 X 10.4 mutations per 
locus per gamete) (Banchs et al. 1994). Depending on their sequence variation and 
length they can be highly polymorphic. A microsatellite is considered polymorphic if it 
has a heterozygosity (the probability that an individual will be heterozygous at a given 
locus) of >10%. SNP genotyping is becoming increasingly popular for haplotype 
analysis (Daly et aJ. 2001; Lin et al. 2005). Our decision to use microsatellites and not 
SNPs was based on the greater informativity (higher heterozygosity) of microsatellite 
markers. In contrast to microsatellites, each SNP only has two possible alleles and a 
higher number of SNPs are therefore needed to form a haplotype block that can 
distinguish one FECH allele from another. 
Published microsatellite markers (X69298, 018S381 and 018S858) were found to be 
unsuitable because of interrupted repeat sequence and low heterozygosity. Therefore, 
three new microsatellite markers spanning a region of ±700kb across FECH were 
designed. Symptomatic individuals and family members were genotyped for these three 
markers, to determine whether a common haplotype was shared among individuals 
carrying the 757 _761 delAGAAG deletion. The maximum heterozygosity of the selected 
markers (where frequencies of all alleles are considered equal) ranged from 90-94%, 













A restricted haplotype [4; C; 8; G] that excludes marker FECH-MM2tg was observed in 
88% of symptomatic individuals carrying the 757 _761deIAGAAG deletion (Table 5.4) 
and a complete haplotype [4; C; 8; G; 4] was present in 47%. These haplotypes were 
shown to be identical by descent as they were present in asymptomatic mutation 
carriers. Haplotype phase for 2 individuals was uncertain because of a lack of parental 
DNA samples. However, alleles corresponding to the complete haplotype were present 
in each of these samples, and it is likely that they do indeed share this haplotype. 
It is important to note that the variability in the haplotypes of this cohort only involves 
the most 3'-marker FECH-MM2tg. This marker lies within 300kb downstream of the 
FECH gene and numerous recombination events are not expected within such a short 
physical distance. Indeed, the recombination rate across this region is reported as 
approximately 1 % for published markers (http://www2.marshfieldclinic.org/RESEARCH/ 
GENETICS/Map_Markers/maps). A single recombination event was observed in this 
cohort for individual EPP2.1, suggesting that recombination may have been a 
mechanism involved in the variability of this marker. This would suggest that, provided 
the deletion was produced by a single ancestral event, this mutation is likely to be very 
old as the haplotype block is small. Many years would be needed to accumulate 
sufficient recombination events that could lead to the observed variability in marker 
FECH-MM2tg. Alternatively. this single intra-familial recombination may suggest a 
recombination hotspot in this region which would account for the marker variability but 
would decrease the time span necessary for such mutations to accumulate. 
As mentioned previously, microsatellite markers are unstable and the variability of 
sequence length is more likely to be the result of insertion-deletion loops that arise from 
'slippage' of the polymerase during replication (Ellegren 2004). Polymerase 'slippage' is 
the result of dissociation of the template DNA strand and newly synthesised strand 
during replication. Misalignment of strands on re-association results in unpaired bases 
forming a loop that, if not repaired, causes reduction or expansion of the repeat 















A comparison of the haplotype associated with the 757 _761deIAGAAG deletion and 
those associated with the 3 family-specific primary mutations supports the presence of 
a distinct common haplotype. In the case of the "non-757 _761deIAGAAG deletion 
carriers", the alleles at each locus, except for FECH-MM2tg, were not consistent with 
the [4; C; 8; G; 4] haplotype. 
To investigate the prevalence of each allele of the common haplotype, 50 randomly 
selected, matched control individuals were genotyped for these markers. Respective 
allele frequencies observed were; 11 % for allele 4 (FECH-MM3gt), 22% for allele 8 
(FECH-MM1ac) and 10% for allele 4 (FECH-MM2gt) in this cohort. A subset of 28 
family members provided a more closely, ethnically-matched control group. The 
frequencies of the above alleles were found to be similar to that of the control cohort. 
The low frequencies of these alleles when compared to the EPP cohort suggest that the 
[4; C; 8; G; 4] haplotype is more prevalent than would be expected by chance 
(p<0.005). These results suggest the presence of a common ancestral allele for the 
757 _761deIAGAAG deletion. 
6.3. Unresolved cases (families EPP11 and EPP8) 
The primary (disease-causing) mutation was not established for two symptomatic 
individuals in our cohort. The first is family EPP11 where the IVS3-48C polymorphism 
was found to be present on a single allele. This family, originally from Canada, is 
unavailable for further investigation and the proband is since deceased. 
It is possible that not all sequence variations may have been detected by the SSCP 
method, particularly in the case of exon 1, where the amplification fragment was 
relatively long, and the high GC-content resulted in smearing of the band(s) on PAGE. 
Where necessary, exon 1 amplification fragments were subjected to direct sequencing 
to overcome such a problem but no sequence variations were identified. 
103 
 











In the second family (EPP8), who are of Jewish ancestry, the IVS3-48C polymorphism 
was not observed. Although this family falls outside the scope of the present study, it is 
of great interest, as a symptomatic individual died of liver disease, most likely 
associated with EPP (Eales et al. 1978a, b). Family EPP8 is distinct from the other EPP 
families in that the disorder appears to act in a highly penetrant fashion, and there are 
more symptomatic individuals than is usually observed. 
Haplotype analysis of the symptomatic individuals in family EPP8 suggested that FECH 
could be excluded as the gene responsible for EPP in this family, as symptomatic 
individuals did not share a single haplotype associated with FECH. Thus it appears that 
although a FECH defect may have a role in modifying the phenotype, the primary 
mutation does not lie at this locus. 
6.4. Patient presentation and perception of their disease 
A total of 28 symptomatic EPP individuals are currently documented in the UCT 
Porphyria Laboratories database. Based on this information and the mid-year (2006) 
population estimates for South Africa (http://www.statssa.gov.za/PublicationsHTMLI 
P03022006/htmI/P03022006.html: accessed 060806) we estimate the prevalence of 
EPP in South Africa to be 0.6 per million and 6.4 per million in the white South African 
population, specifically. 
Our questionnaire revealed that the majority of our EPP subjects experienced their 
disease similarly to those reported in other studies. As with the subjects reported by 
Rufener (1987) our subjects were grateful to be able to discuss their disease with health 
professionals with specialist porphyria knowledge. In many cases this was their first 
opportunity to do so. Subjects readily discussed their disease and were eager to find 
out more about the pathogenesis of EPP, as most had received little information on 
diagnosis. Most subjects were diagnosed before their teens, which is also the 
experience of other populations as reported in the literature (Todd 1998; Schneider-Yin 















Our observation that slightly more males were affected than females is in keeping with 
other reports (Schmidt et aL 1974; Cox et al. 1998), although this appears not to be 
considered significant and. in recent years. has not drawn much comment Interestingly, 
in our patient interviews most men appeared to be more severely affected and 
perceived their symptoms to be worsening with age, whereas women thought that their 
disease activity had improved with advancing age. However, there could be many 
reasons for this, and the aims and nature of our study do not allow us to speculate or 
reach a definitive conclusion. 
Sensitivity to sunlight was the most frequent and dominant symptom that the subjects 
attributed to the porphyria. Other symptoms, not specified on the questionnaire but 
which were reported by the subjects, included slow wound-healing and bruising, fragile 
skin, fatigue, insomnia and anaemia. All these have previously been reported on 
occasion (Sweeney et al. 1963; 8aart de la Faille et al. 1991; Todd 1994; Murphy 
2003). 
The photocutaneous sensitivity observed in our EPP cohort appeared similar to that 
described in the literature (8aart de la Faille et al. 1991; Lecha 2003). In general. few 
physical signs were observed except for the characteristic elliptical scarring on the 
hands, feet and arms of subjects and thickening of the skin on the knuckles. Less 
affected areas were the face, particularly the nose, lips and ears, the neck and elbows. 
Subjects reported taking precautions to minimise exposure to light by avoiding sunlight 
and wearing protective clothing, such as hats. One family found applying sunscreen 
helpful. but most individuals did not report any benefit. The methods used by subjects to 
obtain symptomatic relief (mainly ice and cold water) were similar to those reported 
elsewhere (Todd 1994; Schneider-Yin et at 2000). 
Subjects perceived their disease as moderately to severely limiting, as their lifestyle had 
to be adapted to avoid activities that required them to be in the sun for any length of 
time. Those who reported their disease to be only minimally or mildly limiting felt that 
their lives had been more severely affected when they were younger, and their disease 
had influenced their choice of career and recreational and sporting activities. However, 
all felt they had been able to adapt to their disease. 
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6.5. Biochemical diagnosis of EPP 
6.5.1. Plasma fluorescence scanning 
Initial screening for EPP using plasma fluorescence scanning has proven to be an 
effective method for identifying individuals with increased plasma porphyrin 
concentrations (Poh-Fitzpatrick 1980; Hift et at 2004). Fluoroscanning for 23 of the 
symptomatic individuals in our cohort identified 83% by the presence of a plasma 
porphyrin peak in the 625-632nm range. A peak at ±630nm was observed for 49% of 
these individuals. as expected, and is indicative of increased protoporphyrin IX 
concentrations and therefore EPP (Elder et al. 1990). However, a peak at ±625nm is 
usually associated with VP and 35% of these individuals presented with a peak in this 
range. "Normal" plasma scan profiles were observed for 17% of these symptomatic 
individuals and were generally associated with lower protoporphyrin IX concentrations 
(2700-8200nmoIlL). 
There have been various explanations given for both the lack of a plasma porphyrin 
peak and the presence of a peak at 625nm in EPP samples. It is presumed that a high 
concentration of protoporphyrin IX in the RBCs results in diffusion of this molecule into 
the surrounding plasma down the concentration gradient (Schothorst et al. 1970). On 
this basis, relatively low protoporphyrin IX concentrations in the red blood cells may not 
produce a strong-enough concentration gradient, resulting in a "normal" plasma 
porphyrin fluorescence scan. In 3 of our subjects, a normal scan was observed for 
samples that had high red blood cell protoporphyrin IX concentrations (EPP4.2: 
23800nmo1fL; EPP4.6: 1 0177nmolJL and EPP14.3: 10120nmoIJL). There is no obvious 
explanation for this and we were unable to obtain repeat blood samples. Interestingly, 
only EPP4.2 was symptomatic and EPP4.6 was found to be heterozygous for the IVS3-
48T/C polymorphism but lacked her family-specific FECH mutation. EPP14.3 was a 
primary mutation carrier. 
106 












One suggested reason for the maximum plasma emission peak at 625nm rather than 
the more common 632nm makes reference to bound protoporphyrin IX (e.g. to albumin) 
observed in VP (Lamola 1982; Elder et al. 1990). It has been speculated that this may 
occur as a consequence of the time elapsed prior to sample analysis or the handling of 
samples during transportation (Elder, Porphyria conference 2005). This underlines the 
importance of fresh samples and rapid analysis in the laboratory. This was not always 
achievable in our study as a proportion of the samples were collected from areas 
geographically distant from our laboratory in Cape Town. 
6.5.2. Porphyrin quantitative analysis 
Quantitative analysis confirmed that all symptomatic EPP subjects had raised 
protoporphyrin IX concentrations (range: 2730nmo1/L-50000nmo1lL, mean: 
15843nmoI/L). I n our laboratory we generally consider 1 OOOnmol/L to be the upper limit 
of normal (Day 1978). In the literature the upper limit of normal is variously reported as 
1900nmoi/L (Gouya et al. 2006), 2000nmoi/L (Sil et al. 2004), 4000nmoliL 
(www.porphyria-europe.com) or a total erythrocyte porphyrin of 0.4-1.7~lmoI/L with 
>90% protoporphyrin IX (Goodwin et al. 2006; Wood et al. 2006). It should be noted 
however, that protoporphyrin IX concentration determination varies between 
laboratories, and these reference ranges correspond to different methods. It may 
therefore not be appropriate to equate these directly. 
Symptomatic primary FECH mutation carriers consistently showed increased 
protoporphyrin IX concentrations, as expected. In addition, 65% (11/17) of 
asymptomatic carriers had concentrations above 1000nmoi/L (range: 1271-
10120nmol/L, mean: 2947nmo1/L) or, using an upper limit of normal as 4000nmollL, 
1/17 (6%). This has also been observed previously and highlights the fact that raised 
RBC protoporphyrin IX concentrations alone do not correlate with presence/absence of 
clinical disease. The majority of family studies reveal normal to mildly raised 
protoporphyrin IX concentrations for asymptomatic FECH mutation carriers (Sarkany et 
al. 1994; Imoto et aL 1996; Henriksson et aL 1996; Wang et al. 1997; Frank et al. 1999; 
Chen et al. 2002; Risheg et al. 2003; Bloomer et al. 2005) making molecular techniques 
necessary for unequivocal detection of carriers (Rufenacht et al. 1996). Interestingly, a 
RBC protoporphyrin IX concentration above the normal limit (1760nmoI/L) was 
















In our families, with one exception, the elevated protoporphyrin IX concentrations were 
shown to be predominantly in the free form. This correlates with the accepted 
biochemical presentation of EPP (Elder 1990). The exception was family EPP8, who 
showed a higher proportion of zinc-chelated to free protoporphyrin IX in 3 subjects, yet 
EPP photocutaneous sensitivity is present. In other conditions where zinc-
protoporphyrin IX accumulation is a feature, such as iron-deficiency anaemia, 
photosensitivity is absent. This is the only family in which liver disease was recorded 
and, interestingly, this family has been shown previously to carry a glucose-6-
phosphatase deficiency (Eales et aL 1978a, b). Symptomatic individuals in this family 
report anaemia and a positive response to iron therapy however this does not explain 
the elevated free protoporphyrin IX concentrations. This is one of two families in which 
we were unable to identify a FECH mutation and represents an atypical form of EPP 
possibly similar to that observed in a family by Wilson and De Rooij (personal 
communication 2005). Clearly, further investigation of this family is indicated but, as 




























7.1. In conclusion: 
CHAPTER 7 
Conclusions and Future Studies 
1. Ten FECH sequence variations were identified in the South African EPP cohort 
a) Of these, four were regarded as primary mutations as they were absent in a 
matched control cohort, and three (IVS3+2T>G; 757 _761deIAGAAG; 
IVS7+1 G>A) had been previously reported as disease-causing. The fourth 
(356_362deITTCAAGA) was novel and requires further investigation. 
However the nature of the sequence variation (a 7bp deletion resulting in a 
frameshift) supports a disease-causing status for this mutation. 
b) Of the remaining 6 sequence variations, 5 were previously identified single 
nucleotide polymorphisms, including the IVS3-48C polymorphism, and were 
confirmed to be common in the matched control cohort. We also identified 
one novel common polymorphism (IVS10-61G/A) which was present at a 
frequency of 13% in the matched control cohort. 
2. The IVS3-48C polymorphism was observed in 15 of the 17 South African EPP 
families. Coinheritance of this polymorphism in trans to a defective FECH allele was 
confirmed in 11 of these families. The mechanism of modulating the phenotypic 
expression of EPP, as proposed by Gouya et al (2002), therefore appears to be 
operational in the South African cohort for the majority of families. This polymorphism 











3. Tile 757_761 delAGAAG deletion appeared significant in a local context as it was 
present in 12 of the 17 families in the EPP cohort Haplotype analysis across the 
FECH gene revealed a common haplotype associated with the 757 _761deIAGAAG 
deletion in which the specific alleles are present at a higher frequency than in the 
matched control cohort We speculate that tile 757_761 delAGAAG deletion is the 
product of a single mutational event and suggest that these EPP subjects are likely 
to be descended from a common ancestor. 
7.2. Future studies 
1. For a truly complete genetic characterisation of our cohort, it may be deemed 
necessary to investigate the regulatory (Le. promoter) and untranslated regions of 
FECH 
2 Characterisation of the novel 356_362de1TTCAAGA deletion (family EPP5) should 
be undertaken at an mRNA or protein level to confirm its likely pathogenicity. For 
example, quantitation of the mRNA by reverse transcription or protein expression 
studies may show whether or not FECH concentrations are below a critical threshold 
limit as routinely observed in symptomatic EPP. 
3. Parental DNA samples necessary to complete 3 of the families could, where 
possible, be obtained for complete family haplotype analysis and to determine 
chromosomal phase, in order to confirm that the IVS3-48C polymorphism is inherited 
in trans to the defective allele in these families. 
4. A further microsatellite marker could be designed between FECH-MM1ac and 
FECH-MM2gt and genotyping completed to attempt to obtain a smaller haplotype 
block that is shared by all 757 _761deIAGAAG deletion carriers. 
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5. Further investigation of family EPP8 is essential. Although the FECH locus does not 
appear to be the primary disease-associated site in this family, a role for FECH in 
modifying disease expression is indicated. The biochemistry of EPP in this family 
should be more thoroughly investigated by assaying the FECH functional activity in 
affected individuals, to determine whether or not a reduced FECH activity is present. 
If a FECH deficiency is confirmed to play a role in disease manifestation, then 
mutation detection should be completed for the un investigated regions of the gene, 
including screening for major deletions (e.g. an entire exon which will not be 
identified using peR-based mutation detection methods). A second method, namely 
restriction fragment length polymorphism analysis by southern blotting, may also be 
employed. Hypermethylation of the FECH promoter has been described (Onaga et al 
2004) and has been shown to reduce FECH expression, apparently increasing the 
severity of EPP and is possibly associated with liver disease in a single individual. 
This could be investigated as a possibility in family EPPS. Failing any clear FECH 
anomaly it would be prudent to consider a second disease-associated locus that, 
when mutated, would result in the EPP phenotype, i.e. a phenocopy. As EPP has 
generally not been described as heterogeneous with respect to the disease-
associated locus such a finding would have a significant impact on the molecular 
understanding of EPP, particulal1y as 3 of the 5 symptomatic individuals in this family 



























Patient Information and Consent 
A.1. Patient correspondence and EP P infonnation sheet 
LIVER RESEARCH CENTRE 
OF THE MEDICAL RESEARCH COUNCIL (MRC) 
AND THE UNIVERSITY OF CAPE TOWN 
Medical School, University of Cape Town, Observatory, 7925 
Tel. +27-21-4066332, Fax: +27-21-4479670 or 4486815; Email: RJH@liver.uct.ac.za 
Date: ..... . ..................... . 
Address: .............................................. ................... . 
Name: ................................................................... . 
Re: Genetic Studies in Erythropoietic Protoporphyria 
As you are no doubt aware, erythropoietic protoporphyria (EPP) is a rare form of 
porphyria associated with abnormal sensitivity to sunlight. Attached you will find an 
infonnation sheet about the condition. Currently we are aware of 15 families with EPP in 
South Africa. We have carried out diagnostic and genetic investigations in 14 patients 
representing 12 of these families, including your own. (You may recall having provided 
us with blood samples for these genetic investigations a number of years ago, or we 
may have approached you more recently for samples.) 
When we first approached our families with a view to carrying out this investigation, we 
were not in a position to perform all the necessary research ourselves. Recently 
however, we have fanned a team to carry out the appropriate tests. The project is being 
carried out by Miss Michelle Parker, our postgraduate student, with technical 












EPP is a genetic illness. You may have read that it is an autosomal dominant condition, 
which implies that only one parent need carry a faulty gene for the disease to manifest 
in their children. Over recent years it has become apparent that this is not entirely true. 
Research performed in Europe has suggested that the disease only becomes clinically 
apparent in people who inherit a primary mutation from one parent, but who 
simultaneously inherit a so-called "[ow expression allele" from the other parent. In 
essence, this means that the second gene cannot fully compensate for the gene 
carrying the primary mutation. 
Michelle's study is designed to see whether this applies to our South African families as 
well. Furthermore, she is searching for the primary mutations responsible for EPP in our 
South African families. 
To this point we have turned up some interesting findings. Of the 12 families, we have 
successfully identified a primary mutation in 9. The remaining 3 have proved more 
difficult, and this work will continue. Seven of the 9 families carry the same mutation. 
One of our plans is to test the hypothesis that these families may all share a common 
ancestor. 
Ten of the 12 families carry the same "low expression allele" described from Europe, 
suggesting that the mechanism reported in those European patients operates in most of 
our South African families as well. Two families appear atypical; in one we can find 
neither a primary mutation nor the low expression allele, whereas the second requires 
further investigation. 
We hope that you will find this explanation interesting and potentially relevant to your 
family. We intend contacting you in the next few weeks, either by telephone or in 
person. It will be our pleasure to explain in more detail the relevance of these findings to 
you and your family and to answer any questions you may have. We may ask for your 
permission and cooperation in providing us with the information and samples we need 













This would be a matter of: 
• Answering a few questions about any symptoms experienced by members of your 
family 
• Providing us with the information we need to put together a limited family tree 
• Allowing us, if necessary, to obtain further blood samples from certain members 
of your family. 
• Should you agree to participate further, we will keep you fully informed as to our 
progress, and we will ensure that you benefit as much as possible with as little 
inconvenience as we can manage. 
We believe that our study will allow us to understand the mutations e identify and their 
effect on the expression of EPP in our South African families. Though it will not 
immediately translate into improvements in treatment, it will certainly enable us to 
provide your family with more complete diagnostic information and a better 
understanding of the disease. 
With kind regards 
Yours sincerely 
Professor R J Hift MB ChB MMed(Med) PhD FCP(SA) 























Erythropoietic protoporphyria (EPP) is one of the less common forms of porphyria. 
There are only a few families known to us in South Africa carrying this condition. It 
differs from the other porphyrias in several respects. 
It predominantly affects haem synthesis in red blood cells, rather than other organs 
such as the liver. The major enzyme defect is in red blood cells, and very high levels of 
protoporphyrin are seen in the red blood cells and plasma. Hence we concentrate on 
blood tests for diagnosis. 
Unlike the other porphyrias, where the disease is only usually noted in adult life, 
symptoms of EPP often develop in childhood, and even in infancy. 
EPP is not an acute porphyria. This means that patients with EPP will never suffer the 
acute attack. Patients with EPP for this reason need not follow drug precautions as all 
drugs are safe for them. 
The skin disease of EPP differs from that of the other porphyrias and is described in 
more detail below. 
INHERITANCE OF EPP 
EPP is inherited as an autosomal dominant condition. This means that the disease is 
transmitted from generation to generation, with each child (irrespective of sex) having a 
50% chance of inheriting the defective gene. However, it is known that even where a 
defective gene has been inherited, the person may quite commonly not show the 
disease at aIL In other words, one can inherit the disease without showing any sign of it: 
an example of variable expression. 
The story of the inheritance of EPP is very interesting. Recall that each of us inherits 
two genes for every characteristic: one from the mother, one from the father. It appears 
that those people who have inherited a gene for EPP and show the disease only do so 
because their second gene is a "slow" gene, which does not make as much enzyme as 
a "fast" gene. We call this a low-expression allele. Hence the patient shows signs of 
EPP because: 
One gene carries a mutation, and makes either a faulty enzyme or no enzyme at aiL 
The second gene is slow, and does not make enough normal enzyme to compensate. 
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CLINICAL MANIFESTATIONS OF EPP 
Skin Disease 
The skin disease of EPP is very typical and is quite unlike that of other forms of 
porphyria. The skin becomes exquisitely sensitive to sunlight. After a certain threshold 
of exposure has been reached, the patient experiences very severe burning, tingling, 
pain and sometimes numbness in the exposed areas of the skin, something like a very 
severe sunburn. We call this immediate photosensitivity. Often there is nothing actually 
to be seen in the skin; occasionally the skin may become red and swollen. Children with 
EPP learn from a very early age to avoid the sun. 
This contrasts with the skin disease of variegate porphyria and porphyria cutanea tarda. 
These patients do not have an immediate reaction to the sun. Often they are even 
unaware that the sun has any influence on their condition. However, they develop 
blistering, sores and scabs on the skin of the hands and face. Patients with EPP do not 
show these changes. 
In summary then, patients with EPP react very quickly and badly to the sun, but are left 
with much less permanent damage, whereas patients with VP and PCT suffer no 
immediate ill effects from the sun, but go on to show signs of permanent damage. 
In some cases, however, with continued sun exposure the skin of the patient with EPP 
may become coarse, thickened and rough. This is particularly noted over the bridge of 
the nose and on the knuckles. 
Liver Damage 
In EPP, the red blood cells produce vast amounts of a porphyrin known as 
protoporphyrin. This has three effects: 
Its accumulation in the red blood cells (as well as the interruption in the formation of 
haem) may result in a mild anaemia This is usually of no significance. 
Large amounts of protoporphyrin escape into the plasma and from there into the skin. 
Since porphyrins are light-sensitive, this probably accounts for the severe skin reaction 
to sun evinced in EPP. 
Large amounts of protoporphyrin pass through the liver where they are excreted into 
the bowel, emerging eventually in the stool. These large amounts of protoporphyrin may 
crystallise out in the bile (causing gallstones) and very occasionally sufficient may 
deposit in the liver to interfere with the normal functioning of liver cells. Such patients 
can eventually develop cirrhosis and liver failure. It must be stressed that this outcome 
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causes the liver damage; one has to inherit other less well-understood factors as well 
which is why the liver problems are uncommon. It is however necessary to know of it, 
as patients with EPP should have check-ups from time to time to ensure that this is not 
happening. 
HOW IS EPP DIAGNOSED? 
The finding of very elevated amounts of protoporphyrin in the red blood cells is 
characteristic. For the sake of completeness however we normally test the urine and 
stool as well. 
TREATMENT OF EPP 
Reduce exposure to the sun 
In the initial stages, this is the most effective action to take. Patients should limit their 
exposure to the sun to a period which they know from experience will not result in a 
painful reaction. They can increase the amount of time th y spend outdoors by avoiding 
the hottest part of the day, emerging early in the moming and later in the afternoon. A 
sensible choice of clothing, such as closed shoes, a hat, and long sleeves will be very 
helpful. Clothes should be made of cotton rather than artificial fibres, as cotton is a 
better sunscreen. Obviously as much of the body as possible should be covered, 
particularly the forearms, legs and feet; and the hands if possible. 
It must be stressed that conventional suntan preparations are useless. Though they 
may exclude the short wavelength ultraviolet light which causes sunburn, they do not 
block out those longer wavelengths of light which excite skin disease in porphyria. The 
only agents which may be of use are those containing zinc or titanium dioxide. These 
are often thick, greasy and opaque. Agents which may be helpful include those with 
micronised titanium dioxide and high SPF values, which are less opaque and more 
cosmetically acceptable. 
Use of I' carotene and canthaxanthine 
Beta carotene is a substance which is converted in the body to vitamin A. It is also an 
important constituent of carrots and is responsible for their yellow colour. I\-carotene in 
high doses builds up a protective layer in the skin which is extremely useful in improving 
the skin disease of EPP. When taken in sufficient amounts, the photosenSitivity 
decreases. 
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This means that such people can tolerate increased amounts of exposure to the sun 
before they develop their typical skin reaction. Almost all people with EPP treated with 
II-carotene have been improved to some extent, often markedly so. In some cases, 
people have been able to live entirely normal lives with no skin reactions whatsoever. 
To achieve this effect, Ii-carotene has to be taken in large doses, sufficient to cause a 
yellow discolouration of the skin. If there is no discolouration then there is no 
improvement. 
Vitamin A taken in large doses is not effective and is dangerous. [~-carotene is very 
safe; as it is poorly converted in the body to vitamin A and there is no risk of it becoming 
toxic. No side effects of [I-carotene are known, other than the yellowing of the skin. 
A related substance, called canthaxanthine, may be combined with the I'I-carotene. This 
works just as well, but the resulting discolouration of the skin resembles more closely a 
natural tan rather than the yellowish colour of Ii-carotene alone. This combination has 
also been shown to be of benefit to patients with EPP. Canthaxanthine is safe. 
However, when taken in very large doses, it may cause some deposition of crystals in 
the retina of the eye. This has given rise to concem, though it has not been shown to 
endanger sight. 
Unfortunately I)-carotene is only available commercially at present in capsules and pills 
containing very small doses. Vitaforce, carotene A (Pharma Natura) contains only 1500 
units of fi-carotene (or about 3 mg per capsule). The optimum average adult daily dose 
of Jl-ca rotene is from 50-150 mg daily. It is not feasible to take up to 50 capsules of r~­
carotene per day! Canthaxanthine is not available in a commercially prepared form at 
present. 
Arrangements can be made for canthaxanthine and ~-carotene in adequate dosage to 
be made available to patients with EPP through private pharmacists, or directly from the 
suppliers. Our patients find it most practical to buy carotene in powder form in large 
containers, and then take it in teaspoonfuls! Contact us for details of availability. 
Treatment with /J-carotene 
The required dose is from 50-150 mg daily. In practice, we have found that the best 
method is for the patient to be given the bottles of the raw ingredients themselves, to 
Ie am how much (in teaspoons) the required dose is by an initial weighing, and then to 






















We recommend a starting dose of 100 mg daily. This can be increased to 150 mg daily 
or reduced to 50 mg daily as necessary. It may take 2 or 3 months before a clinical 
result is evident. This coincides with the onset of the pigmentation. Once a response is 
obtained, the dose should be reduced to the minimum required for an effect. 
Since the skin disease is worse during the summer months, it is advisable to start the ]-l-
carotene towards the end of winter, maintain it during summer, and then reduce it 
during autumn and winter again. 
Treatment with beta-carotene and canthaxanthine 
If using a carotene/canthaxanthine mixture, they should be mixed in the ratio 2 parts I~­
carotene and 3 parts canthaxanthine powder. The total dose is the same as for f-l-
carotene on its own. 
We recommend that patients on canthaxanthine undergo eye examinations at 3-6 
monthly intervals to ensure that there is no deposition within the retina. Should there be, 
we would advise that the canthaxanthine be stopped and f-l-carotene used alone. 
Protection against liver injury 
It is highly recommended that all patients with EPP have their liver functions tested at 
least annually. All that is necessary is that a single blood test is taken and the liver 
functions analysed. Should there be any disturbance, specialist advice should be 
sought. Under such circumstances, additional treatment measures can be suggested 
which may allow this porphyrin to be safely cleared from the liver. These include the 
long term use of oral cholestyramine or charcoal which bind porphyrins and allow their 
excretion. 
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A.2. Consent form 
CONSENT FOR ANALYSIS AND STORAGE OF DNA SAMPLES 
Study: Erythropoietic protoporphyria (EPP) 
Subjects: Subjects with EPP and family members 
This study has received ethics approval from the University of Cape Town (UCT), 
Research Ethics Committee No ...................... . 
All individuals participating in the above-mentioned study will be asked to read, 













(name of person giving consent) 
herewith give consent for a blood sample to be taken from the following people: 
,~~~~------~--.. -.,..---~~~~.~--~--~------.. -.----.~.--~---~~..,-~~---~~----.----~--- ~.---.-~-------... 
Participant Relationship to person giving consent 
Name (1) 
Name (2) 
--~.~- .. ---~~--.- . 
Name (3) 
Name (4) 
I understand that this sample will be used to investigate the genetic factors involved in 
erythropoietic protoporphyria. 
1. I acknowledge that I have been supplied with information regarding EPP and the 
nature of this study. 
2. I have been informed that: 
• I am encouraged to ask questions regarding porphyria and the present 
research study 
• Information concerning the ethical aspects of the study can be obtained from 
the UCT Research Ethics Committee 
• I am at liberty to withdraw my consent for this research at any time, and this 
will not in any way affect my relationship with the UCT/GSH Porphyria Clinic or 
my future medical care. 
3 Please initial each of the following paragraphs if you agree: 
Our blood samples/DNA may be stored indefinitely for use in all research 
relating to EPP 
In addition, our blood sample/DNA may be used in all forms of research in 
future 
My doctor may provide clinical information relevant to our condition to the 











I request that results that may have relevance to myself or my family 
should be made known to me. 
Our clinical information and laboratory results may be kept in a computer 
database. I understand that confidentiality will be maintained and that my 
information will not be disclosed to any person not associated with the 
specific purpose of studying EPP. 















A.3. Subject information sheet 
Code: ....................... . 
Surname:,..................................................... First Name(s): ........................................ . 
Related to which known EPP family? ....................................... .. .................................... . 
Contact details: 
Address: .............................................................................................................................. . 
Tel. No: ............................................................... .. Fax no: ................................ . 
Sex: M 0 F 0 
Age: ............................... Date of birth: year ............ Month..................... Day .............. . 
Ethnic origin (Please state ancestry of both your mother and father): ............................ .. 
Your doctor: ....................................... ................................................................................ . 
Address: .............................................................................................................................. . 
Tel. No: ................................................ . Fax no: ........................................... .. 
Reason for Inclusion in study: 
[
.--. --.----.------. --------.. --.---. --~----I--·--· ......... ----- ... --. --.--
Clinically affected *Family member 
- -----. -------_._-- ------~-,<."--~------ ---.. --~---,.---~-
*State relationship to affected .......................................................................................... . 
-------_._--
For laboratory use only: 
Patient laboratory code: ......................... . Hospital no: ......................... . 
DNA no:............................... Vol blood (ml): ..................... Other: .................................. . 














What is your name? _________ _ 
1. Do you suffer from any undue photosensitivity? ______ _ 
Do these (or other) types of light have the most severe effect on your skin? 
2. Sunlight __ 
3. Fluorescent lights __ -------_._---------.-
4. Other 
5. Can you describe the sensation you experience after exposure to light? 
--------- -----
6. Can you give an indication of the maximum tolerance you have to light 
exposure? Le. how long can you spend in the sun without experiencing any 
symptoms? ____ . ___ _ 
--------
7. Does the length of exposure, type of light etc that you are sensitive to vary 
during the year or is the severity of symptoms constant throughout the year? 











9. How do you attempt to relieve the symptoms described above? 
10. Do you experience any other physical symptoms after light exposure or that 
you think may be attributed to porphyria? _____________ . 
11. What specific precautions do you take to limit exposure to sunlight or to 
protect yourself when you are exposed? ___________________ _ 
12. Have you noticed any scarring or thickening of your skin? __ _ 
13. In which areas is this most apparent? 
14. At what age did you/a family member first become aware of the 
photosensitivity? ____ _ ------_. __ ._---
15. At what age were you diagnosed? 
16. Can you describe the level at which you find the disease debilitating? Le. to 
what extent does it affect your lifestyle? 
1 2 3 





17. Have you ever suffered from gall stones? ________ _ 
18. Have you ever been investigated for a liver complaint? ________ _ 













C.1. Red blood cell porphyrin screening 
Equipment and reagents: 
• Desktop microcentrifuge DSCI58T 
[Laboratory and Scientific Equipment Company (Lasec), Cape Town, SA] 
• Ultra violet (UV) light 
• Methanol (CH 30H:MW=32.04g/mol) 
(Kimix Chemical and Laboratory Supplies, Cape Town, SA) 
Method: 
• Whole blood collected in EDTA tubes was centrifuged at 700xg for 10 min 
• Excess plasma was removed leaving only packed red blood cells 
• O.5ml of the red blood cells was mixed with 4ml methanol 
• The methanol (upper) phase was viewed by UV illumination (/.; 400-410nm) 
Interpretation of results 
• Samples that screen positive (+) for porphyrins emit a pink fluorescence while 











C.2. Plasma fluorescence scanning 
Equipment and reagents: 
• Fluorescence spectrophotometer 650-10S (Hitachi Koki Co., Ltd, Japan) 
equipped with a red-sensitive photomultiplier 
• Linear 1200 chart recorder (Spectrum Medical Industries, Los Angeles, USA) 
• 150 Xenon Power Supply (Perkin-Elmer, Acme Electric Corp., New York, UK) 
• Plastic cuvettes 10x10x45mm (Greiner Labortechnik, Lasec) 
• Phosphate Buffered Saline (PBS) (C.2 1) 
Method (poh-Fitzpatrick 1980): 
• 1 OO~tI of plasma, previously separated from whole blood by centrifugation (C.1), 
was added to 900fll PBS 
• The fluorescence spectrophotometer U'ex:405nm; "em:630nm; monochromator 
slit width: 5nm) was zeroed against PBS 
• 1 ml of diluted plasma sample was transferred to a cuvette for analysis 
• An emission scan was performed from 580nm to 650nm O~ex:405nm) at a 
sensitivity of 10 and a scan speed of 60nm/min 
• Profiles of the scan were recorded on a chart recorder (chart speed: 3cm/min) 
and the peak emission wavelength noted 
C.2.1.1X Phosphate buffered saline (pH 1.4) 
Sodium chloride [NaCI:MW=53.44g/mol (BDH Chemicals Ltd, Poole, UK)] 16g 
Potassium chloride (KCI:MW==74.55g/mol) 
(NT Laboratory Supplies, Gauteng, SA) O.4g 
Disodium hydrogen orthophosphate (Na2HP04:MW=141.96g/mol) 
(Associated Chemical Enterprises, Gauteng, SA) 
Potassium dihydrogen phosphate (KH1P04:MW=136.09g/mol) 
(Merck Chemicals, Darmstadt, Germany) 



















C.l. Porphyrin quantitative analysis 
Equipment and reagents: 
• Boiling tube (Lasec) 
• Separating flask (Lasec) 
• Sigma 3-12 Centrifuge (Wirscharn Scientific, Cape Town, SA) 
• Scintered glass funnel (Lasec) 
• Measuring cylinder 25ml (Lasec) 
• Thin-layer chromatography (TLC) plates 
(TLC aluminium sheets 20X20cm Silica Gel-60) (Merck Chemicals) 
• Microsyringe (Hamilton, Bonaduz, Switzerland) 
• Fluoroscanning photodensitometerTLD 100 (Vitatron, UK) 
• Integrator SP4290 (Spectra-Physics, Califomia, USA) 
• Sulphuric acid (H 2S04:MW=98.07) (BDH Chemicals Ltd) 
• Methanol AR (CH30H:MW=32.04g/mol) (Kimix Chemical and Laboratory Supplies) 
• Chloroform (Kimix Chemical and Laboratory Supplies) 
• Ammonia solution (NH 40H MW=35.05) (Kimix Chemical and Laboratory Supplies) 
• Anhydrous sodium sulphate (Glauber's salt: Na;cS04:MW=142.04) 
(BDH Laboratory Supplies) 
• Porphyrin methyl ester calibrator (equal concentrations of uroporphyrin, 
heptacarboxylic porphyrin, hexacarboxylic porphyrin, pentacarboxylic porphyrin, 
coproporphyrin and mesoporphyrin methyl esters) 
(Frontier Scientific Porphyrin Products, Logan, Utah) 
• Carbon tetrachloride (CCI4:MW=153.82g/mol) 
(Riedel-de-Haen, Sigma Aldrich, Gauteng, SA) 
• Dichloromethane (CH2Cb:MW=84.93g/mol) (Merck Chemicals) 
• Ethyl acetate (CH3COOC2Hs:MW=88.11g/mol) 
(SAARCHEM-holpro Analytic, Gauteng, SA) 
• Ethyl propionate (C5H1002:MW=102.13g/mol) (Merck Chemicals) 
• n-Dodecan (C12H26:MW=170.34g/mol) (Merck Chemicals) 
• n-Hexadecan (C 16H34:MW=226.45g/mol) (Merck Chemicals) 






























Method (Day 1978; Hift et aL 2004): 
• O.Sml of packed red blood cells was transferred to a boiling tube with 30ml 5% 
sulphuric acid in methanol 
• The stopper was placed on the boiling tube and, after shaking, this mixture was 
left to esterify ovemight in the dark at room temperature 
• A separating flask was prepared by rinsing in a solution of 
methanol:chloroform:: 1: 1 and adding 60ml 4% ammonia and 1 Oml chloroform in 
a fume hood 
• After overnight esterification, the sample was centrifuged at 700xg for 20 min 
and the supernatant transferred to the separating flask and sealed 
• This was shaken vigorously for 5 to 20 sec intervals, opening the tap periodically 
to release gaseous build-up 
• The flask was then filled to :t:% of its volume with dH20 (:t150ml) 
• The chloroform settled at the bottom of the flask and the mixture was stirred with 
a glass pipette until a clear layer was obtained 
• The scintered funnel was rinsed with chloroform and placed in a measuring 
cylinder 
• Approximately 2g of anhydrous sodium sulphate was added to the funnel 
• The chloroform layer was tapped off into the scintered funnel, and the procedure 
repeated, with the addition of a further 10ml of chloroform to the flask 
• Thin-layer chromatography was then performed on the extracted porphyrins in 
the eluted chloroform (all preparations were performed under semi-dark 
conditions) 
• The volume of chloroform eluted was noted and 60f.l1 was spotted onto a TLC 
plate using a Hamilton microsyringe approximately 1cm from the base of the 
plate 
• Two lanes on each plate were reserved for porphyrin methyl ester calibrators 
• TLC plate was run vertically in a chromatography tank containing; 10ml 
separating solvent (carbon tetrachloride:dichloromethane:ethyl acetate:ethyl 
propionate::2:2: 1: 1 v/v) for 40 min or until the solvent front reached the top of 
the plate 
• Plate was left to dry in the dark and then dipped briefly in a fluorescence-
enhancing solution (chloroform: n-dodecan:n-hexadecan::3:1:1 v/v) in order to 




























• After drying, the plate was read on a fluoroscanning photodensitometer using 
two interference filters (incident filter: 399nm; fluorescence filter: 620nm) 
• Individual species of porphyrin esters were identified by direct comparison of the 
retention times with those of the calibrators 
• The amount of fluorescence in each spot (the area under the curve for each 
peak) was calculated and recorded by the integrator and compared directly with 
those of the calibrators to give quantitative results 
• Results were recorded in a customised porphyrin spreadsheet (Lotus 
123)/database (UCT Porphyria database CDbase 4+) to calculate the individual 












C.4. Determination of free and zinc-chelated protoporphyrin IX 
concentrations in EPP blood samples 
Equipment and reagents: 
• Glass tube (Lasec) 
• Glass bottle (Lasec) 
• Vortex-Genie2 G560-E mixer (Scientific Industries Inc., New York, USA) 
• Fluorescence spectrophotometer 650-1 OS (Hitachi Koki Co., Ltd) 
• Linear 1200 chart recorder (Spectrum Medical Industries Inc.) 
• 150 Xenon Power Supply (Perkin-Elmer, Acme Electric Corp.) 
• Quartz cuvette 10mm light path (Optiglass Ltd, Hainault, UK) 
• Saline [0.9% NaCI: MW=53.44g/mol (BOH Chemicals Ltd)] 
• Acetone (SAARCHEM-holpro Analytic) 
• dH20 
Method (Modified from Hart and Piomelli 1981): 
• All sample preparations were performed under semi-dark conditions 
• 20fJi of whole, packed blood was diluted 1 OX with saline in a glass tube 
• A solution of acetone:dH20::80:20 was prepared and stored in a glass bottle to 
prevent evaporation 
• 5ml of this mixture was added to the blood sample and vortexed for 30 sec 
• Centrifugation at 700xg for 1 min followed 
• The fluorescence spectrophotometer U-ex:420nm; Aem:632nm) was zeroed 
against acetone:dH20 solution 
• 1 ml of the supernatant was transferred to a cuvette for spectrofluorescent 
analysis 
• An emission scan was performed from 400nm to 700nm (AE'x:420nm) at a 
sensitivity of 10 and a scan speed of 60nm/min 
• A profile of the scan was recorded on a chart recorder (chart speed: 3cm/min) 
and the peak emission wavelength recorded 
Note: Zinc protoporphyrin maximum peak emission reading: 588nm 

































DNA Extraction and Purification 
D.1. Genomic DNA isolation 
Equipment and reagents: 
• Microfuge tubes (Greiner, Lasec) 
• Vortex-Genie2 G560-E mixer (Scientific Industries Inc.) 
• Force 14 microfuge (Denver Instruments, Lasec) 
• Techni driblock BD-2D heating block (Lasec) 
• Wizard® Genomic DNA purification kit (Promega, Madison WI, USA) 
• Isopropanol (Riedel-de-Haen, Sigma Aldrich) 
• Ethanol (Riedel-de-Haen, Sigma Aldrich) 
• Gene Quant II, RNA/DNA Calculator (Pharmacia Biotech, Cambridge. UK) 
Method: 
• Blood samples were placed at room temperature for 30 min prior to DNA 
extraction, and mixed thoroughly by inverting the tube 
• 900~1 Cell Lysis solution was aliquoted into a 1.5ml microfuge tube followed by 
addition of 300ftl whole blood 
• After capping, the tube was inverted 6 times and incubated at room temperature 
for 10 min with another 4 inversions to mix at 5 min 
• Centrifugation at 14000xg followed for 1 min at room temperature 
• The supernatant was discarded leaving 1 0-20~1 of liquid and a visible white 
pellet (if the peliet contained visible RBCs the previous 3 steps were repeated) 
• The pellet was completely resuspended in solution by vortexing and 300~d 
Nuclei Lysis solution was added followed by gentle agitation (samples 
containing aggregated cells were incubated at 3rc for ±60 min) 
• 1 OO~I Protein Precipitation solution was added followed by vortexing for 20 sec 
• Centrifugation at 14000xg followed for 3.5 min at room temperature 
• The supernatant was added to a microfuge tube containing 300~1 isopropanol 











• Centrifugation at 14000xg followed for 3.5 min at room temperature 
• The supernatant was discarded and pellet washed with 300~d 70% ethanol 
• Centrifugation at 14000xg was repeated for S min at room temperature 
• Ethanol was decanted and the pellet air-dried for 30 min 
• SOp I DNA Rehydration solution was added to the pellet followed by incubation 
for 60 min at 6SoC 
• DNA concentration and purity was determined using the GeneQuant 
spectrophotometer using DNA Rehydration solution as a reference 
Protocol modifications: 
• Longer centrifugation times (3.S min) were employed to pellet the DNA in order 
to prevent this pellet from being dislodged when decanting the supematant. 
• In order to obtain a white pellet free of red blood cells, cell lysis solution 





















D.2. DNA purification (Isoamyl alcohol:chloroform "clean-up") 
Equipment and reagents: 
• Vortex-Genie2 G560-E mixer (Scientific Industries Inc.) 
• Refrigerated microcentrifuge (Sorvaliinstruments, DuPont, USA) 
• Gene Quant II, RNA/DNA Calculator (Pharmacia Biotech) 
• Isoamyl alcohol (Merck Chemicals) 
• Chloroform (Kimix Chemical and Laboratory Supplies) 
• 3M Sodium acetate (pH 5.2) 
• Ethanol (Riedel-de-Haen, Sigma Aldrich) 
• dH20 (Bodene Pty Ltd, Port Elizabeth, SA) 
Method: 
.1001-11 of previously extracted, stored DNA was used for purification 
• An equal volume of chilled (-20°C) isoamylalcohol:chloroform:.1 :49 (v/v) was 
added and vortexed to mix 
• Centrifugation at 14000xg for 10 min at 4°C followed 
• The upper phase was then removed and the previous two steps repeated until a 
clear upper phase was obtained, the volume of which was noted 
• 2.5 x upper phase volume of chilled (-20"C) 100% ethanol and 1/10 x upper 
phase volume of 3M sodium acetate (pH 5.2) were added and placed at -70°C 
for 30 min 
• DNA was pelleted by centrifugation at 14000xg for 10 min at 4"C 
• The supernatant was decanted and the pellet washed with 1 001-11 chilled (-20°C) 
70% ethanol 
• Centrifugation was repeated and the supernatant removed with a pipette 
• The pellet was air-dried and resuspended in 501-11 dH20 
• The DNA was quantified and the purity determined by a spectrophotometric 
reading of each sample using dH 20 as a reference 
• Working solutions (10ng/l-1l) were stored at 4°C and stock DNA solutions were 




























Analysis of the FECH gene 
E.1. Primer selection for fragment amplification 
Criteria for primer selection: 
• Primer length (18bp to 25bp) 
• GC-content (48% to 55%) 
• Annealing temperature (50°C to 60nC) 
• In addition to using Primer3, primer melting temperatures were determined by 
Oligo Calculator (http://www.pitt.edu/-rsup/OligoCalc.html) 
• Criteria for the selection of primers for the amplification f FECH exon 1 were far 
less stringent, as this is a highly GC-rich region, and primers could not be 











E.2. Polymerase chain reaction (peR) 
Equipment and reagents: 
• Robocycler<lil Gradient 40 Thermal Cycler (Stratagene<lil, California, USA) 
• Thermophilic DNA polymerase 10X buffer 
[10mM Tris-HCI pH 9, 50mM KCI and 0.1% Triton@X-100 (Promega)] 
• MgCb 25mM (Promega) 
• Deoxynucleotide triphosphates (dNTPs) (E.2.1) 
• Taq Polymerase (Promega) 
• Forward and Reverse primers 
(lOT-Integrated DNA Technologies Inc, Coralville lA, USA) 
• dH)O (Bodene Pty Ltd) 
• Mineral oil (Sigma Chemical Company, St Louis MO, USA) 
Method: 
• PCR amplification of all FECH exons was performed on a Robocycler Gradient 
40 Thermal cycler in a total reaction volume of 50fJ,/ 
• Each reaction included 1X buffer, 2,,5mM MgCh. 50f.lM dNTPs each, 1 Unit Taq 
Polymerase and 25pmol of each primer 
• 10ng template DNA (genomic) was routinely included in the above reaction 
mixture, however up to SOng was required for certain samples 
• A negative control that included 1 f.ll dH20 instead of DNA was set up for each 
amplification to confirm that the PCR reagents were not contaminated 
• All samples were overlaid with a single drop of mineral oil to prevent evaporation 
E.2.1 Deoxynucleotide triphosphates (2.5mM) 
dATP, ddCTP, dGTP and dTTP (100mM each) 
dH20 (Bodene Pty Ltd) 
(Promega) 

































F .1. Non-denaturing polyacrylamide gel electrophoresis and frag ment 
visualisation 
Equipment and reagents: 
• Hoefer vertical slab gel electrophoresis unit; SE600 Series 
(Amersham Pharmacia Biotechnology Inc., Califomia, USA) 
• Gel documentation apparatus 
(gel-doc: BTS-20M UVlband vs 99) (UVltec Ltd, Cambridge, UK) 
• Video copy processor, model P90E(B) (UVltec Ltd) 
• K65HM High-density synthetic paper (Whitehead Scientific, Cape Town, SA) 
• Non-denaturing polyacrylamide gel (6%) (F.1.1) 
• 1X TBE buffer (F.1.2.1) 
• 6X loading dye (F.1.2.3) 
• Ethidium bromide (EtBr) solution (F.1.2.4) 
• 100bp DNA Ladder molecular weight marker (F.1.3a) 
Method: 
• Samples were prepared by adding 6X loading dye in the ratio 2'1 to 51-d of PCR 
product and loaded onto the gel 
• A 100bp DNA Ladder molecular weight marker was included on the gel 
• Electrophoresis was performed at 25QV for 90 min in 1 X TBE buffer 












F .1.1. Non-denaturing polyacrylamide gel (6%) 
Equipment and reagents: 
• Hoefer vertical slab gel electrophoresis unit; SE600 Series including 20 bay 
spacer comb (1.5mm), vertical slab gel glass plates, clamps, cams and spacers 
(1.5mm) (Amersham Pharmacia Biotechnology Inc.) 
• PS1200 DC power supply (Amersham Pharmacia Biotechnology Inc.) 
• 10XTBE (F.1.2.1) 
• Acrylamide:bisacrylamide::29:1 (F.1 . 2.2) 
• 10% Ammonium persulfate (APS) (Promega) 
• TEMED (Merck Chemicals) 
Method: 
• Two glass plates, separated by spacers, were clamped together and placed in a 
gel casting stand utilising two cams 
• 4ml1 OX TBE and 8ml acrylamide:bisacrylamide solution were combined and 
the solution made up to 40ml with dH20 
• 400fll APS and 40fll TEMED were added and the solution rapidly mixed and 
poured between the pre-cast plates, avoiding the formation of bubbles in the gel 
• The comb was inserted and the gel allowed to polymerise for 45 min 
140 
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F .1.2. Solutions 
F.1.2.110X TBE (pH 8.0) 
Tris (C4Hl1N03:MW=121.134) (Merck Chemicals) 
Boric Acid (Merck Chemicals) 
EOTA (Merck Chemicals) 
Made up to 1 OOOml with dH?O 
For 1X TBE: 1/10 dilution was made of the 10X TBE 
For 0.6X TBE: 0.6/10 dilution was made of the 10X TBE 
F.1.2.2. Acrylamide:bisacrylamide::29:1 solution 
Acrylamide (Whitehead Scientific) 
Bisacrylamide (Whitehead Scientific) 
Made up to 1 OOml with dH 20 
F.1.2.3. Loading dye (6X) 
Bromophenol Blue (0.25% w/v) (Associated Chemical Enterprises) 
Sucrose (40% w/v) (BOH Laboratory Supplies) 
0.5M EOTA, pH 8 (BOH Laboratory Supplies) 
Made up to 100ml with dH20 
F.1.2.4. Ethidium bromide solution (0.5nghtl) 
EtBr (1 mg/ml) (Roche Diagnostics Pty Ltd, Randburg, SA) 
dH20 (Bodene Pty Ltd) 
F.1.2.5. Sucrose solution (40%) 
Sucrose (BOH Laboratory Supplies) 





























F .1.3. Molecular weight rna rkers 
b) 
Figure F1. a) 100bp DNA Ladder and b) 25bp Step DNA Ladder (Promega) 
A 1/5 dilution of each DNA Ladder stock solution was made in dH 20 (Bodene Pty Ltd) 












Investigation of the IVS3-48T/C polymorphism 
G.1. Restriction endonuclease analysis 
Equipment and reagents: 
• Water bath (Memmert GmbH+Co., KG, Schwabach, Germany) 
• Techni driblock BD-2D heating block (Lasec) 
• 1 OX restriction endonuclease buffer H 
(Roche Diagnostics Corp., Mannheim, Germany) 
• Ita I restriction endonuclease (1 OU/~.d) (Roche Diagnostics Corp.) 
• dH 20 (Bodene Pty Ltd.) 
Method: 
• The restriction endonuclease analysis reaction mixture included 2~d 10X 
restriction endonuclease buffer H, 1 U of Ita I and 5-1 OJ.l1 PCR product as 
required 
• This was made up to a final volume of 20~d with dH:>O 
• Samples were incubated in a water bath at 37°C for 2.5 h 
Note: The above procedure was followed for all other restriction enzymes utilised in 












G.2. Silver staining and visualisation 
Equipment and reagents: 
• Gel documentation apparatus (gel-doc: BTS-20M UVlband vs 99) (UVltec Ltd) 
• Video copy processor, model P90E(B) (UVltec Ltd) 
• K65HM High-density synthetic paper (Whitehead Scientific) 
• UV/white light converter screen (UVltec Ltd) 
• Silver staining solution I (G.2.1.1) 
• Silver staining solution II (G.2.1.2) 
Method: 
• The non-denaturing polyacrylamide gel used for the separation of restriction 
fragments (Appendix F.1) was rinsed thoroughly with dH20 
• Solution I was applied to the gel for 10 min followed by another rinse with dH;>O 
• Solution II was then applied until bold, distinct bands could be observed (1:5 min) 
• A final rinse of the gel in dH 20 completed the staining procedure 
• Gels were photographed on a gel documentation apparatus using a UV/white 
light converter screen for visualisation of dye/silver-stained gels 
G.2.1. Silver staining solutions 
(Prepared immediately before staining) 
G .2.1.1. Silver staining solution I 
Silver Nitrate (AgN03:MW = 169.87g/mol) (Merck Chemicals) 
Made up to 1 OOOml with dH20 
G.2.1.2. Silver staining solution II 
Sodium Hydroxide (NaOH:MW = 40g/mol) (Merck Chemicals) 
Dissolved in dH20 
Followed by the addition of; 
15% Formaldehyde (BDH Laboratory Supplies) 
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G.l. IVSl-48C polymorphism screening 
G.3.1. Selection of restriction endonuclease Ita I and a positive control sample 
Ita I restriction site: 5'-GC N GC-3' 
3''(;G N CGoS' 
t 
Digest of the IVS3-48T allele 






Digest of the IVS3-48C" allele 
5' -ea ag aga gctg gelatt gt ca at gae ct caa gcttct gtttt a aa gg etta atcttgtta 9 gctc t ctaa aatttt gcttttttt 
cttttttaHgaglagaaaacatttctcaggC ( l17bp) 




Figure G1. Expected fragment sizes for respective IVS3-48T 
and IVS3-48C alleles after Ita I digestion 
Wild type: TeA G G T T GeT 
Polymorphism: TeA G G e T GeT 
Figure G2. Direct sequencing (forward) of 
amplification fragment 4A (EPP2.1) indicating 
heterozygosity for the IVS3-48T IC polymorphism. 
Sample subsequently used as a positive control 













Equipment and reagents: 
APPENDIX H 
SSCP Analysis 
• Hoefer vertical slab gel electrophoresis unit; SE600 Series 
(Amersham Pharmacia Biotechnology Inc.) 
• Gel documentation apparatus (gel-doc: BTS-20M UVlband vs 99) (UVltec Ltd) 
• Video copy processor, model P90E(8) (UVltec Ltd.) 
• K65HM High-density synthetic paper (Whitehead Scientific) 
• Techni driblock BD-2D (lasec) 
• 2X MDE® polyacrylamide gel (H .1.1) 
• SSCP loading dye (H.1.2) 
• O.6X TBE buffer (Appendi)( F .1.2.1) 
Method (Orita et al. 1989): 
• 51-1' of each sample was prepared with SSCP loading dye in a 1: 1 ratio 
• These were denatured at 95°C for 5 min and snap-cooled on ice 
• A total volume of 1 O~ll was loaded for each sample 
• Gels were run at room temperature overnight in O.6X TBE 











H.1.1. 2X MOE polyacrylamide gel 
Equipment and reagents: 
• Hoefer vertical slab gel electrophoresis unit; SE600 Series including 20 bay 
spacer comb (1.5mm), vertical slab gel glass plates, clamps, cams and spacers 
(1.5mm) (Amersham Pharmacia Biotechnology Inc.) 
• 2X MDE@ gel solution (Cambrex Bio Science Rockland Inc., Rockland ME, USA) 
• 1 OX TBE (Appendix F.1.2.1) 
• Glycerol ("Optional) (SOH Laboratory Supplies) 
• 10% Ammonium persulfate (APS) (Promega) 
• TEMEO (Merck Chemicals) 
Method: 
• Two glass plates, separated by spacers, were clamped together and placed in a 
gel casting stand utilising two cams 
• 15ml TBE, 1.8ml MDE gel solution and 3ml glycerol were combined and the 
solution made up to 30ml with dH20 ("3ml glycerol replaced with 3ml dH20 if 
glycerol excluded from gel mixture) 
• A gel plug of Sml MOE gel solution, 20~t1 APS and 20,..1 TEMEO was poured 
rapidly between the plates to seal them 
• 175,..1 APS and 17.5~ll TEMED were added to the remaining 30ml MOE gel 
solution 
• This was rapidly mixed and poured between the pre-cast plates avoiding the 
formation of bubbles in the gel 

























H.1.2. SSCP loading dye 
Formamide (95%) (BDH Laboratory Supplies) 
1 N NaOH (1 OmM) (BOH Laboratory Supplies) 
0.5M EDTA pH 8 (20mM) (BDH Laboratory Supplies) 
Bromophenol Blue (0.25% w/v) (Associated Chemical Enterprises) 
Xylene Cyanol (0.25% w/v) (Sigma Chemical Company) 






















DNA purification for sequencing 
1.1. DNA purification from peR product 
Equipment and reagents: 
• Vortex-Genie2 G560-E mixer (Scientific Industries Inc.) 
• Force 14 microfuge (Denver Instruments, Lasec) 
• 1.5ml microfuge tubes (Greiner, Lasec) 
• GFXTM peR DNA and gel band purification kit (Amersham Biosciences Ltd.) 
• dH20 (Bodene Pty Ltd) 
Method: 
• A GFX column was placed into a collection tube and 1 ml capture buffer added 
• PCR amplification products for the relevant fragment (100ng template DNA 
used) were pooled and 90~1 was added to the column 
• The solution of DNA and capture buffer was mixed without disturbing the filter 
• Centrifugation at 14000xg for 1 min followed and the collection tube emptied 
• 1 ml wash buffer was added to the GFX column and centrifugation was repeated 
as above discarding the flow-through 
• The above step was epeated and the GFX column placed in a microfuge tube 
• 50~1 dH20 was applied directly to the top of the glass fiber matrix in the GFX 
column and incubation at room temperature for 5 min followed 











1.2. Agarose gel electrophoresis and DNA purification from agarose 
1.2.1. Agarose gel electrophoresis 
Equipment and reagents: 
• Horizontal mini-gel system (Mgu-202T) (CBS Scientific Co., Inc., Del Mar, USA) 
• Electric power supply (EPS-250 series II) (CBS Scientific Co., Inc.) 
• Gel documentation apparatus (gel-doc: BTS-20M UVlband vs 99) (UVltec Ltd) 
• Video copy processor, model P90E(B) (UVltec Ltd.) 
• K65HM High-density synthetic paper (Whitehead Scientific) 
• Electronic UV Transilluminator (UltraLum, California, USA) 
• Sterile surgical blades; 2.5M-Rads, No.3 (B & M Scientific, Cape Town, SA) 
• 1.5ml microfuge tubes (Greiner, Lasec) 
• Agarose gel (2%) (1.2) 
• 1 X TBE buffer (Appendix F .1.2.1) 
• 40% Sucrose (Appendix F.1.2.5) 
• Ethidium bromide (EtBr) solution (Appendix F.1.2.4) 
• 100bp DNA Ladder molecular weight marker (Appendix F.1.3a) 
• 25bp Step DNA Ladder (Appendix F.1.3b) 
Method: 
• 10111 sucrose was mixed with 40111 of each PCR amplification product and loaded 
onto the gel (H.2) with two molecular weight markers and a negative control 
• Electrophoresis was performed at 120V for 4 h in 1 X TBE buffer followed by 10 
min at 30V to resolve the bands 
• Gels were photographed on a gel documentation apparatus and the relevant 
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1.2.2. Agarose gel (2%) 
Equipment and reagents: 
• Magnetic stirrer (Lasec) 
• Conical flask (Lasec} 
• Microwave (Defy, SA) 
• Horizontal mini-gel system casting tray (CBS Scientific Company Inc.) 
• 12 well comb (CBS Scientific Company Inc.) 
• Metaphor@ agarose (FMC BioProducts, Maine, USA) 
• 1 X TBE (Appendix F.1.2.1) 
• Ethidium Bromide (1mg/ml) (Roche Diagnostics Pty Ltd.) 
Method: 
• 4g agarose was added to 200mi 1 X TBE in a conical flask while stirring on a 
magnetic stirrer to avoid clumping 
• The flask was heated in a microwave for 2 min (after 1 min the solution was 
swirled gently to avoid boiling over) 
• Once dissolved the agarose solution was cooled slightly, followed by the 
addition of 1 OO~tI EtBr 
• Agarose solution was poured into a horizontal casting tray and the comb 
inserted 
• The gel was allowed to set at room temperature for 60 min 
• Once set, the comb was removed and the gel placed in the tank and immersed 


























1.2.3. DNA purification from agarose 
Equipment and reagents: 
• Weighing balance (M-120) (Denver Instrument Co., Colorado, USA) 
• Fine Balance (X-1B10) (Denver Instrument Co., Colorado, USA) 
• Techni driblock BD-2D heating block (Lasec) 
• Force 14 microfuge (Denver Instruments, Lasec) 
• Vortex-Genie2 G560-E mixer (Scientific Industries Inc.) 
• 1.5ml microfuge tubes (Greiner, Lasec) 
• GFXTM PCR DNA and gel band purification kit (Amersham Biosciences Ltd.) 
• dH20 (Bodene Pty Ltd) 
Method: 
• The excised gel fragment was weighed in a microfuge tube 
• For each 10mg of gel slice, 10IJI of capture buff r was added 
• This was mixed vigorously by vortexing and incubated at 65°C for 15 min 
• Centrifugation at 14000xg for 30 sec followed and the supernatant was 
transferred to a GFX column in a collection tube (1.1) 
• After incubating at room temperature for 2 min centrifugation was repeated at 
14000xg for 30 sec and the collection tube emptied 
• 5001-11 wash buffer was added to the GFX column and centrifugation repeated 
• The collection tube containing the wash buffer flow-through was discarded and 
the GFX column transferred to a microfuge tube 
• 50IJI dH20 was applied directly to the top of the glass fiber matrix in the GFX 
column followed by incubation at room temperature for 5 min 






























1.3. DNA purification from acrylamide 
Equipment and reagents: 
• Techni driblock BD-2D heating block (Lasec) 
• Force 14 microfl.1ge (Denver Instruments, Lasec) 
• Vortex-Genie2 G560-E mixer (Scientific Industries Inc.) 
• Syringe barrel (Promex, Bergvleit, SA) 
• Siliconised glass wool (Lasec) plug (±1.Smm) 
• Oiaex II gel extraction kit (Qiagen GmbH, Hilden, Germany) 
• Diffusion buffer (1.3.1) 
• dH20 (Bodene Pty Ltd.) 
Method: 
• The excised gel fragment was weighed in a microfuge tube 
• One volume diffusion buffer was added for every 1 volume gel slice followed by 
incubation at SO°C for 30 min 
• Centrifugation at 14000xg for 1 min followed and the supernatant was retained 
• Remaining polyacrylamide gel in the supernatant was removed using a filter 
(a syringe containing a glass wool plug) 
• The approximate volume of the recovered supernatant was determined and 3 
volumes Buffer OX1 added (the colour of the supernatant was yellow) 
• OIAEX II was vortexed for 30 sec to resuspend and 1O).!1 was added to the 
mixture 
• This was incubated at room temperature for 10 min vortexing every 2 min 
• Centrifugation followed at 14000xg for 30 sec 
• The pellet was washed twice with SOO).!I Buffer PE, repeating the above 
centrifugation in between washes, and then air-dried for 30 min 
• 20j.!1 dH20 was applied and the pellet resuspended by vortexing 
• Incubation at room temperature for S min followed 
• Centrifugation was repeated at 14000xg for 1 min and the supernatant 

































1.3.1. Diffusion buffer 
Ammonium acetate (0.5M) (SDH Laboratory Supplies) 
Magnesium acetate (10mM) (Merck Chemicals) 
10% Sodium Oodecy1 Sulphate (0.1%) (SOH laboratory Supplies) 
0.5M EDTA pH 8 (SDH Laboratory Supplies) 

















J.1. Marker genotyping 
Equipment and reagents: 
APPENDIX J 
Haplotype Analysis 
• ASI PRISM® 3100 automated sequencer 
(PE Applied Biosystems, Foster City, CA, USA) 
• Hi-Dye formamide {PE Applied Biosystems} 
• Rox-SOO (PE Applied Siosystems) size standard (J.2) 
• 96-well plate (PE Applied Biosystems) 
• Hybaid Touchdown Thermal cycler (Hybaid Ltd. T eddington, UK) 
• ASI PRJSM@ GeneMapperTM software vs 3.0 (PE Applied Siosystems) 
Method (Wenz et al. 1998): 
• Amplified peR products were diluted to either 1/10. 1120 or 1140 depending on 
peR product intensity on PAGE 
• 8~LI of Hi-Dye formamide and O.2S~LI of Rox-SOO size standard was aliquoted into 
the appropriate wells on a 96-well plate 
• Samples were denatured at 95"C for 2 min and cooled immediately on ice 
• 2J..d of each diluted sample was then added to the respective wells 
• Samples were loaded onto the ABl PRISM 3100 automated sequencer and run 
with filter set 0 and the appropriate run and analysis modules 
• The ASI PRISM GeneMapper software vs 3.0 (PE Applied Siosystems) was 
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Figure K1: Pedigree of Family EPP1 showing haplotype 
segregation of both the allele associated vvith the primary 
mutation: 757_761 delAGAAG (red bar) and the allele associated 
with the secondary mutation: IVS3-48C (blue bar). Squares 
represent males and circles represent females. Symptomatic 
individuals are represented by filled symbols while clear symbols 
represent asymptomatic individuals. Primary and secondary 
mutation carriers are indicated by symbols that are half-filled or 
contain a dot, respectively_ Inferred genotypes are given in 
brackets. A line through a symbol indicates a deceased individual. 
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Figure K2: Pedigree of Family EPP2 showing haplotype 
segregation of both the allele associated with the primary 
mutation 757 _761deIAGAAG (red bar) and the allele associated 
with the secondary mutation: IVS3-48C (blue bar). Squares 
represent males and circles represent females. Symptomatic 
individuals are represented by filled symbols while clear symbols 
represent asymptomatic individuals. Primary and secondary 
mutation carriers are indicated by symbols that are half-filled or 
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Figure K3: Pedigree of Family EPP3 showing haplotype 
segregation of both the allele associated with the primary 
mutation: 757_761 delAGAAG (red bar) and the allele associated 
with the secondary mutation: IVS3-48C (blue bar). Squares 
represent males and circles represent females. Symptomatic 
individuals are represented by filled symbols while clear symbols 
represent asymptomatic individuals. Primary and secondary 
mutation carriers are indicated by symbols that are half-filled or 
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Figure K4: Pedigree of Family EPP4 showing haplotype segregation of both the allele associated with the primary 
mutation: 757_761de1AGAAG (red bar) and the allele associated with the secondary mutation: IVS3-48C (blue bar). 
Squares represent males and circles represent females. Symptomatic individuals are represented by filled symbols 
while clear symbols represent asymptomatic individuals. Primary and secondary mutation carriers are indicated by 
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Figure K5: Pedigree of Family EPPS showing haplotype 
segregation of both the allele associated with the primary 
mutation: 356_362delTTCAAGA (red bar) and the allele 
associated with the secondary mulation: IVS3-48C (blue bar). 
Squares represent males and circles represent females. 
Symptomatic individuals are represented by filled symbols while 
clear symbols represent asymptomatic individuals. Primary and 
secondary mutation carriers are indicated by symbols that are half-
filled or contain a dot, respectively. Inferred genotypes are given in 
brackets. A line through a symbol indicates a deceased individual. 
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Figure K6: Pedigree of Family EPP6 showing genotyping results 
for individuals EPP6.1 and EPP6.2 and possible haplotypes for 
alleles associated with the primary: 757 _761 de IAGAAG (red bar) 
and secondary: IVS3-48C (blue bar) mutations, respectively. 
Infomnation is insufficient to detemnine haplotype phase. Squares 
represent males and circles represent females. Symptomatic 
individuals are represented by filled symbols while clear symbols 
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Figure K7: Pedigree of Family EPP7 showing haplotype 
segregation of both the allele associated with the primary 
mutation: IVS7+1A (red bar) and the allele associated with the 
secondary mutation: IVS3-48C (blue bar). Squares represent 
males and circles represent females. Symptomatic individuals are 
represented by filled symbols while clear symbols represent 
asymptomatic individuals. Primary and secondary mutation 
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Figure K8: Pedigree of Family EPP8 showing haplotype segregation (different patterns indicate distinct haplotypes). Squares 
represent males and circles represent females. Symptomatic individuals are represented by filled symbols while clear symbols 
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Figure K9: Pedigree of Family EPP9 showing haplotype 
segregation of both the allele associated with the primary 
mutation: 757_761 delAGAAG (red bar) and the allele associated 
with the secondary mutation: IVS3-48C (blue bar). A distinct allele 
containing the IVS3-48C polymorphism is indicated by a black bar. 
Squares represent males and circles represent females. 
Symptomatic individuals are represented by filled symbols while 
clear symbols represent asymptomatic individuals. Primary and 
secondary mutation carriers are indicated by symbols that are half-
filled or contain a dot, respectively. Inferred genotypes are given in 
brackets. A line through a symbol indicates a deceased individual. 
'?' = phenotype unknown. 
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Figure K10: Pedigree of Family EPP10 showing haplotype 
segregation of both the allele associated with the primary 
mutatio : 757_761 delAGAAG (red bar) and the allele associated 
with the secondary mutation: IVS3-48C (blue bar). Squares 
represent males and circles represent females. Symptomatic 
individuals are represented by filled symbols while clear symbols 
represent asymptomatic individuals. Primary and secondary 
mutation carriers are indicated by symbols that are half-filled or 
contain a dot, respectively. Inferred genotypes are given in 
brackets. A line through a symbol indicates a deceased individual. 























Figure K11: Pedigree of Family EPP11 showing genotyping 
results for individual EPP11.1 and one possible haplotype for the 
allele associated with the secondary mutation: IVS3-48C (blue 
bar). No primary mutation was identified for this individual and 
Information is insufficient to determine haplotype phase. Squares 
represent males and circles represent females. Symptomatic 
individuals are represented by filled symbols while clear symbols 
represent asymptomatic individuals. A line through a symbol 
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Figure K12: Pedigree of Family EPP12 showing haplotype 
segregation of both the allele associated with the primary 
mutation: 757 _761deIAGAAG (red bar) and the allele associated 
with the secondary mutation: IVS3-48C (blue bar). Squares 
represent males and circles represent females. Symptomatic 
individuals are represented by filled symbols while clear symbols 
represent asymptomatic individuals. Primary and secondary 
mutation carriers are indicated by symbols that are half-filled or 
contain a dot, respectively. Inferred genotypes are given in 
brackets. A line through a symbol indicates a deceased individual. 
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Figure K13: Pedigree of Family EPP13 showing haplotype 
segregation of both the allele associated with the primary 
mutation: IVS3+2G (red bar) and the allele associated with the 
secondary mutation: IVS3-48C (blue bar). Squares represent 
males and circles represent females. Symptomatic individuals are 
represented by filled symbols while clear symbols represent 
asymptomatic individuals. Primary and secondary mutation 
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Figure K14: Pedigree of Family EPP14 showing haplotype 
segregation of both the allele associated with the primary 
mutation: 757_761 delAGAAG (red bar) and the allele associated 
with the secondary mutation: IVS3-48C (blue bar). Squares 
represent males and circles represent females. Symptomatic 
individuals are represented by filled symbols while clear symbols 
represent asymptomatic individuals. Primary and secondary 
mutation carriers are indicated by symbols that are half-filled or 
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Figure K15: Pedigree of Family EPP15 showing haplotype 
segregation of both the allele associated with the primary 
mutation: 757 _761deIAGAAG (red bar) and the allele associated 
with the secondary mutation: IVS3-48C (blue bar). Squares 
represent males and circles represent females. Symptomatic 
individuals are represented by filled symbols while clear symbols 
represent asymptomatic individuals. Primary and secondary 
mutation carriers are indicated by symbols that are half-filled or 
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Figure K16: Pedigree of Family EPP16 showing haplotype 
segregation of both the allele associated with the primary 
mutation: 757_761 delAGAAG (red bar) and the allele associated 
with the secondary mutation: IVS3-48C (blue bar). Squares 
represent males and circles represent females. Symptomatic 
individuals are represented by filled symbols while clear symbols 
represent asymptomatic individuals. Primary and secondary 
mutation carriers are indicated by symbols that are half-filled or 






























Figure K17: Pedigree of Family EPP17 showing genotyping 
results for individuals EPP17.1 and EPP17.2 and possible 
haplotypes for alleles associated with the primary: 
757_761 delAGAAG (red bar) and secondary: IVS3-48C (blue bar) 
mutations, respectively. Information is insufficient to determine 
haplotype phase. Squares represent males and circles represent 
females. Symptomatic individuals are represented by filled 
symbols while clear symbols represent asymptomatic individuals. 






















Abitbol M, Bernex F, Puy H, Jouault H, Deybach JC, Guenet JL, Montagutelli X (2005) 
A mouse modal provides eVIdence that genetIc background modulates anemia and 
liver injury in erythropoietic protoporphyria. Am J Physiol Gastrointest Liver Physio! 
288:G 1208-16 
Al-Karadaghi S, Hansson M, Nikonov S, Jonsson 8, Hederstedt L (1997) Crystal 
structure of ferrochelatase: the terminal enzyme in heme biosynthesis. Stmcture 
5:1501-10 
Alemzadeh R. Feehan T (2004) Variable effects of beta-carotene therapy in a child with 
erythropoietic protoporphyria. Eur J Pediatr 
AI/oisio N, Morle L, Marechal J, Roux AF, Ducluzeau MT, Guetarni D, Pothier B, 
Bakloutl F, Ghanem A, Kastally R, et al. (1991) Sp alpha V/41: a common spectnn 
polymorphism at the alpha IV-alpha V domain junction. Relevance to the expression 
level of hereditary elliptocytosis due to alpha-spectrin variants located in trans. J 
Clin Invest 87:2169-77 
Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, 
Desnick RJ (2005) Recommendations for the diagnosis and treatment of the acute 
porphyrias. Ann Intern Med 142:439-50 
Andrew TL, Riley PG (1990) Regulation of heme biosynthesis in higher animals. In: 
Dailey HA (ed) Biosynthesis of heme and chlorophylls. McGraw-Hili Publishing 
Company, New York, pp 163-200 
Anstey AV (2002) Systemic photoprotection with alpha-tocopherol (vitamin E) and beta-
carotene. Clin Exp Dermatol 27: 170-6 
Aplin C, Whatley SO, Thompson P, Hoy T, Fisher P, Singer C, Loven CR, Elder GH 
(2001) Late-onset erythropoietic porphyria caused by a chromosome 18q deletion in 
erythroid cells. J Invest Dermatol 117: 1647-9 
Atkins AM, Nedorost ST (2003) Swollen upper extremities. Clin Pediatr (Phila) 42:827-9 
Baart de la Faille H, Bijlmer-Iest JC, van Hattum J, Koningsberger J, Rademakers LH.. 
van Weelden H (1991) Erythropoietic protoporphyria: clinical aspects with emphasis 
on the skin. Curr Prahl Oermatol 20: 123-34 
Badminton MN, Elder GH (2005) Molecular mechanisms of dominant expression in 











Bailey GG, Needham LL (1986) Simultaneous quantification of erythrocyte zinc 
protoporphyrin and protoporphyrin IX by liqUId chromatography. Cfin Chern 32:2137-
42 
Banchs I, Bosch A. Guimera J, Lazaro C, Puig A. Estivill X (1994) New alleles at 
mlcrosatetlite loci in CEPH families mainly arise from somatic mutations in the 
Iymphoblastoid cell lines. Hum Mutat 3:365-72 
Baran R, Juhlin L (2002) Photoonycholysis. Photodermatol Photoimmunol Photomed 
18:202-7 
Battersby AR (1978) The discovery of nature's biosynthetic pathways. Experientia 34:1-
13 
Battersby AR, Fookes CJ. Matcham GW. McDonald E (1980) Biosynthesis of the 
pigments of ute: formation of the macrocycle. Nature 285:17-21 
Battersby AR, McDonald E (1975) In: Smith KM (ed) Porphyrins and metaJloporphyrins. 
2'ld ed. Elsevier, Amsterdam, pp 61-122 
Bishop OF, Henderson AS, Astrin KH (1990) Human detta-aminolevulinate synthase: 
assignment of the housekeeping gene to 3p21 and the erythroid-specific gene to 
the X chromosome. Genomics 7:207-14 
Bissell OM (1985) Peculiar purine nucleotides and liver regeneration. Gastroenterology 
89:914-6 
Bissell OM, Schmid R (1987) Hepatic Porphyrias. tn: Schiff l, Schiff ER (eds) Diseases 
ofthe liver. 6th ed. JB Lippincott, Philadelphia Toronto, pp 1075·1092 
Blackwood ME Jr, Rush TS III. Medlock A, Dailey HA, Spiro TG (1997) Resonance 
raman spectra of ferrochelatase reveat porphyrin distortion upon metat binding. 
JAm Chem Soc 119:12110-12174 
Blackwood ME, Jr., Rush TS, 3rd, Romesberg F, Schultz PG, Spiro TG (1998) 
AlternatIve modes of substrate distortion in enzyme and antibody catalyzed 
ferrochelation reactions. Biochemistry 37: 779-82 
Bloks V'vV, Piosch T, van Goor H, Roelofsen H, Balier J, Havinga R, Verkade HJ, van 
To! A, Jansen PL, Kuipers F (2001) Hyperlipidemia and atherosclerosis associated 
wITh liver disease in ferrochelatase-deficienl mice. J Lipid Res 42A1-50 
Bloomer JR, Enriquez R (1982) Evidence that hepatic crystalline deposits in a patient 
with protoporphyria are composed of protoporphyrin. Gastroenterology 82:569-73 
Bloomer JR Hill HD, Kools AM, Straka JG (1991) Heme synthesis in protoporphyria. 

















Bloomer J, Bruzzone C, Zhu L, Scarlett Y, Magness S, Brenner 0 (1998) Molecular 
defects in ferrochelatase in patients with protoporphyria requiring liver 
transplantation. J Clin Invest 102:107-14 
Bloomer J, Wang Y, Singhal A, Risheg H (2005) Molecular studies of liver disease in 
erythropoietic protoporphyria. J Clin Gastroenterol 39:S 167 -75 
Bloomer JR. Wang Y, Singhal A. Risheg H (2006) Biochemical abnormaHty in 
erythropoietic protoporphyria: cause and consequences. J Pediatr Gastroenterol 
Nutr 43 Suppl 1 :S36~40 
Bonkovsky HL. Barnard GF (1998) Diagnosis of porphyric syndromes: a practical 
approach in the era of molecular biology. Semin Liver Dis 18:57-65 
Bonkowsky HL, Bloomer JR, Ebert PS, Mahoney MJ (1975) Heme synthetase 
deficiency in human protoporphyria. Demonstration of the defed in liver and 
cultured skin fibroblasts. J Clin Invest 56: 1139-48 
Boulechfar S, Lamoril J, Montagutelli X, Guenet JL, Oeybach JC, Nordmann Y, Dailey 
H. Grandchamp B. de Verneuil H (1993) Ferrochelatase structural mutant 
(Fechm1 Pas) in the house mouse. Genomics 16:645-8 
Brenner DA, Frasier F (1991) Cloning of murine ferrochelatase. Proc Natl Acad Sci 
USA 88:849-53 
Brenner DA, Didier .1M, Frasier F, Christensen SR, Evans GA, Dailey HA (1992) A 
molecular defect in human protoporphyria. Am J Hum Genet 50:1203-10 
Brun A, Western A, Malik Z, Sandberg S (1990) Erythropoietic protoporphyria: 
photodynamic transfer of protoporphyrin from intact erythrocytes to other cells. 
Photochem Photobiol 51 :573-7 
Brun A, Sandberg S (1991) Mechanisms of photosensitivity in porphyric patients with 
special emphasis on erythropoietic protoporphyria. J Photochem Photobiol B 
10:285-302 
Burden AE, Wu C, Dailey TA, Busch JL, Dhawan IK, Rose JP, Wang B, Dailey HA 
(1999) Human ferrochelatase: crystallization, characterization of the [2Fe-2S] 
cluster and determination that the enzyme is a homodimer. Biochim Biophys Acta 
1435:191-7 
Camadro ~IM, Labbe P (1982) Kinetic studies of ferrochelatase in yeast. Zinc or iron as 
competing substrates. Biochim Biophys Acta 707:280-8 
Camadro JM, Ibraham NG, Levere RD (1984) Kinetic studies of human liver 
ferrochelatase. Role of endogenous metals. J Bioi Chern 259:5678-82 
177 















Camadro JM, Labbe P (1988) Purification and properties of ferrochelatase from the 
yeast Saccharomyces cerevisiae. Evidence for a precursor form of the protein. J 
Bioi Chem 263: 11675-82 
Chakrabarti A, Tan CY (2002) Dietary fish oils as a therapeutic option in erythropoietic 
protoporphyria. Clin Exp Dermatol 27:324-7 
Chang YH, Su WH, Lee TC, Sun HF, Chen CH, Pan WH, Tsai SF, Jou YS (2005) 
TPMD: a database and resources of microsatellite marker genotyped in Taiwanese 
populations. Nucleic Acids Res 33:0174-7 
Chen FP, Risheg H, Liu Y, Bloomer J (2002) Ferrochelatase gene mutations in 
erythropoietic protoporphyria: focus on liver disease. Cell Mol Bioi (Noisy-ie-grand) 
48:83-9 
Cobbold C, Roberts A, Badminton M (2006) Erythropoietic proto porphyria: A functional 
analysis of the leader sequence of human ferrochelatase. Mol Genet Metab 
Cox TC, Bawden MJ, Martin A, May BK (1991) Human erythroid 5-aminolevulinate 
synthase: promoter analysis and identification of an iron-responsive element in the 
mRNA Embo J 10: 1891-902 
Cox TM (1997) Erythropoietic protoporphyria. J Inherit Metab Dis 20:258-69 
Cox TM, Alexander GJ, Sarkany RP (1998) Protoporphyria. Semin Liver Dis 18:85-93 
Cripps OJ, MacEachern WN (1971) Hepatic and erythropoietic protoporphyria. Delta-
aminolevulinic acid synthetase, fluorescence, and microfluorospectrophotometric 
study. Arch Pathol91 :497-505 
Crouse BR, Sellers VM, Finnegan MG, Dailey HA, Johnson MK (1996) Site-directed 
mutagenesis and spectroscopic characterization of human ferrochelatase: 
identification of residues coordinating the [2Fe-2S] cluster. Biochemistry 35: 16222-9 
Dailey HA, Fleming JE (1983) Bovine ferrochelatase. Kinetic analysis of inhibition by N-
methyl protoporphyrin, manganese, and heme. J Bioi Chem 258: 11453-9 
Dailey HA (1990) Conversion of coproporphyrinogen to protoheme in higher eukaryotes 
and bacteria: Terminal three enzymes. In: Dailey HA (ed) Biosynthesis of heme and 
chlorophylls. McGraw-Hili Publishing Company, New York, pp 139 
Dailey HA, Sellers VM, Dailey TA (1994) Mammalian ferrochelatase. Expression and 
characterization of normal and two human protoporphyric ferrochelatases. J Bioi 
Chem 269:390-5 
Dailey HA (1997) Enzymes of heme biosynthesis .. JBIC 2: 411-417 
Dailey HA, Dailey TA, Wu CK, Medlock AE, Wang KF, Rose JP, Wang BC (2000) 
Ferrochelatase at the millennium: structures, mechanisms and (2Fe-2S] clusters. 
















Dailey HA, Dailey TA (2003) In: Kadish KM, Smith KM, Guilard R (eds) Ferrochelatase 
- the iron and cobalt pigments: Biosynthesis, structure and degradation. Academic 
Press. California USA, 12:93-121 
Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES (2001) High-resolution 
haplotype structure in the human genome. Nat Genet 29:229-32 
Davenport RD (2004) Transfusion medicine illustrated. Erythropoietic protoporphyria. 
Transfusion 44:1401 
Davies R. Schuurman A, Barker CR. Clothier B, Chernova T, Higginson FM, Judah OJ, 
Dinsdale D, Edwards RE, Greaves P. Gant TW, Smith AG (2005) Hepatic gene 
expression in protoporphyic Fech mice is associated with cholestatic injury but not a 
marked depletion of the heme regulatory pool. Am J Pathol 166: 1 041-53 
Day RS, Pimstone NR, Eales l (1978) The diagnostic value of blood plasma porphyrin 
methyl ester profiles produced by quantitative TlC. Int J Biochem 9:897-904 
de Goeij AF, Christianse K, van Steveninck J (1975) Decreased haem synthetase 
activity in blood cells of patients with erythropoietic protoporphyria. Eur J Clin Invest 
5:397-400 
De Matteis F, Gibbs AH (1975) Stimulation of the pathway of porphyrin synthesis in the 
liver of rats and mice by griseofulvin, 3,5-Diethoxycarbonyl-1,4-dihydrocollidine and 
related drugs: evidence for two basically different mechanisms. Biochem J 146:285-
7 
De Smet C, lurquin C, lethe B, Martelange V. Boon T (1999) DNA methylation is the 
primary silencing mechanism for a set of germ line- and tumor-specific genes with a 
CpG-rich promoter. Mol Cell 8ioI19:7327-35 
Deleo VA, Poh-Fitzpatrick M, Mathews-Roth M, Harber LC (1976) Erythropoietic 
protoporphyria. 10 years experience. Am J Med 60:8-22 
den Dunnen JT, Antonarakis SE (2001) Nomenclature for the description of human 
sequence variations. Hum Genet 109: 121-4 
Di Pierro E, Cappellini MD, Mazzucchelli R, Moriondo V, Mologni 0, Poma BZ, Riva A 
(2005) A point mutation affecting an SP1 binding site in the promoter of the 
ferrochelatase gene impairs gene transcription and causes erythropoietic 
protoporphyria. Exp Hematol 33:584-91 
Do KO, Banner BF, Katz E. Szymanski 10, Bonkovsky Hl (2002) Benefrts of chronic 
plasmapheresis and intravenous heme-albumin in erythropoietic protoporphyria 
after orthotopic liver transplantation. Transplantation 73:469-72 
Doss MO, Frank M (1989) Hepatobiliary implications and complications in 












Doss MO, Kuhnel A, Gross U (2000) Alcohol and porphyrin metabolism. Alcohol 
35:109·25 
Eales L. Dowdle EB (1968) Clinical aspects of importance in the porphyrias. 8r J Clin 
Pract 22:505-15 
Eales L, Day RS, Pimstone NR (1978) Erythrohepatic protoporphyria (EHP) in South 
Africa. Ann CUn Res 10:195-204 
Eales L, Day RS, Pimstones NR (1978) Protoporphyrin (proto)-determined hepatopathy 
in a South African Jewish family. Ann Clin Res 10:205-13 
Eichbaum QG. Dzik WHo Chung RT. SzczepiorK.owski 2M (2005) Red blood cell 
exchange transfusion in two patients with advanced erythropoietic protoporphyria. 
Transfusion 45:208-13 
Elder GH. Smith SG. Smyth SJ (1990) Laboratory investigation of the porphyrias. Ann 
Clin Siochem 27 ( Pt 5):395-412 
Elder G (2005) Normal dermal ferrochelatase activity does not protect human sk.in from 
protoporphyrin-induced photosensitivity. J Invest Dermatol 125:580; author reply 
580-1 
EHegren H (2004) Microsatetlites: simple sequences with complex evolution. Nat Rev 
Genet 5:435-45 
Elliott W, Bishop P, Daley W, Nowicki MJ (2004) Erythropoietic protophyria in an 
adolescent female. J Hepatol 40:353 
Farr PM, Diffey BL, Matthews IN (1990) Inhibition of photosensitivity in erythropoietic 
protoporphyria with terfenadine. Sr J Dermatol 122:809-15 
Ferreira GC, Franco R lloyd SG, Pereira AS, Moura I, Moura JJ, Huynh BH (1994) 
Mammalian ferrochelatase, a new addition to the metalloenzyme family. J Bioi 
Chem 269:7062-5 
Ferreira GC (1999) Ferrochelatase. Int J Biochem Celt Bioi 31:995-1000 
Findlay GH, Scott FP, Cripps OJ (1966) Porphyria and lipid proteinosis. A clinical, 
histological and biochemical comparison of 19 South African cases. Sr J Oermatol 
78:69-80 
Fischer H, Orth H (1934) Die chemie des pyrrols. 3 Bands. Akademische 
Verlagsgesellschaft MBH, Leipzig 
Fontanellas A, Mendez M, Mazurier F, Cario-Andre M, Navarro S, Ged C, Taine l, 
Geronimi F, Richard E. Moreau-Gaudry F. Enriquez De Salamanca R. de Vemeuil 
H (2001) Successful therapeutic effect in a mouse model of erythropoietic 
proto porphyria by partial genetic correction and fluorescence-based selection of 




t nr n t i .













Franco R, Ma JG, Lu Y, Ferreira GC, Shelnutt JA (2000) Porphyrin interactions with 
wild-type and mutant mouse farrochalatase. 8iochemistrf39:2517-29 
Frank M, Doss MO (1991) Severe liver disease in protoporphyria. Curr Probl Oermatol 
20:160-7 
Fujita H (1997) Molecular mechanism of heme biosynthesis. Tohoku J Exp Med 183:83-
99 
Fusaro RM, Runge WJ (1970) Erythropoietic protoporphyria. IV. Protection from 
sunlight Br Med J 1 :730-1 
Gant TW, Baus PR Clothier B, Riley J, Davies R Judah OJ, Edwards RE, George E, 
Greaves P, Smith AG (2003) Gene expression profiles associated with 
inflammation, fibrosis, and cholestasis in mouse liver after griseofulvin. EHP 
T oxicogenomics 111 :37-43 
Girotti AW (1990) Photodynamic lipid peroxidation in biological systems. Photochem 
Photobiol 51 :497-509 
Goldstein BO, Harber LC (1972) Erythropoietic protoporphyria: lipid peroxidation and 
red cell membrane damage associated with photohemolysis. J Clin Invest 51 :892-
902 
Goodwin RG, Kell WJ, Laidler P. Long CC, Whatley SO. McKinley M, Badminton MN, 
Burnett AK, Williams GT, Elder GH (2006) Photosensitivity and acute liver injury in 
myeloproliferative disorder secondary to lata-onset protoporphyna caused by 
deletion of a ferrochelatase gene in hematopoietic cells. Blood 107:60-2 
Gordeuk VR, Brittenham GM, Hawkins CW, Mukhtar H, Bickers DR (1986) Iron therapy 
for hepatic dysfunction In erythropoietic protoporphyria. Ann Intern Med 105:27-31 
Gouya l. Deybach JC, LamonI J. Da Silva V. Beaumont C. Grandchamp B, Nordmann 
Y (1996) Modulation of the phenotype in dominant erythropoietic protoporphyria by 
a low expression of the normal ferrochelatase allele. Am J Hum Genet 58:292-9 
Gouya L, Puy H. LamonI J, Oa Silva V. Grandchamp B, Nordmann Y, Oeybach JC 
(1999) Inheritance in erythropoietic protoporphyria: a common wild-type 
ferrochelatase allelic variant with low expression accounts for clinical manifestation. 
Blood 93:2105-10 
Gouya L, Puy H, Robreau AM, Bourgeois M, Lamoril J, Oa Silva V, Grandchamp B, 
Oeybach JC (2002) The penetrance of dominant erythropoietic protoporphyria is 
modulated by expression of wildtype FECH. Nat Genet 30:27-8 
Gouya (2004) Modulation of penetrance by the wild-type allele in dominantly inherited 
erythropoietic protoporphyria and acute hepatic porphyrias. Human Genetics 
114:256-262 
181 


















Gcuya l, Martin-Schmitt C, Robreau AM, Austerlitz F, Da Silva V, Brun P, Simonin S, 
Lyourni S1 Grandchamp B, Beaumont C. Puy H, Daybach JC (2006) CcntribtJtion of 
a common single-nucleotide polymorphism to the genetic predisposition for 
erythropoietic protoporphyria. Am J Hum Genet 78:2-14 
Gray CH, lim CK, Nicholson DC (1977) The differentiation of the porphyrias by means 
of high pressure liquid chromatography Clin Chim Acta 77:167-78 
Guberman AS, Scassa ME, Giono lE, Varone Cl, Canepa ET (2003) Inhibitory effect 
of AP-1 complex on 5-aminolevulinate synthase gene expression through 
sequestration of cAMP-response element protein (CRE)-binding protein (C8P) 
coactivator. J Bioi Chem 278:2317-26 
Guo R, lim CK, Peters TJ (1991) High-performance liquid chromatographic assays for 
protoporphyrinogen oxidase and ferrochelatase in human leucocytes. J Chromatogr 
566:383-96 
Haeger-Aronsen 8 (1982) \"Vhy is the patient with lead mtoxication not light sensitive? 
Acta Derm Venereol Suppl (Stockh) 100:67-71 
Hamilton JW, Bement WJ, Sinclair PR, Sinclair JF, Alcedo JA, Wetterhahn KE (1991) 
Heme regulates hepatic 5-aminolevulinate synthase mRNA expression by 
decreasing mRNA half-life and not by altering its rate of transcription. Arch Biochem 
Biophys 289:387-92 
Harber LC, Poh-Fitzpatrick MB, Walther RR, Grossman ME (1982) Cutaneous aspects 
of the porphyrias, Acta Derm Venereol Supp! (Stockh) 100:9-15 
Hart 0, Piome!li S (1981) Simultaneous quantitation of zinc protoporphyrin and free 
protoporphYrin in erythrocytes by acetone extraction. elin Chern 27:220-2 
Hayashi K (1992) PGR-SSCP: a method for detection of mutations. Genet Anal Tech 
AppI9:73-9 
Henriksson M, T;monen K, Mustajoki P, Pihlaja H, Tenhunen R. Pettonen l, Kauppinen 
R (1996) Four nove! mutations in the ferrochelatase gene among erythropoietic 
protoporphyria patients. J Invest Dermatol 106:346-50 
Hift Rj, Meissner PN (2005) An analysis of 112 acute porphyric attacks in Cape Town, 
South Africa: Evidence that acute intermittent porphyria and variegate porphyria 
differ in susceptibility and severity. Medicine (Baltimore) 84:48-60 
Hirsch RE, Un MJ, Plliakhandam UR, Nagei Rl, Sandberg S (1993) Hemoglobin 






" .... o ... r-"" t t t  











Holme SA, Anstey AV, Finlay AY, Elder GH, Badminton MN (2006) Erythropoietic 
protoporphyria in the U.K.: clinical features and effect on quality of life. Br J Dermatol 
155:574-81 
Holme SA, Anstey AV, Finlay AY, Elder GH, Badminton MN (2006) Abstract No.1 
Epidemiology of erythropoietic protoporphyria: the U.K. experience. Br J Dermatol 
155:866 
Honigsmann H, Gschnait F, Konrad K, Stingi G, Wolff K (1976) Mouse model for 
protoporphyria. III. Experimental production of chronic erythropoietic protoporphyria-
like skin lesions. J Invest Dermatol 66: 188-95 
Imoto S, Tanizawa Y, Sato Y, Kaku K, Oka Y (1996) A novel mutation in the 
ferrochelatase gene associated with erythropoietic protoporphyria. Br J Haematol 
94:191-7 
Inafuku K, Takamiyagi A, Oshiro M, Kinjo T, Nakashima Y, Nonaka S (1999) Alteration 
of mRNA levels of delta-aminolevulinic acid synthase, ferrochelatase and heme 
oxygenase-1 in griseofulvin induced protoporphyria mice. ~I Dermatol Sci 19: 189-98 
Jones MS, Jones OT (1969) The structural organization of haem synthesis in rat liver 
mitochondria. Biochem J 113:507-14 
Jones A, Reed R, Weyers J (1994) In: Practical skills in biology. Longman Group Ltd, 
UK, pp 165-167 
Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, 
Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH (2002) The 
breast cancer resistance protein protects against a major chlorophyll-derived dietary 
phototoxin and protoporphyria. Proc Natl Acad Sci USA 99: 15649-54 
Karr SR, Dailey HA (1988) The synthesis of murine ferrochelatase in vitro and in vivo. 
Biochem J 254:799-803 
Kauppinen R (2005) Porphyrias. Lancet 365:241-52 
Key NS, Rank JM, Freese 0, Bloomer JR, Hammerschmidt DE (1992) Hemolytic 
anemia in protoporphyria: possible precipitating role of liver failure and photic stress. 
Am J Hematol 39:202-7 
Kirsch RE. Meissner PN, Hift RJ (1998) Variegate porphyria. Semin Liver Dis 18:33-41 
Kohno H, Okuda M, Furukawa T, Tokunaga R, Taketani S (1994) Site-directed 
mutagenesis of human ferrochelatase: identification of histidine-263 as a binding 
site for metal ions. Biochim Biophys Acta 1209:95-100 
Komatsu H, Sajima Y. Imamura K, Masuda H, Yonei Y, Dohmori K, Kokutoh M, Ishii K, 
Ishii H (2000) An ultrastructural study of the liver in erythropoietic protoporphyria. 

















Komatsu H, Ishii K, Imamura K, Maruyama K, Yonei Y, Masuda H, Tsuchihashi T, 
Sajima Y (2000) A case of erythropoietic protoporphyria with liver cirrhosis 
suggesting a therapeutic value of supplementation with alpha-tocopherol. Hepatol 
Res 18:298-309 
Kosenow W, Treibs A (1953) [Light hypersensitivity and porphyrinemia.]. Z Kinderheilkd 
73:82-92 
Krook G, Haeger-Aronsen B (1982) beta-Carotene in the treatment of erythropoietic 
protoporphyria. A short review. Acta Derm Venereal Suppl (Stockh) 100:125-9 
Labbe-Bois R (1990) The ferrochelatase from Saccharomyces cerevisiae. Sequence, 
disruption, and expression of its structural gene HEM15. J Bioi Chem 265:7278-83 
Lamola AA, Yamane T (1974) Zinc protoporphyrin in the erythrocytes of patients with 
lead intoxication and iron deficiency anemia. Science 186:936-8 
Lamola AA, Piomelli S, Poh-Fitzpatrick MG, Yamane T, Harber LC (1975) 
Erythropoietic protoporphyria and lead intoxication: the molecular basis for 
difference in cutaneous photosensitivity. II. Different binding of erythrocyte 
protoporphyrin to hemoglobin. J Clin Invest 56: 1528-35 
Lamora AA, Asher I, Muller-Eberhard U, Poh-Fitzpatrick M (1981) Fluorimetric study of 
the binding of protoporphyrin to haemopexin and albumin. Biochem J 196:693-8 
Lamola AA (1982) Fluorescence studies of protoporphyrin. Transport and clearance. 
Acta Derm Venereol Suppl (Stockh) 100:57-66 
Lamori! J, Boulechfar S, de Verneuil H, Grandchamp B. Nordmann Y, Deybach JC 
(1991) Human erythropoietic protoporphyria: two point mutations in the 
ferrochalatase gena. Biocham Biop/lys Ras Commun 181:594-9 
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, et at 
(2001) Initial sequencing and analysis of the human genome. Nature 409:860-921 
Lareu V, Pestoni C, Phillips C, Barros F, Syndercombe Court 0, Lincoln P, Carracedo A 
( 1998) Normal and anomalous electrophoretic behavior of polymerase chain 
reaction-based DNA polymorphisms in polyacrylamide gels. E/ectroplloresis 
19:1566-72 
Lathrop JT. Timko MP (1993) Regulation by heme of mitochondrial protein transport 
through a conserved amino acid motif. Science 259:522-5 
Lavallee OK (1988) Porphyrin metalation reactions in biochemistry. In: Liebman JF, 
Greenberg A (eds) Mechanistic principles of enzyme activity. VCH Publishers Inc, 
New York, pp 279-314 
leboulche P and Mathews-Roth M (2005) Skin ferrochelatase levels and 
















Lecerof D. Fodje M. Hansson A. Hansson M, AI-Karadaghi S (2000) Structural and 
mechanistic basis of porphyrin metaliation by ferrochelatase. j Mol Bioi 297:221-32 
Lecha M (2003) Erythropoietic protoporphyria. Photodermatol Photoimmunol Photemed 
19:142-6 
Leeming JA, Kramer S (1968) Four cases of erJthropoietic protoporphyria, S Afr Mad J 
42:586-9 
Leone N, Marzano A, Cerutti E, Actis GC, Marchesa PE, David E, Sa/izzoni M, Rizzette 
M (2000) Liver transplantation for erythropoietic protoporphyria: report of a case 
with medium-term follow-up. Dig Liver Dis 32:799-802 
Lewin B (2000) In. Genes VII. Oxford University Press, UK, pp 678-681 
Lev.;ontln RC (1964) The Interaction of Selection and Linkage. Ii. Optimum Models. 
Genetics 50:757-82 
Lim HW, Poh-Fitzpatrick MS, Gigli I (1984) Activation of the complement system in 
patients with porphyrlas after irradiation in vivo. J Clin Invest 74:1961-5 
Lim HW (2005) Pathogenesis of photosensitivity in the cutaneous porphyrias_ J Invest 
DermatoI124:xvi-xvii 
Un HF, Juo SH, Cheng R (2005) Comparison of the power between microsatel/ite and 
single-nucleotide polymorphism markers for linkage and linkage disequilibrium 
mapping of an electrophysiological phenotype. BMC Genet 6 SuppJ 1 :S7 
Longas MO, Poh-Fitzpatrick MB (1982) A tightly bound protein-porphyrin complex 
isolated from the plasma of a patient with variegate porphyria. Clin Chim Acta 
118:219-28 
Magness ST, Tugores A, Diala ES, Brenner DA (1998) Analysis of the human 
ferrochelatase promoter in transgenic mice. Blood 92:320-8 
Magness ST, Maeda N, Brenner OA (2002) An exon 10 deletion in the mouse 
ferrochelatase gene has a dominant-negative effect and causes mild 
protoporphyria. Blood 100:1470-7 
Magnus lA, Jarrett A, Prankerd TA, Rimington C (1961) Erythropoietic protoporphyria. A 
new porphyria syndrome wIth solar urticaria due to protoporphyrinaemia. Lancet 
2:448-51 
Marini JC, Levene SO, Crothers OM, Englund PT (1982) Bent helical structure in 
kinetoplast DNA. Proc Natl Acad Sci USA 79:7664-7668 
Mathews-Roth MM, Pathak MA Fitzpatrick TB. Harber LC. Kass EH (1970) Beta-
carotene as a photoprotective agent in erythropoietic protoporphyria. Trans Assoc 




















Mathews-Roth MM (1974) Letter: Anemia in erythropoietic protoporphyna. Jama 
230.824 
Mathews-Roth MM (1977) Erythropoietic protoporphyria--diagnosis and treatment N 
Engl J Med 297:98-100 
Mathews-Roth MM, Drouin Gl, Duffy L (1987) Isolation of human ferrochelatase. Arch 
Dermatol 123:429-30 
Mathews-Roth MM, Rosner S (2002) Long-term treatment of erythropoietic 
protoporphyria with cysteine. Photodermatol Photoimmunoi Photorned 18:307-9 
May BK, Dogra SC, Sadlon T J, Bhasker CR, Cox TC, Bottomley SS (1995) Molecular 
regulation of heme biosynthesis in higher vertebrates. Prog Nucleic Acid Res Mol 
Bioi 51: 1-51 
McClements 8M, Bingham A, Callender ME, Trimble ER (1990) Erythropoietic 
proto porphyria and iron therapy. Sr J Dermatol 122:423-4 
Meerrnan L (2000) Erythropoietic protoporphyria. An overview with emphasis on the 
liveL Scand J Gastroenterol Suppl:79-85 
Meissner PN, Hift RJ (2005) Diagnosis of porphyria in South Africa. CMF The SA 
journal of CPO 23:412-414 
Meissner PN, Hift RJ. Kirsch RE (2001) The porphyrias. In: Arias 1M, Boyer JL, Chisari 
FV, Fausto N, Schachter D, Shafritz DA (eds) The liver: biology and pathobiology. 
4th ed. Lippincott Williams & Wilkins, Philadelphia, pp 311-329 
Michal G (1999) In. Biochemical pathways: An at/as of biochemistry and molecular 
biology. John Wiley & Sons Inc, New York, pp 68-69 
Milligan A, Graham-Brown RA, Sarkany I, Baker H (1988) Erythropoietic proto porphyria 
exacerbated by oral iron therapy. Bf J Dermatol 119:63-6 
Moore MR, McColl KEL, Rimington C, Goldberg A (1987) In: Disorders of porphyrin 
metabolism. Plenum Press, New York, pp 21-35 
Moore MR, McColl KEL, Rimington C, Goldberg A (1987) In: Disorders of porphyrin 
metabolism. Plenum Press, New York, pp 3 
Moore MR, McColl KEL, Rimington C, Goldberg A (1987) In: Disorders of porphyrin 
metabolism. Plenum Press, New York. pp 38 
Moore MR (1990) Historical introduction to porphyrins and porphyrias. In: Dailey HA 
(ed) Biosynthesis of heme and chlorophylls. McGraw~HiII Publishing Company, Ne .... J 
York, pp 1-4 
Morris SO, Mason NG, Elder GH, Hawk JL, Sarkany RP (2002) Ferrochelatase gene 
polymorphism analysis for accurate genetic counselling in erythropoietic 



















Murphy GM, Hawk JLM, Corbett MF (1985) The UK erythropoietic protoporphyria 
regtster: a progress report. Sf J Derrrlatot 113 (Suppf. 29): 11 
Murphy GM (2003) Diagnosis and management of the erythropoietic porphyrias 
Dermatol Ther 16:57 ~64 
Najahi~Missaoui W. Dailey HA (2005) Production and characterization of erythropoietic 
protoporphyric heterodimeric ferrochelatases. Blood 106: 1 098-1 04 
Nakahashi Y, Taketan; S, Okuda M, Inoue K, Tokunaga R (1990) Molecular cloning and 
sequence analysis of cDNA encoding human ferrochelatase. Biocham Biophys Res 
Commun 173:748-55 
Nakano H, Nakano A, Toyomaki Y, Ohashi S, Harada K, Moritsugu R, Takeda H, 
Kawada A, Mitsuhashi Y, Hanada K (2006) Novel Ferrochelatase Mutations in 
Japanese Patients with Erythropoietic Protoporphyria: High Frequency of the Splice 
Site Modulator IVS3-48C Polymorphism in the Japanese Population. J Invest 
Dermatol 
Nordmann Y (1992) Erythropoietic protoporphyria and hepatic complications. J Hepatol 
16:4-6 
Nordmann Y1 Otl'i ..... , H (2002) Human h€lreditari hepatic porphyrias. Clio Chim Acta 
325:17-37 
Ohgari Y, Sawamoto M, Yamamoto M, Kohno H, Taketani S (2005) Ferrochelatase 
consisting of wild-type and mutated subunits from patients with a dominant-inherited 
disease, erythropoietic protoporphyria, is an active but unstable dimeL Hum Mol 
Genet 14:327-34 
Onaga Y, Ida A, !...,'to H. Hasuike S. Kusumoto K. Moriuchi A, Numata M, Nagata K, Hori 
T, Hayashi K, Tsubouchi H (2004) Hypermethylation of the wild-type ferrochelatase 
allele is closely associated with severe liver complication in a family with 
ery1.hropoletic protoporphyrta. Biochem Biophys Res Commun 321:851-8 
Orita M, Suzuki Y. Sekiya T, Hayashi K (1989) Rapid and sensitive dete<..iion of point 
mutations and DNA polymorphisms using the polymerase chain reaction Genomics 
'::·07A n v.v, -,.-a 
Pathak MA, West JD (1982) Porphyrias. office procedures and laboratory tests for 
diagnosis of porphyrin abnormalities_ Acta Derm Venereol Suppl (Stockh) 100:91-
in&:; 
IV" 
Pawliuk R, Bachelot T, Wise RJ, Mathews-Roth MM, Leboulch P (1999) Long-term cure 
of the photosensitivity of murine erythropoietic proto porphyria by preselective gene 
therapy. ~~at t'W1ed 5:768-73 
187 
 
















Pawliuk R, Tighe R, Wise RJ, Mathews-Roth MM, Leboulch P (2005) Prevention of 
murine er,1hropot@ttc protoporphyna-tissoclatsd sKin pnotoSS:lsrt1vrty dnd InJ-cr nV~1 
disease by dermal and hepatic ferrochelatase. J Invest Dermato1124:256-62 
Piomelli S, Lamola AA, Poh-Fitzpatrick MF, Seaman C, Harber LC (1975) Erythropoietic 
protoporphyria and lead intoxication: the molecular basis for difference in cutaneous 
photosensitivity. L Different rates of disappearance of protoporphyrin from the 
erythrocytes, both in vivo and in vitro. J Clin Invest 56:1519-27 
PI'ome"; ~ (1 0 77) cree e'"'lthro"yte po ..... h"r ....... "In thn ~et"ct'''''"' ,,4' u"'~ue ab .. "'r .... h"' ... "f III v v I I I 'Y III \.,.I ....... ,11110 I 11'0' U f.,g\.,.lIVII VI 1I\.oJ OV ........... VII Vi 
Pb and of Fe deficiency. Cain Chern 23:264-9 
Plosch T, Sioks VW, Baller JF, Havinga R, Verkade HJ, Jansen PL, Kuipers F (2002) 
Mdr P-gtycoprotsing ar€ not agsentiaf for biliary excretion of th€ hydrophob:c hem€ 
precursor protoporphyrin in a griseofulvin-induced mouse model of erythropoietic 
protoporphyria. Hepatology 35:299-306 
Poh-Fitzpatricl< MS, Lamola AA (1976) Direct spectrofluorometry of diluted erythrocytes 
and plasma: a rapid diagnostic method in primary and secondary porphyrinemias. J 
Lab Clin Med 87:362-70 
Poh-Fitzpatrick MB (1980) A plasma porphyrin fluorescence marker for variegate 
porphyria. Arch DermatoI116:543-7 
Poh-Fitzpatrick MB (1985) Porphyrin-sensitized cutaneous photosensitivity: 
pathogenesis and treatment. Clin Dermatol 3:41-82 
Poh-Fitzpatrick MB (1989) The "priming phenomenon" in the acute phototoxicity of 
erythropoietic proto porphyria. JAm Acad Dermatol 21 :311 
Poh-Fitzpatrick MB, Wang X, Anderson KE, Bloomer JR, Bolwell S, Lichtin AE (2002) 
Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation 
for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene 
mutations. JAm Acad DermatoI46:861-6 
Prasad AR, Dailey HA (1995) Effect of cellular location on the function of 
ferrochelatase. ~I Bioi Chem 270: 18198-200 
Prolla TA (1998) DNA mismatch repair and cancer. Curr Opin Cell BioI 10:311-6 
Rademakers LH, Koningsberger JC, Sorber CW, Baart de la Faille H, Van Hattum J, 
Marx JJ (1993) Accumulation of iron in erythroblasts of patients with erythropoietic 
protoporphyria. Eur J Clin Invest 23: 130-8 
Richard E, Mendez M, Mazurier F, Morel C, Costet P, Xia P, Fontanellas A, Geronimi F, 
Cario-Andre M, Taine L, Ged C, Malik P, de Verneuil H, Moreau-Gaudry F (2001) 
Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-















Richard E, Robert E, Cario-Andre M, Ged C, Geronimi F, Gerson SL, de Verneuil H, 
Moreau-Gaudry F (2004) Hematopoietic stem cell gene therapy of murine 
protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug 
selection. Gene Ther 11: 1638-47 
Rimington C, Cripps DJ (1965) Biochemical and Fluorescence-Microscopy Screening-
Tests for Erythropoietic Protoporphyria. Lancet 17:624-6 
Risheg H, Chen FP, Bloomer JR (2003) Genotypic determinants of phenotype in North 
American patients with erythropoietic protoporphyria. Mol Genet Metab 80:196-206 
Roberts JE, Mathews-Roth M (1993) Cysteine ameliorates photosensitivity in 
erythropoietic proto porphyria. Arch Dermatol 129: 1350-1 
Roberts AG, Elder GH (2001) Alternative spliCing and tissue-specific transcription of 
human and rodent ubiquitous 5-aminolevulinate synthase (ALAS 1 ) genes. Biochim 
Biophys Acta 1518:95-105 
Roelandts R (1995) Photo(chemo)therapy and general management of erythropoietic 
protoporphyria. Dermatology 190:330-1 
Romeo G (1977) Enzymatic defects of hereditary porphyrias: an explanation of 
dominance at the molecular level. Hum Genet 39:261-76 
Rufenacht UB, Schneider-Yin X, Schafer BW, Taketani S, Deybach JC, Minder EI 
(1998) Rapid molecular diagnosis of erythropoietic protoporphyria among Swiss 
patients. Clin Chem Lab Med 36:763-5 
Rufener EA (1987) Erythropoietic proto porphyria: a study of its psychosocial aspects. 
Br J Dermatol 116:703-8 
Sambrook J, Fritsch EF, Maniatis T (1990) Standard gel electrophoresis protocol. In: 
Molecular cloning: A laboratory manual. Cold Spring Harbour Laboratory, Cold 
Spring Harbour, NY 
Sarkany RP, Alexander GJ, Cox TM (1994) Recessive inheritance of erythropoietic 
protoporphyria with liver failure. Lancet 343: 1394-6 
Schneider-Yin X. Gouya L, Meier-Weinand A, Deybach JC, Minder EI (2000) New 
insights into the pathogenesis of erythropoietic protoporphyria and their impact on 
patient care. Eur J Pediatr 159: 719-25 
Schneider-Yin X, Rufenacht UB, Hergersberg M, Schnyder C, Deybach JC, Minder EI 
(2001) Haplotype analysis in determination of the heredity of erythropoietic 
protoporphyria among Swiss families. J Invest DermatoI117:1521-5 
Schoenfeld N, Mamet R, Minder EI , Schneider-Yin X (2003) A "null allele" mutation is 














liver transplantation: relationships among biochemical, clinical, and genetic 
parameters. Blood Cells Mol Dis 30:293-301 
Scholnick PL. Hammaker LE. Marver HS (1972) Soluble delta-aminolevulinic acid 
synthetase of rat liver. It. Studies related to the mechanism of enzyme action and 
hemin inhibition. J BioI Chern 247:4132-7 
Schothorst AA, Van Steveninck J, Went LN, Suurmond D (1970) Protoporphyrin-
induced photohemolysis in protoporphyria and in normal red blood cells. Clin Chim 
Acta 28:41-9 
Schothorst AA, Suurmond D, PI oem JS (1977) In vitro studies on the protoporphyrin 
uptake and photosensitivity of normal skin fibroblasts and fibroblasts from patients 
with erythropoietic protoporphyria. J Invest Dermatol 69:551-7 
Scott AI, Townsend CA, Okada K. Kajiwara M. Whitman PJ (1972) Biosynthesis of 
corrinoids. Concerning ithe origin of the methyl groups in vitamin B 12. J Am Chern 
Soc 94:8267-9 
Sellers VM. Johnson MK, Dailey HA (1996) Function of the [2FE-2S] cluster in 
mammalian ferrochelatase: a possible role as a nitric oxide sensor. Biochemistry 
35:2699-704 
Sellers VM, Wang KF. Johnson MK. Dailey HA (1998) Evidence that the fourth ligand to 
the [2Fe-2S] cluster in animal ferrochelatase is a cysteine. Characterization of the 
enzyme from Drosophila melanogaster. J Bioi Chern 273:22311-6 
Sellers VM, Wu CK. Dailey TA. Dailey HA (2001) Human ferrochelatase: 
characterization of substrate-iron binding and proton-abstracting residues. 
Biochemistry 40:9821-7 
Sharp PA. Sugden B. Sambrook J (1973) Detection of two restriction endonuclease 
activities in Haemophilus parainfJuenzae using analytical agarose--ethidium bromide 
electrophoresis. Biochemistry 12:3055-63 
Sheffield VC. Beck JS, Kwitek AE, Sandstrom OW, Stone EM (1993) The sensitivity of 
single-strand conformation polymorphism analysis for the detection of single base 
substitutions. Genomics 16:325-32 
Shehade SA Chalmers RJ, Prescott RJ (1991) Predictable and unpredictable hazards 
of erythropoietic protoporphyria. Clin Exp Dermatol 16: 185-7 
Sil S, Bose T, Roy D, Chakraborti AS (2004) Protoporphyrin IX-induced structural and 
functional changes in human red blood cells, haemoglobin and myoglobin. J Biosci 
29:281-91 















Soret JL (1883) Recherches sur I'absorption des rayons ultraviolets par diverses 
substances. Arch Sci Phys Nat 10:430-485 
Srivastava G, Borthwick IA. Maguire OJ, Elferink CJ. Bawden MJ. Mercer JF. May BK 
(1988) Regulation of 5-aminoJevulinate synthase mRNA in different rat tissues. J 
8iol Chern 263:5202-9 
Straka JG, Bloomer JR Kempner ES (1991) The functional size of ferrochelalase 
determined in situ by radiation inactivation. J Bioi Chem 266:24637-41 
Sweeney GO, Dowdle Ea, Saunders SJ, Eales L (1963) ErythropoietiC Protoporphyria. 
A Brief Report of the First South African Case. S Afr J Lab Clin Med 14:247-9 
Takeshita K, Takajo T, Hirata H, Ono M, Utsumi H (2004) In vivo oxygen radical 
generation in the skin of the prctoporphyria model mouse with visible light exposure: 
an L-band ESR study. J Invest Oermatol 122:1463-70 
Taketani S, Tokunaga R (1981) Rat liver ferrochelatase. Purification, properties, and 
stimulation by fatty acids. J Bioi Chem 256:12748-53 
Taketani S, Inazawa J, Nakahashi y, Abe T. Tokunaga R (1992) Structure of the 
human ferrochelatase gene. Exon/intron gene organization and location of the gene 
to chromosome 18. Eur J Biochem 205:217-22 
Taketani S, Fujita H (1995) The ferrochelatase gene structure and molecular defects 
associated with erythropoietic protoporphyria. J Bioenerg Biomembr 27:231-8 
Thompson JR. Marcelino LA, Polz MF (2002) Heteroduplexes in mixed-template 
amplifications: formation. consequence and elimination by 'reconditioning peR'. 
Nucleic Acids Res 30:2083-8 
Thuneli S, Harper P, Brun A (2000) Porphyrins, porphyrin metabolism and porphyrias. 
IV. Pathophysiology of erythyropoietic protoporphyria--diagnosis, care and 
monitoring of the patient. Scand J Clin Lab Invest 60:581-604 
Todd OJ, Burrows 0 (1992) Predictable hazards of erythropoietic protoporphyria. elin 
Exp Oermatof 17'141 
Todd OJ, Hughes AE, Ennis KT, Ward AJ, Burrows 0, Nevin NC (1993) Identification of 
a single base pair deletion (40 del G) in exon 1 of the ferrochelatase gene in 
patients with erythropoietic proto porphyria. Hum Mol Genet 2: 1495-6 
Todd OJ (1994) Erythropoietic protoporphyria, Br J DermatoI131:751-66 
Tugores A, Magness ST, Brenner OA (1994) A single promoter directs both 
housekeeping and erythroid preferential expression of the human ferrochelatase 
gene. J BioI Chern 269:30789-97 
Tutois S, Montagutelli X, Oa Silva V, Jouault H, Rouyer-Fessard P, Leroy-Viard K, 




















protoporphyria in the house mouse. A recessive inherited ferrochelatase deficiency 
with anemia, photosensitivity, and liver disease. j Clin Invest 88:1-'30~6 
Upchurch DA, Shankarappa R, Mullins JI (2000) Position and degree of mismatches 
and the mobility of DNA heteroduplexes. Nucleic Acids Res 28:E69 
Van der Walt JJ, Heyt 1 (1971) Lipoid proteinosis and erythropoietic protoporphyna. A 
histological and histochemical study_ Arch DermatoI104:501-7 
Van Hattum J, Baart de la Faille H, Van den Berg JW. Edixhoven-Bosdijk A, Wilson JH 
(1986) Chenodeoxycholic acid therapy In erythrot"lepatic protoporphyna. J Hepatol 
3:407-12 
Varma S, Haworth A, Keefe M, Anstey AV (2000) Delayed onset of cutaneous 
symptoms in erythropoietic protoporphyria. Br J Oermatol 143221-3 
Wang X, Poh-Fitzpatrick M, Carriero D, Ostasiewicz L. Chen T, Taketani S. Piomelli S 
(1993) A novel mutation in erythropoietic protoporphyria: an aberrant ferrochelatase 
mRNA caused by exon skipping during RNA splicing. Biochim Biophys Acta 
1181:198-200 
Wang X, Poh-Fitzpatrick M, Piomelli S (1994) A novel splicing mutation in the 
ferrochefatase gene responsible for erythropoietic proto porphyria. Blochim Biophys 
Acta 1227:25-7 
Wang X, Poh-Fitzpatrick M, Chen T, Malavade K, Carriero D, Piomelli S (1995) 
Systematic screening for RNA with skipped exons--splicing mutatIons of the 
ferrocheiatase gene. Biochim Biophys Acta 1271:358-62 
Wang X (1996) Molecular characterization of a novel defect occurring de novo 
associated with erythropoietic protoporphyria. Blochim Biophys Acta 1316:149-52 
Wang X. Yang L. Kurtz L. Uchtin A Deleo VA. Bloomer J. Poh-Fitzpatrick MB (1999) 
Haplotype analysis of families with erythropoietic protoporphyria and novel 
mutations of the ferrocheiatase gene. J Invest Dermatol 113:87-92 
Warnich l, Kotze MJ. Groenewald 1M. Groenewald JZ. van Brakel MG. van Heerden 
CJ, de Villiers IN. van de Ven WJ, Schoenmakers EF, Taketani 8, Retief AE (1996) 
Identification of three mutations and associated haplotypes in the 
protoporphyrinogen oxidase gene in South African families with variegate porphyria. 
Hum Mol Genet 5:981-4 
Watanabe N, Hayashi N, Kikuchi G (1983) delta-Amlnolevullnate synthase isozymes :n 
the liver and erythroid cells of chicken. Biochem Biophys Res Commun 113:377-83 
Watanabe N, Hayashi N, Kikuchi G (1984) Relation of the extra~sequence of the 
precursor form of chicken liver delta-arninolevulinate synthase to its quaternary 



















Weiss G, Houston T, Kastner S, Johrer K. Grunewald K, Brock JH (1997) Regulation of 
ce;tuiai iron rn3tabctisrn by erythropoietin: activation of iron-regulatory protein and 
upregu!ation of transferrin receptor expression in erythroid cells. Blood 89:680-7 
Went LN, Klasen EC (1984) Genetic aspects of erythropoietic protoporphyria. Ann Hum 
Genet 48 (Pt 2):105-17 
Wenz H, Robertson JM, Menchen S. Oaks f. Demorest OM. Scheibler D. Rosenblum 
BB, Wike C, Gilbert OA, Efcavitch JW (1998) High-precision genotyping by 
denaturing capillary electrophoresis. Genome Res 8:69-80 
Whatley SO. Mason NG. Khan M. Zamiri M, Badminton MN, Missaoui WN. Dailey T.h., 
Dailey HA, Douglas WS, Wainwright NJ, Elder GH (2004) Autosomal recessive 
erythropoietic protoporphyria in the United Kingdom: prevalence and relationship to 
liver disease. J Med Genet 41: e 1 05 
Whitcombe DM, Albertson DG, Cox TM (1994) Molecular analysis of functional and 
nonfunctional genes for human ferrochelatase: isolation and characterization of a 
FECH pseudogene and its sublocalization on chromosome 3. Genomics 20A82-6 
Williams M, Krootjes Be, van Steveninck J, van der Zee J (1994) The pro- and 
antioxidant properties of protoporphyrin IX. Biochim Bloph,s Acta 1211:310-6 
Wiman A. Floderus Y. Harper P (2003) Nove! mutations and phenotypic effect of the 
splice site modulator lVS3-48C in nine Swedish families with erythropoietic 
protoporphyria. J Hum Genet 48:70-5 
Wood LH, Whatley SD, McKenna K, Badminton MN (2006) Exonic deletions as a cause 
of erythropoietic protoporphyria. Ann Clin Biochem 43:229-32 
Wu CK, Dailey HA, Rose JP, Burden A, Sellers VM, Wang BC (2001) The 2.0 A 
structure of human ferrochelatase, the terminal enzyme of heme biosynthesis. Nat 
Struct Bioi 8: 156-60 
Yasui Y, Muranaka S, Tahara T, Shimizu R, Watanabe S, Horie Y, Nanba E, Uezato H, 
Takamiyagi A, Taketani S, Akagi R (2002) A new ferrochelatase mutation combined 
with low expression alleles in a Japanese patient with erythropoietic protoporphyria. 
Clin Sci (Lond) 102:501-6 
Yotsumoto G, Masuda H, Iguro Y, Kinjo T, Matsumoto H, Sakata R (2003) Aortic valve 
replacement in a patient with erythropoietic protoporphyria. Ann Thorac Surg 
75:1003-5 
Zhou S, Zong Y, Ney PA, Nair G, Stewart CF, Sorrentino BP (2005) Increased 
expression of the Abcg2 transporter during erythroid maturation plays a role in 
decreasing cellular protoporphyrin IX levels. Blood 105:2571-6 
193 
 












De Rooij FWM, de Baar-Heesakkers E, Minderman-Voortman GJ, Wilson JHP (1996) 
Abstract: Similarity in mutations of the ferrochelatase gene between Dutch and 
Japanese patients with erythropoietic protoporphyria. Netherlands Journal of 
Medicine 48 
Kauppinen Rand Timonen K (2005) Abstract: Spectrum of mutations in the 
ferrochelatase gene identified among Finnish erythropoietic protoporphyria patients 
including a novel splicing defect Porphyrins and Porphyrias Conference, Cape 
Town 2005 
*Note: Referencing convention - American Journal of Human Genetics 
194 
 
o"to z,nt'l N
 
